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In advanced drug development and delivery, fluorescence studies have clarified and 
improved aspects such as biodistribution, stability and metabolism with respect to the 
complexities imposed by the biological systems. The ultimate aim of this study was to 
assess the delivery kinetics of a synthesised fluorescently labelled insulin in an 
implantable artificial pancreas (INsmart device) developed by Taylor et al, 2016, which 
is currently being tested in-vivo. 
The first objective of this thesis was to produce a fluorescein isothiocyanate (FITC)-
insulin conjugate which shows equivalent biological activity to native insulin under 
novel reaction conditions without the need for using protecting groups and multi-step 
synthetic conditions. Secondly, the stability and solubility profiles of the synthesised 
FITC-insulin conjugate in solution will be investigated for long-term storage and future 
applications. Thirdly, physiologically relevant glucose concentrations will be used to 
assess the performance of FITC-insulin delivery from an INsmart device. Lastly, other 
dyes such as eosin isothiocyanate (EITC) and rhodamine B isothiocyanate (RBITC) will 
be assessed as labelling candidates to produce other derivatised insulin conjugates. 
Mono-labelled FITC-insulin conjugate was successfully synthesised using a molar ratio 
of 2:1 (FITC: insulin) with short reaction times (up to 18h) at pH7 after studies were 
conducted to examine the effects of reaction time, molar ratio and pH. The labelling 
position of this mono-labelled species was identified by MS-Orbitrap Fusion at the B1 
residue (MonoB1). However, during synthesis, MonoB1conjugate always contains 
some trace amounts of unlabelled insulin that required further purification by RP-HPLC 
using a gradient method. This HPLC method could identify four FITC-insulin conjugates 
including two mono-labelled species (labelled at the A1 or B1 position), di-labelled 
species (labelled at the A1 and B1) and tri-labelled species (labelled at the A1, B1 and 
B29). Further analysis was performed using MALDI-MS to confirm the molecular weight 
of each conjugate produced. 
The biological activity of four FITC-insulin conjugates was assessed in human umbilical 
vein endothelial cells (HUVEC) and skeletal muscle cells (C2C12) via the insulin 
signalling pathway by examining the levels of AKT phosphorylation (pAKT) and cell 
surface GLUT4. There was no significant difference in pAKT and the GLUT4 cell 
surface levels observed for synthesised MonoB1 compared to native insulin, 
highlighting that this conjugate was as biologically active as native insulin. 
The enhanced stability and solubility of FITC-insulin conjugate using diluting fluid 
containing m-cresol, glycerol and zinc oxide, which is typically contained in most 
commercial insulin formulations are beneficial for setting up the in-vitro delivery study 
of the INsmart device. Because it allows a concentrated depot of FITC-insulin in the 
device for release over an extended time. Improvement in the smart gel formulation 
with diluting fluid and the use of correct membrane pore size showed promising and 
reproducible results in the extended experiments where the INsmart device has been 
set up and triggered multiple times with glucose and other dietary saccharides which 
act as controls to show the specificity of the gel to glucose challenges. The results 
indicated that the device is capable of delivering basal insulin dose which can be 
boosted in response to multiple (11x) mealtime glucose surges over a 5-day period. 
EITC and RBITC were used as fluorescent candidates to assess whether the same 
synthetic methodology of fluorescently labelled insulin was applicable to different dye 
sizes. Mono-labelled insulin conjugate with EITC was achieved using the same 
reaction conditions as in FITC-insulin synthesis. Further development is still needed to 
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%RSD   percentage relative standard deviation  
~    approximately  
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Acry/Bis   Acrylamide/Bis-acrylamide  
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con A-MA methacrylated concanavalin A (concanavalin A 
methacrylamide) 
CPE    carboxypeptidase E 
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Di  Di-labelled FITC-Insulin analogues/ Actrapid® conjugate  
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eNOS   endothelial nitric oxide synthase 
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Fn-3   fibronectin type III domains-3  




FSC    fluorescein  
GAPs   GTPase-accelerating proteins 
GDM   Gestational Diabetes Mellitus 
GEFs   guanine nucleotide exchange factors 
GFP   Green fluorescence protein 
GLUT4  insulin-dependent glucose transporter 4 
GLUTs   facilitated diffusion glucose transporters  
GVS    glucose transporter 4 storage vesicles  
HbA1c   glycated haemoglobin (HbA1c 
HCl    hydrochloric acid  
HI    human insulin  
HMWT   higher molecular weight transformation 
HNF-1 α  hepatocyte nuclear factor-1 alpha  
HPLC   High-Performance Liquid Chromatography 
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i.e.   that is 
IP    intraperitoneal  
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IR    insulin receptor  
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KATP-channels  ATP-sensitive K+-channels  
KBs   ketone bodies 
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L2   leucine-rich repeat domain 2 
LADA   Latent Autoimmune Diabetes in Adults 
LCT   long-chain triglyceride  
LSGS   Low Serum Growth Supplement  
LOD    Limit of detection  
LOQ    Limit of quantitation  
MAPK   mitogen-activated protein kinases  
MCA   7-methoxycoumarin-4-acetic acid 
m-cresol  meta cresol 
MCT   medium-chain triglyceride 
MDI   multiple-dose injection 
MI   myocardial infarction 
min   minutes 
mL   millilitre 
MODY   Maturity-Onset Diabetes of the Young  
Mono    singly labelled FITC-insulin conjugate   





MonoB1 singly labelled FITC-insulin or Actrapid® conjugate at the 
B1 position 
MS    mass spectrometry  
Na2HPO4  disodium hydrogen phosphate 
NaCl    sodium chloride  
NDM   Neonatal Diabetes Mellitus 
NaH2PO4  sodium dihydrogen phosphate 
NaOH   sodium hydroxide 
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NICE    National Institute for Health and Care Excellence  
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 . Introduction 
 
The main objectives of the thesis were to: 
• produce a biologically active fluorescein isothiocyanate (FITC)-insulin 
conjugate by modifying certain reaction conditions such as molar ratio, 
reaction time and pH. 
• confirm FITC labelling position on the insulin molecule by fragmentations 
of the modified insulin for mass spectrometry (MS) analysis. 
• examine the biological activity of FITC-insulin candidates by investigating 
their stimulation effect in HUVEC and skeletal muscle cells via the insulin 
signaling pathways. 
• investigate the stability and solubility profiles of FITC-insulin conjugate in 
solution for long-term storage and future application in both in-vitro and 
in-vivo testing as well as optimising mast production. 
• assess other dyes such as eosin isothiocyanate (EITC) and rhodamine B 
isothiocyanate (RBITC) as labelling candidates to produce further 
coloured insulin conjugates. 
• investigate the performance and kinetics of insulin delivery from an 
implantable closed-looped insulin delivery device (INsmart) using FITC-











The thesis begins with a general introduction chapter about diabetes mellitus 
and the development of a closed-loop insulin delivery system. Chapter 2 
presents the synthesis and identification of FITC-insulin conjugates from 
commercially available insulin preparations, followed by chapter 3 which studies 
the biological activity of FITC-insulin species synthesised inhouse. Chapter 4 
investigates the stability and solubility profiles of FITC-insulin while chapter 5 
examines the drug delivery mechanism of FITC-insulin from the INsmart device. 
Chapter 6 looks at the synthesis and identification of EITC-insulin and RBITC-
insulin conjugates. Lastly, there will be a summary chapter including 
suggestions for future work. 
This introductory chapter provides a basic understanding of diabetes mellitus, 
its current management guidelines and the disease-associated complications. 
An insight into insulin structure, the evolution of clinically used insulin 
pharmaceutical preparations and routes of insulin delivery will also be 
discussed. The main focus is to understand the insulin structure and the 
properties behind it to be fully engaged in its labelling process. The 
development of an artificial pancreas as a possible treatment option for insulin 
users will also be summarised with details about the in-vivo study for the 
performance of an implantable INsmart device developed by Taylor et al., 2016. 
Lastly, fluorescent labelling technique and its applications will be discussed, 











1.1 Diabetes mellitus  
1.1.1 Overview of glucose homoeostasis 
Generally, all living organisms require energy which comes from different 
sources such as sunlight, food, drinks, or supplements to maintain life (growing 
and reproducing). For instance, carbohydrates (CHO) nutrition like glucose is 
the most fundamental source of energy for survival in mammalian cells. At the 
cellular level, glucose is rapidly metabolised to produce a high energy end 
product known as ATP (adenosine triphosphate). In the body, glucose is 
continuously used as the primary energy source to carry out daily activities, 
including movements, balancing, thinking and even sleeping. Glucose 
homeostasis can be defined as a process of maintaining intercellular glucose 
concentrations at a steady-state level within a living cell, organism and to a 
larger scale, the human body. Cellular processes of glucose uptake during CHO 
ingestion, peripheral glucose consumption and hepatic glucose production are 
tightly regulated by specific hormones, namely insulin and glucagon released 
from the pancreatic cells to maintain glucose homeostasis. (O'Brien et al., 2020; 
Dunn and Grider, 2020; Aronoff et al., 2004). While glucagon is responsible for 
increasing blood glucose (BG) level, insulin reduces it (Error! Reference source n
ot found.). Therefore, their antagonistic effects help maintain BG level within an 
acceptable range of 4.0 to 5.9 mM pre-prandial (before meal) and under 7.8 mM 
at least 90 minutes (min) postprandial (after meal) (National Institute for Health 





Figure 1-1: The maintenance of glucose homeostasis. (Taken from Röder et al. 2014) 
Hypoglycaemia can result in seizures, unconsciousness and even death, 
whereas long-lasting hyperglycaemia eventually can lead to blindness, 
cardiovascular disease (CVD), renal failure, and neuropathy. Glucose 
homeostasis is crucial for both healthy individuals and people with diabetes to 
maintain long-term health. In addition to the tightly regulation of insulin and 
glucagon hormones, glucose homeostasis is also maintained by the body 
performance of various contribution factors. These include the rate of dietary 
CHO consumption and intestinal absorption, the rate of glucose utilisation by 
peripheral tissues as well as rate of glucose elimination or release by the liver 
and the rate of glucose reabsorption by the kidney (Röder et al., 2016a; 
Szablewski, 2011). These cellular activities in glucose homeostasis are defined 
into five phases namely phase I (Well-fed state), II (Glycogenolysis), III 
(Glucogenesis), IV (Glucose, Ketone bodies oxidation) and V (Fatty acid, 




Table 1-1: Phases of glucose homeostasis (Information is summarised mainly from the original work of George F Cahill, 1959) 
 Phase I Phase II Phase III Phase IV Phase V 
Stimuli Food intake when dietary glucose 
supply is exhausted 
(During early fasting) 
When glycogen 
stores in the liver 
are exhausted 
(<20h) 










Hepatic and renal 
gluconeogenesis 




The liver removes ~70% 
glucose load after a CHO meal. 
Glucose absorbed from the gut 
is supplied to all cells, signalling 
insulin released from pancreatic 
β-cells. 
Some glucose is converted to 
glycogen for storage in the liver 
(glycogenesis) - Excess 
glucose is converted to fatty 
acids (FA) and triglycerides in 
the liver in response to insulin 
secretion. 
Gluconeogenesis is inhibited 
Hypoglycaemia signals 
glucagon released from 
pancreatic α-cells. 
Hepatic glycogenolysis 
(break down of 
glycogen into glucose) 
and gluconeogenesis 
(synthesis of glucose 
from non-carbohydrate 
sources) maintain the 












Gluconeogenesis starts to 
decrease.  
The peripheral cells switch to 
using alternative fuels.  
FA oxidation increases ketone 
bodies (KBs) accumulation. 
Glycerol and amino acids 
released form adipose and 
muscle tissues respectively are 
used for glucose production. 
KBs enter the brain and muscle 
for energy production.  
The brain uses both glucose and 
KBs for energy. 
Less dependence on 
gluconeogenesis. Energy 
production for all body tissues 
usage mainly from FA and 
KBs oxidation. 
High levels of KBs and 
glucose inhibit proteolysis in 
the muscle (conservation of 
muscle)  
When all FA and KBs are 
used up, the body uses 
muscle protein (alanine and 
glutamine) to maintain blood 





(Utilisation rate is 
slower in hepatic, 
muscle and adipose 
tissue) 
All  
(Utilisation rate is 
slower in hepatic, 
muscle and adipose 
tissue) 
Brain, red blood cells (RBCs), 
Renal medulla and small amount 
used by muscles cells 
Brain at a slower rate, RBCs 











In healthy individuals, there is a constant release of insulin from the pancreatic 
β-cells to maintain glucose homeostasis during the basal state of fasting and 3-
5h after a meal when food absorption has ceased, this endogenous level of 
insulin is referred to as basal insulin (Home, 2015; Navale and Paranjape, 
2016). Physiologically, an increase or decrease in the level of insulin release 
would match higher or lower BG concentrations. For instance, the insulin 
secretory response at 10 mmol/L glucose is reported to be twice as high the 
response at 5 mmol/L glucose (Rorsman and Ashcroft, 2018). Notably, it is 
highlighted that insulin secretion is detectable in the human pancreas at glucose 
concentrations as low as 3 mmol/L (Henquin, Dufrane and Nenquin, 2006; 
Doliba et al., 2012; Braun et al., 2010; Rorsman and Ashcroft, 2018). 
Figure 1-2 demonstrates the cellular activity in pancreatic cells that resulted in 
insulin and glucagon secretion in response to low and high BG levels. 
 
Figure 1-2:Illustration of insulin and glucagon secretion in response to the change in blood 
glucose levels (Adapted from Gaisano, MacDonald and Vranic, 2012) 
Typically following a meal, increased insulin secretion from the pancreatic β-
cells is stimulated by elevated BG level. Initially, a high influx of circulating 
glucose into the pancreatic β-cells is facilitated by the glucose transporter 




these intracellular glucose molecules then undergo glycolysis, thereby 
generating ATP from the breakdown of glucose (Nicholls, 2016; Perego et al., 
2019; Aronoff et al., 2004; Das et al., 2020)(Detailed process of glucose 
metabolism via a glycolytic pathway and Kreb cycle can be found from recent 
reviews by (Marchetti et al., 2020; Roma and Jonas, 2020; Westermeier et al., 
2019). The resulting ATP production leads to an increased ATP/ADP ratio, 
thereby inducing the closure of ATP-sensitive K+-channels (KATP-channels). 
Under non-stimulated conditions, these channels are open to transport K+-ions 
down their concentration gradient out of the cell, therefore, securing the 
maintenance of resting potential. Upon closure, the subsequent reduction 
of K+ efflux leads to an increase in the inward current of the membrane resting 
potential thereby depolarising the bilayer. The resultant membrane 
depolarisation causes the opening of voltage-dependent Ca2+channels 
(VDCCs), which facilitates extracellular Ca2+ influx to the pancreatic β-cells. The 
increasing intracellular Ca2+ concentration eventually triggers the fusion of 
insulin-containing granules stored in the pancreatic β-cells with the membrane 
for subsequent releasing of their content (Rorsman and Braun, 2013; Rorsman 
and Ashcroft, 2018; Skelin Klemen et al., 2017). Meanwhile, in response to 
elevated glucose levels, the pancreatic β-cells will increase the production of 
insulin to maintain homeostasis. Notably, the secretion of insulin can be 
understood as a two-phased process that is (i.e) the initial rapid release of 
preformed insulin and an increase in insulin synthesis and release in response 
to elevated BG level. Once released into the bloodstream insulin is picked up 
mainly by insulin-responsive tissue such as skeletal muscle, adipose and 
hepatic (Marchetti et al., 2020; Jones et al., 2018; Röder et al., 2016b). Here, 
insulin can be understood to act as a facilitator for glucose transportation from 
the blood into tissues where glucose can be utilised for instant energy source, 
while excess glucose can be stored as glycogen or fat via glycogenesis and 
lipogenesis processes respectively. In order to reduce circulating glucose level, 
insulin also acts on the liver to decrease glucose production and increase 
glycogenesis (Tokarz, MacDonald and Klip, 2018; Patel and Goyal, 2019; 




elevated BG level, there will be a high influx of glucose into tissues for energy 
usage/storage and low output of glucose from the liver leading to a decline in 
BG level and thereby maintain glucose homeostasis (Podobnik et al., 2020; 
Gerich, 1993; Tokarz, MacDonald and Klip, 2018; Röder et al., 2016) 
Conversely, when BG levels fall below a critical threshold (<3mmol/L), the 
pancreatic α-cells respond by releasing glucagon. This counter-regulatory 
hormone stimulates hepatic glucose production and promotes the breakdown of 
glycogen and lipids to release more glucose to the bloodstream to bring back 
normal BG level. The autonomic nervous system activation and the glucose 
action at the islet levels are responsible for the stimulation of glucagon secretion 
to correct hypoglycaemia (Marty, Dallaporta and Thorens, 2007; Cryer, 2012; 
Gilon, 2020; Gromada, Chabosseau and Rutter, 2018). However, the overall 
physiology of glucagon secretion by pancreatic α-cells in response to low BG 
level is still a debatable research area mainly due to the scarce population of α-
cells. Its lack of functional identification patterns and the technical limitations of 
conventional methods have also rendered α-cells more challenging to study 
than β-cells (Briant et al., 2016; Gilon, 2020; Gaisano, MacDonald and Vranic, 
2012). Nevertheless, in the past decade, remarkable progress has been made 
in the study of pancreatic α-cell function at the cellular level. It is documented 
that KATP channels also play a fundamental role in the releasing of glucagon by 
the α-cells because they contribute to the variations of extracellular glucose 
level and the alterations of membrane action potential. As in pancreatic β-cells, 
α-cells are also electrically excitable since they are furnished with specific ion 
channels that generate action potentials of Na+ and Ca2+ in the absence or at 
low levels of glucose. Glucagon exocytosis is also triggered by Ca2+ entry 
through VDCCs except that voltage-dependent Na+ channels (NaV) are thought 
to play a more prominent role in glucagon secretion (Briant et al., 2016; Gilon, 
2020; Bankir et al., 2018; Gaisano, MacDonald and Vranic, 2012; Gylfe and 
Gilon, 2014). 
In general, the pancreas plays vital roles in the regulation of macronutrient 
digestion by releasing various digestive enzymes and pancreatic hormones and 




body maintaining glucose homeostasis is primarily regulated by glucagon and 
insulin hormones released from the pancreatic α and β-cells respectively in 
response to change in BG levels. For individuals with diabetes mellitus, which is 
a lifelong metabolic disease, there is a disruption in the balance action of these 
two opposing regulatory hormones leading to persistent high BG level (Ajmera 
et al., 2013; Padhi, Nayak and Behera, 2020a; Nath et al., 2018). Since insulin 
is the main hormone that is responsible for reducing the BG level, defects in 
insulin secretion or/and action would result in impaired glucose metabolism and 
eventually lead to chronic hyperglycaemia (Szablewski, 2011; Gerich, 1993; 
Röder et al., 2016c; Kharroubi and Darwish, 2015)  
1.1.2 Prevalence of diabetes mellitus 
Diabetes mellitus is one of the most common endocrine disorders that is on the 
rise, affecting 4.7 million people in the UK, of whom 90% have type 2 (Whicher, 
O’Neill and Holt, 2020; Magliano et al., 2019) and 442 million adults around the 
world (World Health Organisation (WHO),2016). According to WHO report 
2016, the global prevalence of diabetes (most of which is type two) in the adult 
population has almost doubled since 1980, rising from 4.7% to 8.5%. Although 
this dramatic increase was partly due to the population growth and ageing 
(accounting for 40%), other contributing factors include age-specific prevalence 
and changes in how people eat or drink and live. 
Besides the economic burden on the health-care system and the wilder global 
economy, diabetes also largely affects the quality of life in those who have the 
disease and their families in terms of health-care cost; reduction in family 
income associated with disability and premature loss of life. Moreover, it was 
also recorded in 2012 that there were 1.5 million deaths directly caused by 
diabetes worldwide with the addition of 2.2 million deaths due to the 
consequence of prolonged high BG level leading to increased risks of 
cardiovascular and other diseases, making diabetes the eighth leading cause of 
death in 2012 (WHO,2016; Taverna, 2018).  
Currently, in the UK, it is proposed that 1 in 15 people (both diagnosed and 




the complications of having diabetes, at least 10,350 people in the UK have 
end-stage kidney failure while more than 1,700 people have had their sight 
severely affected. Every week diabetes also leads to more than 169 
amputations, 530 heart attacks, 680 strokes and almost 2,000 cases of heart 
failure (Diabetes UK facts and stats,2019). Additionally, there are even more 
than 500 premature deaths every week in the UK due to diabetes. It is predicted 
in the next decade there will be 5.5 million people in the UK who have diabetes. 
These figures are highly alarming and still on the rise, marking diabetes one of 
the biggest health challenges not only in the UK but also worldwide. Although 
there is no cure for diabetes, type 2 diabetes is reversible and both types can 
be treated and well-controlled by specific pharmacological medications in 
conjunction with appropriate diet and exercise However, early diagnosis 
especially in type 2 is vital since complications from diabetes can begin five to 
six years before a confirmed diagnosis (Diabetes UK facts and stats,2019). 
1.1.3 Classification of diabetes mellitus 
Diabetes mellitus is classified according to each aetiology of the disease 
characteristic. The severity of symptoms is dependent on the type and duration 
of diabetes. It is important to classify different types of diabetes to establish 
appropriate treatment strategies tailored to individual need. Generally, there are 
two main types of diabetes, namely, type 1 and type 2 as proposed by the 
American Diabetes Association in 1997 (American Diabetes Association, 2020) 
Besides these two main types, Gestational Diabetes Mellitus (GDM) is also 
classified in the UK. Other rarer specific types of diabetes include Maturity-
Onset Diabetes of the Young (MODY), Neonatal diabetes mellitus (NDM), 
and Latent Autoimmune Diabetes in Adults (LADA) (Ke et al., 2020; 
Maniruzzaman et al., 2017). 
Type 1 diabetes mellitus  
Type 1 diabetes mellitus (T1DM), also known as insulin-dependent diabetes is 
an autoimmune disease that causes destruction to the insulin-secreting 
pancreatic β-cells, preventing them from being able to produce insulin, thus 
resulting in an absolute deficiency of insulin. Besides the apparent lack of 




against the pancreatic islet cells. These include islet cell autoantibodies, 
autoantibodies to insulin (IAA), glutamic acid decarboxylase (GAD, GAD65), 
protein tyrosine phosphatase (IA2 and IA2β) and zinc transporter protein 
(ZnT8A). These markers can be detected in the serum of people with T1DM 
months or years before the onset of the disease. The autoimmune destruction 
of pancreatic β-cells is also proposed to involve responses from T-cell mediated 
inflammatory (insulitis) as well as humoral (B-cell) (Norris, Johnson and Stene, 
2020; Jean-Baptiste et al., 2017; Kharroubi and Darwish, 2015). Although the 
exact cause of T1DM is unclear, the complex interlinks between genetic 
predisposition and several environmental factors such as viral infections, 
allergic pollutants, early infant cow milk nutrition or other autoimmune disease 
have been considered to involve in the aetiology of the disease. However, no 
specific environmental risk factor has been linked to the significant number of 
cases (WHO, 2016). Notably, other pieces of evidence seem to support the 
causative effect of virus infections contributing to T1DM (Sabouri et al., 2020; 
Wernroth et al., 2020; Morse et al., 2020; Principi et al., 2017; Jean-Baptiste et 
al., 2017). 
The majority of T1DM cases manifest in children and adolescents before the 
age of 20. T1DM accounts for 8% of all diabetes mellitus cases in the UK 
(Diabetes Facts and Stats updated, 2019). The condition often develops 
suddenly and rapidly resulting in minor to severe symptoms including excessive 
thirst, polyuria, involuntary urination, lethargy, fatigue, polyphagia, sudden 
weight loss, slow wound healing, recurrent infections, vision changes and 
possibly severe dehydration (Casu et al., 2020; Lucier and Weinstock, 2020). 
As the BG level is affected by daily dietary intake and physical activity, insulin is 
crucial for the regulation of how the body uses glucose for energy and storage 
(Gonzalez and Betts, 2019a; Murphy, Watt and Febbraio, 2020; Brown et al., 
2020). However, in patients with T1DM, pancreatic β-cell destruction would 
prevent insulin secretion, therefore, leading to insulin deficiency. The resultant 
accumulation of circulating glucose causes extreme high BG level because 
there is no insulin available to aid the intracellular absorption of glucose for 




avoid further complications and possibly loss of life. The complete lack of insulin 
means that patients with T1DM are dependent on exogenous administration of 
insulin for survival; (Sims and DiMeglio, 2019; Tan et al., 2019; Lucier and 
Weinstock, 2020; Khursheed et al., 2019).  
Type 2 diabetes mellitus 
Type 2 diabetes mellitus (T2DM), is by far the most prevalent form of diabetes 
that accounts for almost 90% of all cases (Diabetes Facts and Stats updated, 
2019). In T2DM there is a relative deficiency of insulin due to either the 
pancreatic β-cells inability to secrete sufficient insulin to cope with the body’s 
demands or a decline in tissue’s responsiveness to the hormone, referred to as 
insulin resistance. Some insulin-responsive tissues, including skeletal muscle, 
adipose and to a lesser extent, hepatic lose their sensitivity to the hormone as a 
result of insulin resistance in the initial development stage of T2DM. The 
reduction in glucose transport into muscle, liver and fat cells leads to the 
breakdown of other energy sources such as fat while hyperglycaemia occurs 
(Marchetti et al., 2020; Kahn, Cooper and Del Prato, 2014; Weir, Gaglia and 
Bonner-Weir, 2020). In the presence of prolonged insulin resistance, the 
pancreatic β-cells are incapable of producing sufficient insulin to overcome the 
resistance and correct high BG level, thereby resulting in chronic 
hyperglycaemia. This incapability could lead to a decline in insulin production 
and eventually fails in pancreatic β-cell function (Marchetti et al., 2020; Sampath 
Kumar et al., 2017; Vandana Saini, 2010). Recently, the impairment of 
pancreatic α-cells function has also been recognised to be involved in the 
pathophysiology of T2DM. Following a meal, pancreatic α-cells dysfunction fails 
in the suppression of glucagon released and hepatic glucose production, which 
normally occurs during the fasting stage. Given that BG level rises following a 
meal, the continuous glucagon secretion in addition to increased insulin 
resistance and inadequate levels of insulin secretion would lead to persistent 
hyperglycaemia eventually leading to T2DM (Grubelnik et al., 2020; Moon and 





This condition is usually but not exclusively associated with obesity which is a 
contributing factor to the development of insulin resistance. According to 
Diabetes UK,2019 obesity is held responsible for up to 85% of someone’s risk 
to develop T2DM. In the obese state, the amount of triglyceride intake exceeds 
the storage capacity in adipose tissue. Further CHO overload causing excess 
adipose build-up eventually lead to fat accumulation in ectopic tissues such as 
liver, heart and skeletal muscle (Longo et al., 2019; Ferrara et al., 2019). This 
disturbed fat distribution is proposed to interfere with the insulin signalling 
pathway (refer to section 3.1.1) and reduce the ability of insulin receptor 
substrates to propagate the insulin signal, thereby making tissues resistant to 
insulin (Guilherme et al., 2019; Guo, 2014; Dai et al., 2013). Meanwhile, in an 
attempt to bring back insulin activity to correct hyperglycaemia, the pancreatic 
β-cells respond by releasing even more insulin (hyperinsulinemia). During this 
pre-diabetic stage, the high level of amylin co-secretion with insulin results in 
the formation of amyloid through aggregation in the vicinity of the pancreatic β-
cells. This triggers β-cells apoptosis and leads to long-term damage to the 
pancreatic islet, thereby reducing its capability to release insulin (Brannick and 
Dagogo-Jack, 2018; Kiriyama and Nochi, 2018; Verma et al., 2020). The 
impairment of insulin secretion develops progressively over a sustained period 
and if continued, will eventually result in T2DM. Notably, T2DM was formerly 
referred to as non-insulin-dependent diabetes in contrast to T1DM where there 
is a complete dependence on exogenous insulin administration. However, there 
is a significant number of patients with T2DM requiring insulin as the condition 
progresses, the terminology of non-insulin-dependent diabetes can be 
misleading and is therefore no longer applicable (Boarder et al. 2017). 
Gestational diabetes mellitus 
GDM as its name suggests, refers to a condition of glucose intolerance 
develops during pregnancy. Although it is a temporary condition that usually 
ends shortly after giving birth, it also carries long-term risk of developing 
diabetes and cardiovascular diseases (CVDs) (Johns et al., 2018; Szmuilowicz, 
Josefson and Metzger, 2019; Walker, Flannery and Mackillop, 2020). In the UK, 




diabetes mellitus (Stacey et al., 2019). Women with GDM as well as their 
babies could be at increased risks of developing complications during 
pregnancy and giving birth if the condition is not well managed (Bordin et al., 
2020 and Li, Y.,et al 2020). GDM can happen at any stage of pregnancy; 
however, during the second and third trimester, it is more common. GDM does 
not usually cause any symptoms and is diagnosed during antenatal screening 
when there are one or more risk factors determined (Stacey et al., 2019; 
Kachikis et al., 2017; Bordin et al., 2020; Johns et al., 2018). There are several 
risk factors and markers for GDM including mainly age; overweight or obesity 
(IBM > 30) and excess glucose in urine or excessive weight gain during 
pregnancy or previously gave birth to babies who weighed ≥ 4.5kg(10lb). Other 
history factors contributing to the risk include a family history of diabetes, 
ethnicity, GDM during a previous pregnancy and a history of stillbirth or giving 
birth to an infant with congenital abnormalities (Stacey et al., 2019; Ménard, 
Sotunde and Weiler, 2020; Li, Y. et al., 2020; Sweeting et al., 2019). Diabetes in 
pregnancy or GDM also increase the risk of future obesity and T2DM in 
offspring (WHO,2016). Although the exact cause remains uncertain, the 
hormonal changes during pregnancy are proposed to play a role in the 
development of GDM by putting some pregnant women at a higher risk of 
insulin resistance (Plows et al., 2018; Johns et al., 2018; Egan, Dow and Vella, 
2020). Infants born to mothers who have suffered from GDM usually have 
additional fat resulting from the excessive circulating glucose that crosses the 
placenta, therefore, explaining the heavier weights that are normally seen in 
those infants (Prentice et al., 2019; Andersson-Hall et al., 2019; Stacey et al., 
2019). In most cases, GDM can be well managed by the appropriate diet and 
physical activity. Some rare cases will require insulin to ensure good BG control 
(NICE, 2015a; Laredo-Aguilera et al., 2020; Egan, Dow and Vella, 2020). 
Other specific types of diabetes mellitus  
MODY is a group of monogenic disorders categorised by an autosomal 
dominant inherited non-insulin-dependent form where hyperglycaemia occurs at 
an early age. The most common gene defect concerns a mutation in the 




3). Another defect is caused by mutations in the glucokinase gene on 
chromosome 7p. These mutations account for a small number of people with 
diabetes (1%) but are important in determining therapeutic approaches (Oliveira 
et al., 2020; Aarthy et al., 2020).  
NDM is another form of monogenic disorders that occurs in the first 6 to 12 
months of life. However, it is very rare, occurring in around 1 in 300,000 to 
400,000 births. NDM may or may not require insulin treatment so, diagnosis by 
genetic testing is recommended (Habeb et al., 2020; Dahl and Kumar, 2020).  
LADA is another different form of autoimmune diabetes which occurs during 
adulthood rather than in childhood and adolescents as seen in T1DM. It is 
distinct from T1DM by the older age of onset and slower destructive progression 
of pancreatic islet towards insulin requirement. However, there is a substantial 
proportion of people with LADA who have an initial clinical diagnosis of T2DM 
as they also show some degrees of insulin resistance. It is therefore important 
to identify LADA features to ensure appropriate treatment for good glycaemic 
control (Maddaloni et al., 2020; Verma, Sharma and Rangari, 2019). 
 
1.1.4 Disease management 
Currently, there are two main groups of pharmacological medications used for 
diabetes treatment, including insulin and antidiabetic drugs (Stubbs, Levy and 
Dhatariya, 2017; Feingold, 2020). As previously discussed, exogenous insulin 
administration is essential for survival in patients with T1DM. The ultimate goal 
for T1DM management is the lifelong control of normal BG level. This is 
achievable through a carefully combined strategy of insulin replacement therapy 
to closely mimic the standard release of insulin in healthy people and dietary 
intake with adequate exercise for an individual patient (Neupane and Evans, 
2019; Subramanian et al., 2016; Khardori and Griffing, 2017). Most clinically 
used insulin formulations nowadays are manufactured using genetic 
engineering and recombinant DNA technologies. They are generally classified 
following their speed of onset or duration of action (Vajo, Fawcett and 
Duckworth, 2001; Baeshen et al., 2014; Khan et al., 2016). There are four main 




and long-acting (detailed in section 2.1.1). The most common method of 
exogenous insulin administration is by subcutaneous (SC) injection. The 
intravenous (IV) route of delivery is mainly used in an emergency to achieve a 
rapid response.  
The initial treatments for T2DM tailored to individual patient usually involve a 
good lifestyle and diets control in addition to a single oral antidiabetic drug if 
lifestyle intervention alone cannot achieve good glycaemic control. It is highly 
encouraged to have non-pharmacological management, including weight loss, 
smoking cessation and regular exercise which can help to reduce 
hyperglycaemia and reduce cardiovascular risk. There are several classes of 
oral antidiabetic drugs with a wide-range mechanism of action available for the 
treatment of T2DM as summarised in Table 1-2. The choice of drug is generally 
based on effectiveness, safety and tolerability. The patient’s comorbidities and 
concomitant medication with co-existing diseases should also be considered. 
However, as the disease progresses, insulin therapy becomes typically 
necessary owing to the decline in pancreatic β-cells function (Seidu et al., 2020; 




Table 1-2: Summary of antidiabetic drugs used in the treatment of Type 2 Diabetes Mellitus. (The information is taken mainly from the BNF online and 
Boarder et al. 2017) 
Therapeutic class Drugs Mechanism of action Common adverse drug reactions 
Biguanides Metformin Decrease gluconeogenesis and increase peripheral glucose ultilisation; 
since it acts only in the presence of endogenous insulin it is effective only 
if there are some residual functioning pancreatic islet cells 
Gastrointestinal (GI) disturbances  
Decreased vitamin B12 absorption 
Lactic acidosis (discontinue) 
Sulfonylureas Glibenclamide, Tolbutamide 
Gliclazide, Glimepiride, 
Glipizide, 
Block ATP-dependent K+ channels on pancreatic β-cells to cause 
depolarisation, leading to an influx of Ca2+ through VDCCs, thereby 
increasing insulin secretion. They are effective only when some residual 
pancreatic β-cell activity is present; They also show an extra-pancreatic 
action in long-term use. 




Meglitinides  Nateglinide, 
 Repaglinide 
Stimulates insulin secretion similar to sulfonylureas Diarrhoea; GI discomfort; 
 hypoglycaemia; nausea 
Thiazolidinedione  Pioglitazone Reduces peripheral insulin resistance, leading to a reduction of blood-
glucose concentration. 
Bone fracture; increased risk of 
infection; numbness; visual 
impairment; weight increased 
α-glucosidase 
inhibitors 
Acarbose Reversible inhibition of α-glucosidase; Reduce post-prandial peak of 
glucose by slowing intestinal glucose absorption. 
Bloating, Flatulence, Diarrhoea 
Dipeptidylpeptidase-4 
(DPP-4) inhibitors  
 Alogliptin, Linagliptin,  
Sitagliptin, Saxagliptin, Vilda
gliptin 
Competitively inhibits DPP-4 to increase insulin secretion and reduce 
glucagon secretion. 
Headache, Nausea, Infections 
Sodium-glucose co-





Reversibly inhibits SGLT2 in the renal proximal convoluted tubule to 
reduce glucose reabsorption and increase urinary glucose excretion. 
Hypotension 





 Dulaglutide, Exenatide,  
Liraglutide, Lixisenatide 
Mimic action of GLP-1, enhancing glucose-dependent insulin secretion 
from pancreatic β-cells while inhibiting glucagon released from pancreatic 
α-cells, and slows gastric emptying. 








1.1.5 Diabetes mellitus-associated complication  
When diabetes is not treated or well managed, short and long-term 
complications can develop that threaten the health and even endanger life. 
Maintaining good glycaemic control is therefore essential in the management of 
diabetes mellitus to achieve better health outcome. Abnormally low BG level 
may lead to seizures or unconsciousness. It could happen after skipping a meal 
or exercising more than usual, or if the dosage of insulin /anti-diabetic 
medication is too high, resulting in a dramatic drop in BG level. Persistently high 
BG level over time owing to poorly controlled diabetes can also result in 
damage to the heart, blood vessels, eyes, kidneys and nerves, increasing the 
risk of cardiovascular diseases (CVD) and stroke. Diabetic complications are 
the leading cause of mortality and morbidity associated with the disease. The 
high healthcare cost to manage these associated complications has also been a 
huge burden not only to the patients and their family but also to the healthcare 
system providers (Aarthy et al., 2020; Papatheodorou et al., 2018).  
Acute complications of diabetes mellitus are commonly associated with T1DM 
and are often metabolic emergencies that can be life-threatening. Diabetic 
ketoacidosis (DKA) is a dangerous complication that can lead to coma or even 
death if it is not treated quickly. DKA mainly occurs in T1DM as a result of the 
uncontrolled breakdown of fats and proteins due to the body lacking sufficient 
insulin to allow enough glucose to enter cells. Since energy is essential for the 
body to function when there is a shortage of glucose, the body switches to 
burning fatty acids to compensate the energy need, resulting in accumulation of 
acidic KBs. A high level of KBs in the blood can cause nausea, vomiting and 
seriously disturb the body acid-base balance, leading to acidosis. In an attempt 
to correct acidosis, hyperventilation may occur while the breath may smell of 
acetone due to the excreted ketones. A decrease in plasma pH in addition to 
dehydration can lead to a coma that requires urgent medical attention (Duca et 
al., 2019; Kreider, 2018). In the UK, nearly 4.3% of people with T1DM 




2019). Treatment of DKA requires IV fluids administration to correct dehydration 
and to replace any salts that could be lost from excessive urine excretion during 
ketoacidosis. Insulin is also required via IV administration to suppress the KBs 
that the body produces instantly. Although people with T2DM that produce very 
little of their insulin may also be affected by DKA, it is very rarely observed since 
sufficient insulin is usually available to prevent excessive lipolysis in adipose 
tissue and the liver (Diabetes UK, 2019; Boarder et al. 2017) 
Long-term complications of diabetes mellitus due to uncontrolled 
hyperglycaemia mainly associated with macrovascular and microvascular 
diseases that can result in visual loss, kidney failure, lower limb amputation and 
several other long-term consequences leading to significant impacts on the 
quality of life (Visaria et al., 2020; Hippisley-Cox and Coupland, 2016). 
Sustained hyperglycaemia can cause damage to a wide range of organs and 
cells via various mechanisms, including RBC, blood vessels, nerves, the liver 
and kidney, and the lens of the eye (Lotfy et al., 2017a; Yaribeygi, Atkin and 
Sahebkar, 2019). The elevated glucose level inside these cells can cause non-
enzymatic binding of glucose with other molecules such as FA, proteins and 
nucleic acids to produce advanced glycation end-products. These can lead to 
altered functions underlying many of the pathological changes and 
characteristic of the chronic diabetic state (Yang et al., 2019; Park et al., 2019; 
Yaribeygi, Atkin and Sahebkar, 2019). Haemoglobin in RBC and structural 
proteins like collagen and elastin are some important examples (Szablewski 
and Sulima, 2017; Yang et al., 2019). In particular, collagens become cross-
linked by the transformed glucose groups, disturbing turnover and function. The 
glycated molecules thicken basement membranes, leading to alterations in 
permeability and transport mechanism of cells. Especially, cells of the kidney 
are particularly at high risk to these structural alterations, resulting in deflective 
filtration and kidney damage (nephropathy) (McKay, Priyadarsini and 
Karamichos, 2019; Amorim et al., 2019; Hippisley-Cox and Coupland, 2016). 
Accumulation of the advanced glycation end-products can also increase risk of 
inflammation while glycation of the α-crystalline protein in the lens of the eye 




2018). An altered affinity for oxygen is usually seen in glycated haemoglobin 
(HbA1c), resulting in reduced oxygen supply to many tissues; thus, may 
compromise their body function. Similarly, vascular endothelium is also affected 
at an early stage. The key features include an increase in vascular permeability 
and the loss in the vasodilatory influence of nitric oxide, which contributes to the 
pathogenesis of both microvascular and macrovascular complications 
associated with diabetes (Lotfy et al., 2017b; Forbes and Cooper, 2013). 
Meanwhile, damage to smaller blood vessels (microvascular disease) caused 
by hyperglycaemia can lead compilations involving the eye, kidneys and nerves 
(Mauricio, Alonso and Gratacòs, 2020; Lotfy et al., 2017; Chawla, Chawla and 
Jaggi, 2016). Diabetic retinopathy is the leading cause of blindness in people 
aged under the 60s in developed countries. It is estimated that over 80% of 
patients who have had diabetes mellitus for more than 20 years are also 
affected by this condition (Saleh et al., 2018; Rabiu et al., 2020; Zhu, Titone and 
Robertson, 2019). Chronic renal failure (nephropathy) is the most common 
consequence of diabetes mellitus. Although the exact mechanism of 
hyperglycaemia resulting in kidney damage has not yet been fully understood, 
the obvious outcome is the compromised glomerular filtration and the presence 
of protein in the urine. High blood pressure also significantly contributes to this 
kidney damage which in turn is associated with an increased risk of CVD. 
Prolonged high BG level also predisposes to nerve damage, leading to the 
progressive loss of peripheral nerves fibres that include autonomic, sensory and 
motor nerves, referring to as diabetic neuropathy. Patients who suffer from 
diabetic neuropathy can sometimes experience numbness and profound pain 
which often does not respond to conventional analgesia, causing considerable 
morbidity (Anders et al., 2018; Braunwald, 2019; Amorim et al., 2019). 
Unfortunately, there is no specific treatment for diabetic neuropathy despite the 
availability of various drugs to relief their symptoms. The primary goal for 
management is to control symptoms and prevent worsening of neuropathy by 
improving glycaemic control. Furthermore, the combined effects of neuropathy 
and macrovascular damage can result in diabetic foot problems owing to the 




patients noticing due to nerve damaged and can even necessitate amputation 
(Braunwald, 2019; Lotfy et al., 2017; Hippisley-Cox and Coupland, 2016). 
Most importantly, complications associated with damage to large blood vessels 
owing to high levels of circulating glucose has accounted for the significant 
increases in mortality related to diabetes mellitus (Visaria et al., 2020; Dal 
Canto et al., 2019). Macrovascular complications of diabetes can develop from 
uncontrolled hyperglycaemia, excess free FA, and insulin resistance, leading to 
CVD such as heart attacks, strokes and insufficiency in blood flow to legs, 
genitals, feet and toes. CVD is the major cause of mobility and mortality in 
patients who suffer from diabetes mellitus (Glovaci, Fan and Wong, 2019; 
Anders et al., 2018). The early stage of the macrovascular disease is 
associated with atherosclerotic plaques in the vasculature supply of blood to the 
heart, brain or limbs. Later disease stage involves the complete obstructions of 
these vessels that can contribute to the risk of myocardial infarction, stroke, 
claudication and foot gangrene. The process of atherosclerosis (built-up of 
plaque inside the arteries) resulting in the narrowing of arterial walls is believed 
to be the main pathophysiology in macrovascular disease. In addition to the 
formation of plaque, there is strong evidences of increased platelet adhesion 
and hypercoagulability in T2DM patients where compromised production of 
nitric oxide, altered calcium regulation and the increase in free radical formation 
of platelets could promote platelet aggregation. Elevated levels of plasminogen 
activator inhibitor type 1 may also impair fibrinolysis in these patients. The 
combined effects of hypercoagulability and impaired fibrinolysis are, therefore, 
likely to further escalate the risk of vascular occlusion and CVD in T2DM 
(Fowler, 2008; Raghavan et al., 2019). 
1.2 Insulin  
1.2.1 Insulin discovery and structure 
Before the discovery of insulin in the 1920s, the prognosis for people with 
diabetes mellitus requiring insulin replacement was very poor. There were 
hardly any treatment options available and therefore, usually resulted in high 




diabetes had been confirmed, eventual complications and subsequent deaths 
were usually observed within two years at the most. At that time, the condition 
had to be managed through dietary modification alone, meaning that some 
affected individuals were restricted to a diet with an almost negligible CHO 
intake with the hope of controlling their BG levels. In those circumstances, the 
benefit of repeated fasting and prolonged undernourishment, was relatively 
short-lived since it was only a modest extension of life. Furthermore, there was 
little or no evidence in supporting the longer-term efficacy of undernourishment 
therapy, yet it more likely resulted in poorer health accompanied by a risk of 
infection, exhaustion from lack of nourishment, and poor quality of life 
(Hilgenfeld et al., 2014; Vecchio et al., 2018; Didangelos, 2011). Undoubtedly, 
the discovery of insulin as an injected therapeutic agent by Banting and Best in 
1922 for the treatment of insulin-requiring diabetes mellitus has been the most 
important and controversial breakthroughs in modern medical history. Their 
research groups successfully isolated a concentrated pancreatic secretion from 
crude extracts of cow, pig and sheep pancreas. This product demonstrated a 
reduction of BG level with relatively low toxicity firstly in animals and under 
careful control in humans with diabetes. Following its discovery, insulin has 
remained as an indispensable mainstay of treatment for T1DM and GDM for 
almost a century later. There are also many more people with T2DM requiring 
insulin treatment as their diabetic condition progresses (Nwaneri, 2015; Flier, 
2019; Vecchio et al., 2018). 
In addition to its key role in the regulation of human metabolism, the insulin 
polypeptide with all the structural features of a large protein is an ideal model 
molecule for studying the structure, properties and characteristic of proteins. 
Insulin, therefore, remains one of the most extensively studied molecules of 
biochemistry for nearly a century (Yaribeygi et al., 2019a; Vecchio et al., 2018; 
Didangelos, 2011; Quianzon and Cheikh, 2012). Although, the first insulin 
preparations were originated from porcine (pig) - and/or bovine (cow), the 
continuous evolution of insulin had progressively developed after the 1980s 
when semi-synthetic human insulin (HI) production became clinically available. 




animal species in their amino acid sequences. However, the folding and 
packing of the two chains into their three-dimensional (3D) conformation are 
essentially similar. HI has the closest structure and function to bovine or porcine 
insulin (Jacob, 2015). The difference in their amino acid residues is summarised 
in Table 1-3. 
Table 1-3: Difference in the amino acid residues between human insulin, bovine insulin and 
porcine insulin (Taken from Jacob 2015). 
Residue Human insulin Bovine insulin Porcine insulin 
A8 Threonine Alanine Threonine 
A10 Isoleucine Valine Isoleucine 
B30 Threonine Alanine Alanine 
 
 
Figure 1-3: Insulin structure from (a) the initial insulin synthesis to its final 
structure of insulin monomer and (b) amino acid sequences of connecting C-
peptide (grey) as well as insulin A&B chains (blue) (taken from Chhabra 2012). 
 presents the overall changes in the insulin structure from its initial synthesis as 
pre-proinsulin to its monomer form of insulin (a) and the detailed amino acid 





Figure 1-3: Insulin structure from (a) the initial insulin synthesis to its final structure of insulin 
monomer and (b) amino acid sequences of connecting C-peptide (grey) as well as insulin A&B 
chains (blue) (taken from Chhabra 2012). 
 
The insulin hormone is originally produced by the pancreatic β-cells in the form 
of a single polypeptide chain called preproinsulin, which is composed of 110 
amino acids. The ‘signal peptide’ (in black, Figure 1-3a) of 24 amino acids is 
removed from one end of the chain by enzymatic action when it passes through 
the endoplasmic reticulum, leaving pro-insulin behind. Further two amino acids 
are removed by another enzyme carboxypeptidase E (CPE). The pro-insulin 
has the middle C-peptide consisting 33 amino acids which connect the amino 
terminus (NH2-) of the A chain to the carboxyl terminus (-COOH) of the B chain. 
This connecting peptide section is then removed by the action of prohormone 
convertase 1 and 2 enzymes, leaving the final primary structure of the insulin 
molecule consisted of the A and B chains (in blue, Figure 1.3) (Vasiljević et al., 
2020; Liu et al., 2014; Liu et al., 2018).  
Principally, biologically active insulin exists as a monomer, comprising A and B 
polypeptide chains. The two chains are linked to each other by two disulphide 




A20 and B19. Chain A has 21 amino acid residues with an additional disulphide 
loop between A6 and A11, whereas the longer B chains consist of 30 residues. 
(Weiss, Steiner and Philipson, 2014; Liu et al., 2018; Xiong et al., 2020).  
Figure 1-4: Insulin monomer 3D structure of the A chain (blue), highlighting the 
two parallel α- helices (A2-A8 and A13-A20) and the B chain (grey) with the 
large α-helix (B9-B19). Three disulphide bridges are shown in yellow (Adapted 
from Lierop et al., 2017). 
 shows the 3D version of the insulin monomer.   
 
Figure 1-4: Insulin monomer 3D structure of the A chain (blue), highlighting the two parallel α- 
helices (A2-A8 and A13-A20) and the B chain (grey) with the large α-helix (B9-B19). Three 
disulphide bridges are shown in yellow (Adapted from Lierop et al., 2017). 
 
Insulin can adopt different structures depending on its concentration. At a low 
concentration of <10µM, insulin only exists as a monomer of a compact globular 
structure with a hydrophobic core.Within the insulin folding of its secondary 
structure, the A chain forms a compact unit containing two sections (A2 - A8 
and A13 – A20) of the α-helix in between presenting a fairly flat ribbon. This 
allows each α-helix section to lie alongside one another, and thereby brings the 
side chains of A2 and A19 close enough to allow Van der Waals contact. The B 
chain, which wraps around the A chain comprises a more extensive section 
of α-helix (B9 - B19) and the smaller glycine residues at B20 and B23, enabling 
it to fold into a V shape. The resulting V-folding brings the C terminal residues 




form the globular structure of the insulin monomer. At higher concentration (> 
10 µM) relevant for pharmaceutical formulations, each insulin monomer joins in 
two to form a dimer, as shown in Figure 1-5 A (Weiss, Steiner and Philipson, 
2014; Hilgenfeld et al., 2014; Liu et al., 2018; Hjorth et al., 2016a). 
 
Figure 1-5: 3D illustration of insulin dimer (A) showing antiparallel β-sheet in black dotted line 
with the A chain coloured in green, B chain in magenta and disulphide bridges in yellow. In the 
presence of zinc ions, the three dimers then associate to form a hexamer (B) (Adapted from 
Hilgenfeld et al. 2014).  
Each insulin dimer consists of two insulin molecules held together by nonpolar 
forces and four hydrogen bonds (between B24 and B26 residues). They are 
arranged as an antiparallel β-sheet structure (Figure 1-5A) between the two 
COOH-terminal strands of the B chain. The arrangement of the chains buries 
the nonpolar cysteine A6-A11 and the aliphatic side chains of residues A2, A16, 
B11 and B15 in the hydrophobic core contributing to its stability, which is also 
lent by the disulfide bridges. While B25-B30 and B1-B8 segments can vary in 
conformation, the A-chain and the B9-B19 helix form a stable structure unit of 
insulin. Furthermore, within the pH range of 4-8 and at 10 to 200 µM 
concentrations, three insulin dimers then assemble in the presence of two zinc 
ions located above and below the 2-fold axis to form an insulin hexamer, a 
globular protein structure (Figure 1-5B). Meanwhile, at ≥ 2mM concentration, 




(Weiss, Steiner and Philipson, 2014; Hilgenfeld et al., 2014; Liu et al., 2018; 
Banerjee, Mondal and Bagchi, 2018).  
Generally, there are three structural families of insulin hexamers (T6, T3 Rf3, and 
R6) formed, as shown in Figure 1-6 when insulin exists in crystals and solution 
(Weiss, Steiner and Philipson, 2014). 
 
Figure 1-6: Structural families of insulin hexamers showing (A): Schematic representation of the 
three types of zinc-insulin hexamers, designated T6, T3 Rf3, and R6 and their corresponding 
ribbon representation of wild-type crystal structures (B) with zinc ions coloured in magenta and 
phenol molecules in white (Taken from Weiss et al.,2014). 
 
Insulin hexamer is also referred to as an allosteric protein, which possesses 
ligand-mediated cooperative binding sites. The presence or absence of specific 
ligands would result in different conformational states namely T6, T3Rf3, and R6 
hexamers. These states are differentiated by the change in conformation of the 
B-chain residues, in which fully extended form of B1-B8 residuals results in the 
conformation of T state. Whereas, the long B1-19 helix continuation to the N-
terminus leading to a helical structure is responsible for Rf or R state (Březina et 
al., 2018; Weiss, Michael A., 2009; Lierop et al., 2017). The frayed Rf state 
presents B1-B3 in extended conformation and B4-B8 in helical conformation 
which is similarly observed in the conformation of the R state (Palmieri et al., 




The equilibrium of the R6, T6 and Rf arrangements of insulin hexamers are 
modulated by the interaction between the allosteric ligands (favours the T state) 
such as lyotropic anions (Cl-1, SCN-1) or bivalent metal ions (Zn2+, Co2+) and the 
binding of phenolic ligands (favours the R state or frayed Rf state) (Gast et al., 
2017a; Maikawa et al., 2020; Weiss, 2009; Wollmer et al., 1987). The T6 insulin 
hexamer comprises six insulin molecules associated into three dimeric units 
that are connected by a threefold symmetry axis. Each dimeric unit holds a 
pseudo twofold symmetry axis, which rotates perpendicularly to the threefold 
axis. Although each insulin monomer within the dimers shares the same amino 
acid sequence of the A and B chain structure, they are not identical in the 
arrangement of certain side chains, thereby, breaking the twofold symmetry. In 
particular, the most apparent difference is that in one monomer the B25 side 
chain is folded in towards the hydrophobic core while the other has it folded 
outwards. Within the polar central axis of the hexamer, two axial zinc ions 
situate on the threefold symmetry, each of which is coordinated by three 
B10 residues (histidine) and three water molecules in an octahedral 
arrangement (Weiss, Steiner and Philipson, 2014; Liu et al., 2018; Weiss and 
Lawrence, 2018; Rege et al., 2018). 
Meanwhile, high concentrations of sodium chloride would result in the classical 
“rhombohedral transition” of zinc insulin crystals, referred to as T3Rf3 hexamers 
or 4-Zn insulin. Proposed that each dimeric unit consists of two monomer 
molecules (monomer I and monomer II). Within the hexameric unit, monomer I 
trimer (T3) shares the same octahedral zinc-ion coordination as in the 
T6 hexamer whist monomer II trimer (Rf3) displays substantially more structural 
reorganisation, especially at the N-terminal of the B-chain residues. The 
T3Rf3 hexamers can also be induced at lower salt concentrations in the 
presence of phenolic ligands in which three bound phenolic molecules are 
contained in the Rf3 trimer. Whereas, high concentrations of phenolic ligands 
would lead to the conformational change of the R6 hexamers (Fili et al., 2015; 
Palivec et al., 2017; Palmieri et al., 2013; Weiss, Steiner and Philipson, 2014). 
There are usually six (or uncommonly seven) bound phenolic ligands 




dimer-dimer interphase, phenol molecules bind to a largely hydrophobic pocket 
which is made up by the side chains of B5 and B11 residuals from each 
different dimer in addition to A6 and A11 residuals. The orientations of phenol 
molecules in these pockets usually vary within one hexamer as well as from 
various insulin analogues. However, in all cases, it is the basic formation of two 
hydrogen bonds between the phenolic hydroxyl groups and cysteine residues at 
A6 and A11 positions, in combination to the hydrophobic contact with the B5 
side chain that holds each phenol molecule in position (Weiss, Steiner and 
Philipson, 2014; Berchtold and Hilgenfeld, 1999; Palivec et al., 2017).  
In general, the T3 Rf3 hexamer and R6 hexamer have a similar arrangement to 
the classical T6 hexamer. The equilibrium of these three structural families is 
largely affected by the concentration gradients of salts and phenolic ligands 
(Brange et al., 1997; Berchtold and Hilgenfeld, 1999; Weiss, Michael, Steiner 
and Philipson, 2014a). More importantly, in the presence of phenolic ligands, 
the R6 hexamer of insulin in solution was reported to be the most 
thermodynamically stable structure (Gast et al., 2017; Maikawa et al., 2020; 
Derewenda et al., 1989; Wollmer et al., 1987). Whereas, the T6 hexamer 
resembles the solution structure of insulin as a monomer in solution (Fili et al., 
2015; Maikawa et al., 2020; Hua et al., 1996). T6 insulin hexamer has widely 
been employed as the prototypic insulin structure owing to its defined structural 
characters of hydrophobic, solvent-exposed, and potential binding surfaces of 
insulin (Mukherjee et al., 2018a; Liu et al., 2018; Weiss, Steiner and Philipson, 
2014). Commercially available insulin preparations are formulated at high 
concentration of 100Unit/mL (0.6mM) to 500Unit/mL (3mM), with the addition 
of allosteric ligands, such as Zn2+ and phenolic compounds or at neutral pH, 
thus promoting insulin to exist in its hexameric state. The standard structural 
unit of insulin hexamer is, therefore, typically present in all clinically used insulin 
injections to ensure sufficient shelf life for long-term storage (Rege et al., 2018; 
Maikawa et al., 2020; Gast et al., 2017). However, it is emphasised that the 
monomeric state is essential for the instantaneous action of insulin. 




of dissociation to monomer insulin after SC injection are two key features in 
the development of clinically used insulin formulation.  
There are various types of clinically used insulin pharmaceutical preparations 
(namely rapid-acting, short-acting and long-acting) that exhibit different 
dissociation rate and thus onset of insulin action owing to their excipient 
contents such as phenol or meta cresol (m-cresol), zinc oxide, glycerine, and 
protamine sulphate. It was reported that T6 and R6 insulin hexamers exhibit 
different dissociation rate, which is known to be the rate‐limiting step for SC 
absorption thus determining the onset of insulin action (Gast et al., 2017; 
Banerjee, Mondal and Bagchi, 2018; Liu et al., 2018). For instance, many rapid-
acting insulin analogues such as Novorapid® and Humalog® are formulated in 
excess Zn2+ to promote the T6 hexameric state (Maikawa et al., 2020; Gast et 
al., 2017). Whereas the addition of phenol or m-cresol stabilises the R6 insulin 
hexamer by forming hydrogen bonds between dimers (Maikawa et al., 2020). 
Phenolic ligands were traditionally employed in insulin formulations for their 
bacteriostatic properties. However, they were also found to facilitate the stability 
of insulin hexamer against deamidation and intermolecular cross-linking 
reactions (Weiss, Steiner and Philipson, 2014; Derewenda et al., 1989; 
Hilgenfeld et al., 2014; Maikawa et al., 2020). Besides having modifications to 
the insulin amino acid sequence, the content of zinc ions and phenolic ligands 
(phenol or m-cresol) also contributes to different onset of actions for each 
insulin analogue. For example, Apidra® (insulin glulisine) has asparagine at B3 
replaced by lysine and glutamic acid substituted for lysine at B29 to aid rapid 
absorption from the SC tissue. It is also formulated without Zn2+ to facilitate 
monomeric insulin formation and has been found to demonstrate slightly faster 
onset and peak of action than Novorapid® and Humalog®, but overall similar 
control of glucose levels (Donner and Sarkar, 2019a; Home, 2012; Maikawa et 
al., 2020). Nevertheless, since insulin binds to its receptor and imparts its 
biological effects as a monomer, the presence or adoption of the monomeric 
state of insulin (rate of dissociation) after SC injection is the most essential 
factor in the use of insulin replacement therapy for the treatment of diabetes 




or in combination, is to help patients with diabetes mellitus to mimic the 
physiologic pattern of insulin secretion by pancreatic -cells and thereby 
achieving at least approximately (~) metabolic homeostasis (Donner and 
Sarkar, 2019; Weiss, Steiner and Philipson, 2014; Hilgenfeld et al., 2014). 
1.2.2 The evolution of clinically used insulin pharmaceutical preparations  
Soon after the first use of isolated insulin extraction from the animal pancreas 
by Banting and Best for the administration of insulin replacement in a patient 
with T1DM in 1922, tremendous efforts were carried out to obtain pure and 
crystalline insulin preparations. Although the first administration resulted in a 
slight reduction in BG levels, no clinical benefits and severe local reactions, 
including abscesses were also observed owing to the insulin extract impurities. 
Thanks to Collip, who subsequently provided a better extract of insulin with 
higher purity for further testing. It was reported that frequent administration to 
the same patient over the first 24h of insulin treatment resulted in immediate 
improvement, with BG levels dropping from 28.9 mmol/L to 6.7 mmol/L and 
glucose excretion reducing from 71.1 to 8.7 g. Ketonuria was also eliminated, 
following improvements in associated symptom. This purer and more consistent 
extract of insulin resulted in fewer injection-site reactions, emphasising the 
importance of purification to obtain an insulin extract as pure as possible 
(Vecchio et al., 2018; Wright Jr, 2020; Zimmerman, Forlenza and Schatz, 
2020). Since then, there has been a high demand in the manufacturing of 
insulin worldwide owing to its life-saving properties for the treatment of T1DM, 
thereby urging the development of improved large-scale production and 
purification techniques. The initial approach was to establish the manufacture of 
bovine and porcine insulin. However, the scaling up in productions of insulin has 
encountered numerous challenges owing to the heating process for alcohol 
evaporation. This process often destroyed some of the insulin products thus, 
leading to a reduction in yields and potency comparing to the original extract. As 
a result, the production of insulin during this time was inconsistent, with wide 
batch-to-batch variation in potency, meaning a close monitor of the treatment 
was crucial. The problem was overcome in 1922 when both Walden and 




method of insulin purification under mildly acidic conditions. By adjusting the 
solution to insulin’s isoelectric point, the production of insulin at a higher purity 
with reduced batch-to-batch potency variation has been successful. By 1925, 
there were 12 different pharmaceutical companies producing insulin, 
highlighting the enormous global demand for insulin (Karamitsos, 2011; 
Didangelos, 2011; Hilgenfeld et al., 2014; Heinemann et al., 2019). 
After the achievement of crystallised insulin on a large-scale production, it was 
understood for several years that many pharmaceutical companies could 
produce principally pure insulin formulated in pharmaceutical preparations from 
the animal pancreas. Meanwhile, HI extract from human cadaveric pancreases 
had been available in small quantities since the 1960s. However, due to the 
limited availability in quantity, it was mainly used as reference material in insulin 
radioimmunoassay or physicochemical identity tests. Alternatively, it was also 
used clinically in a restricted manner for skin-testing of insulin-allergic 
individuals, pharmacokinetic studies and short-term clinical studies (Hilgenfeld 
et al., 2014). By the late 1960s as many important analytical methods such as 
partition chromatography and gel filtration were developed, it became 
progressively clear that insulin purified solely by crystallisation also contained 
impurities. Steiner et al.,1968 later identified these impurities with a higher 
molecular weight than that of insulin to be mainly proinsulin, proinsulin 
intermediates and a covalent insulin dimer. For many years after the 
identification of impurities in animal insulin pharmaceutical preparations, great 
efforts were commenced to produce a synthetic version of HI in the belief that 
HI was preferable to animal insulin (Heinemann et al., 2019; Baeshen et al., 
2014; Brange and Volund, 1999; Vecchio et al., 2018).  






Figure 1-7: Timeline development of clinically available human insulin injections. 
Newer generations of insulin analogues have been developed to further 
improve on many features of an ideal basal insulin regime. These include 
protracted duration of action beyond 24h without possessing an action peak, 
having little intra-individual and inter-individual day-to-day variability of action, 
and minimal risk for inducing hypoglycaemia and incurring weight gain. 
However, the inherent ability of insulin therapy to cause hypoglycaemia is still 
recognised as a major drawback in achieving tight glycaemic control in most 
insulin-requiring patients. Hypoglycaemia is an important adverse event that 
can potentially impair the patient’s quality of life while imposing other burdens 
such as costly complication. Moreover, nocturnal hypoglycaemia, which occurs 
during sleep, is particularly dangerous since patients (especially children) are 
unlikely to recognise symptoms or awake during an episode (Eliaschewitz and 
Barreto, 2016; Standl and Owen, 2016a). 
Table 1-4 summarises different types of clinically used insulin preparations that 
are currently available in the UK for the treatment of insulin-dependent patients. 




Table 1-4: Summary of clinically used insulin preparation currently available on the NHS, UK (The information was largely taken from online BNF, EMC 
and NICE guideline NG17) 

















1 and 4h 
30 to 60min  Up to 9h For maintenance regimens 














~ 2–5h For maintenance regimens 
Administration immediately before meals. 
Avoiding routine use of post-meal injections  
Associated with poorer glucose control, increased 










30min-2h Within 10min 3-5h For maintenance regimens 
Administration up to 2min before meals or up to 
20min after staring the meal. 
Fiasp® has a quicker onset of action and shorter 













3–12h ~ 1–2h 12-18h and up to 
24h depending on 
the ratio mixed with 
rapid-acting insulin   
Maybe given as one or more daily injections 
alongside separate meal-time short-acting insulin 
injections, or mixed with a short-acting (soluble or 








No peak  90min Up to 24h 
16-24h 
Both provide insulin cover for 24h, independent of 
mealtime. 










No peak 90min 
 
Up to 6h 
Up to 24h 
 
Up to 36h 
Both provide insulin cover for 24h, independent of 
mealtime. 




Overall, after the introduction of insulin replacement therapy nearly a century 
ago for insulin-requiring patients, improvements for this therapy remain a major 
attention to achieve good glycaemic control. Despite continuous efforts and 
improvements in the development of various insulin analogues serving as bolus 
and basal insulin to mimic the normal physiological activity of endogenous 
insulin, the risk of hypoglycaemia remains the most challenging obstacle for the 
evolution of insulin therapy to overcome. Nevertheless, the introduction of 
insulin glargine and insulin detemir as long-acting insulin analogues has 
showed notable improvement with a significant reduction in the risk of 
hypoglycaemia, especially nocturnal, compared with earlier-developed 
intermediate-acting insulin analogues (Swinnen et al., 2010; Standl and Owen, 
2016b; Ratner et al., 2013; Rosenstock et al., 2013). The most recently 
available new ultra-long-acting basal insulin analogues namely insulin degludec 
and the more concentrated insulin glargine U300 both exhibit superior 
pharmacokinetic/pharmacodynamics (PK/PD) properties with an even more 
prolonged action lasting beyond 24h and a much lower variability compared 
with other clinical used basal insulin preparations (Riddle et al., 2014; Mathieu, 
Gillard and Benhalima, 2017; Tambascia and Eliaschewitz, 2015). In addition, 
the development of a more concentrated formulation of soluble HI (Humulin R® 
500Unit/mL) has also been beneficial for patients with severe insulin resistance 
that might require significantly higher insulin dose than others (Dashora et al., 
2016; Heinemann et al., 2019). The main clinical benefits of these recently 
developed basal insulin including the flexibility of insulin administration timing 
and the lack of weight gain or even weight loss have contributed to an overall 
improvement in health-related quality-of-life for numerous insulin-dependent 
patients. 
1.2.3 Insulin routes of delivery 
Because gastrointestinal enzymes can quickly inactivate insulin, the ideal route 
of insulin administration has always been to bypass this effect while still 
mimicking the normal physiological delivery of endogenous insulin and so far, 
insulin delivery directly into the systemic circulation, i.e., by injection is the most 




administration is the most common and standard route of delivery for 
exogenous insulin injections. In general, insulin is injected into a body area with 
plenty of SC fat, usually the abdomen which has the fastest absorption rate or 
outer thighs/buttocks. Insulin absorption from a limb site can vary considerably 
(20–40% in both inter- and intra-day), particularly in children. In addition to the 
effect of various insulin formulations, the rate of insulin absorption is also 
affected by numerous environmental factors including local tissue reactions, 
injection site and depth, blood flow, changes in insulin sensitivity and the 
amount of insulin injected. Furthermore, increased blood flow around the 
injection site due to exercise can also increase insulin absorption (Taylor et al., 
2016; Donner, 2015; Shah et al., 2016; Zhang et al., 2018; Matteucci et al., 
2015). There is an increasingly high demand for delivering insulin in the least 
invasive or non-invasive way with most physiologically acceptable method while 
still maintaining accuracy and preciseness to reduce patient burden. Table 1-5 
summaries different approachable routes for insulin delivery that are currently 





Table 1-5: Characteristics of different routes for insulin delivery (Information was largely collected from Shah, R. B. et al., 2016; Matteucci et al., 2015; 
Zhang et al., 2018; Mikhail, 2016) 
Routes of 
insulin delivery 
Advantages Disadvantages Clinical remarks 
SC  Vial and 
syringe 
Instant delivery of insulin when required More pain; Patient unfriendly 
Psychological issues  
Inconvenient to carry around 
Reduce accuracy compared with pen 




Convenient, easier to use, shorter needle; 
Reduce pain, more accurate and precise 
compared with the syringe. 
More expensive than the syringe 
Two insulin types cannot be mixed 




Greater flexibility with meals, exercise, and 
daily schedule improved physical and 
psychological well-being continuous delivery of 
insulin for smoother glycaemic control  
Risk of infection  
More frequent hypoglycaemia  
Higher risk of developing DKA  
Constant physical reminder of diabetes 
The computerised device can be faulty 
Certain criteria need to be met before commencing 
insulin pump treatment. 
Need patient education and motivation 
Better glycaemic control, however, requires 
contentious CGM (continuous glucose monitor) 
Oral  Most preferred form; Non-invasive 
Delivered directly to the liver via the portal 
circulation. 
Extremely low bioavailability due to GI 
degradation of insulin. 
Unpredictable and inconsistent absorption. 
Variable bio-efficacy.  
No oral insulin formulation is commercially available.  
Very few clinical trial reports with human data 
Buccal Patient-friendly 
Bypass GI degradation of insulin 
Non-invasive 
Increase portal insulin concentration 
Poor bioavailability Oral-lyn approved by FDA in 2009 under the 
Treatment Investigational New Drug program. 
Data still lacking appropriately designed and 
performed phase II and III trials 
Intranasal No interfere with pulmonary function  
Non-invasive 
Increase portal insulin concentration 
Nasal & local irritation 
Reduced bioavailability (15-25%) 
Nasulin is still undergoing phase 3 trial 
Inhale  Rapid absorption due to the large surface area 
(~145 m2) and the close proximity of the air 
and blood compartments 
Non-invasive 
Reduced bioavailability 
Inhalational device issues 
Transient cough 
Reduced lung function  
Exubera was withdrawn from the market in 2007 due 
to low cost-effectiveness. 
Technosphere insulin (Afrezza) was approved by the 
FDA in 2014. 
Uncertainties about efficacy and safety remain in 
addition to considerably higher cost may result in 
termination  
Intraperitoneal Direct delivery to the portal vein 
More physiological  
Invasive; Increased cost, risk of infection and 
portal vein thrombosis. 
Long-term data not available 
Transdermal Non-invasive, needle-free  Inefficient passive insulin absorption through the 
skin  
Skin irritation, blister formation and redness 
No long-term trials 




1.3 Development of an artificial pancreas as a possible treatment option 
for people with T1DM and T2DM. 
Although it is generally accepted that there is no cure for diabetes mellitus 
especially in those require exogenous insulin at present, significant time and 
efforts have been put in all over the world with an attempt to bring insulin 
replacement therapy as close as possible to mimic the normal endogenous 
insulin release profile and action to achieve good glycaemic control. To date, 
the overall development of insulin treatment covering various types of insulin 
analogues and route of delivery has been targeted to minimise hypoglycaemia 
episodes experienced by patients while maintaining a good PK/PD profile of 
exogenous insulin equivalent to normal physiology (Owens and Bolli, 2020; 
Kovatchev, 2019). Principally, the type of control provided and the site at which 
insulin is delivered would indicate different methods of insulin delivery classified 
as open-loop and closed-loop. The open-loop insulin delivery relies on patients 
administering insulin to themselves at different times of the day whereas the 
involvement of patients in maintaining glucose control is minimised in the 
closed-loop method. Although the SC insulin injection remains the most 
common method of open-loop insulin delivery, further improvement involves the 
development of the external insulin pump that can provide a basal insulin 
throughout the day. Notably, all open-loop delivery systems require the 
involvement of patients or physicians to take BG measurements and consider 
meal consumption in order determine an empirical estimate of the insulin 
requirement (Owens and Bolli, 2020; Farmer Jr, Edgar and Peppas, 2008a; 
Taylor, Sahota and Chauhan, 2019). 
One of the most cutting-edge technology in the development of insulin 
replacement therapy is the introduction of a closed-loop delivery system, 
referred to as an artificial pancreas. As its name suggests, this system uses 
man-made technology to mimic the way a pancreas works so that insulin is 
released in response to changing BG levels as similar to normal physiology. 
Ideally, this system would be able to determine the insulin requirement in real-




Donner, 2015). Currently, there are three main artificial pancreas systems being 
studied as summarised in Table 1-6 
Table 1-6: Summary of currently studied artificial pancreas systems (Information is taken from 


















Horizon 2020 trial to 
assess the efficacy of 
the device in children. 
The system includes an externally worn 
insulin pump communicating wirelessly to 
a CGM worn as a patch on the skin. The 
CGM measures BG levels and the result is 
fed into a small computer which calculates 
the required dose of insulin to be delivered 









FDA approval in 2018 to 
begin recruitment for 
home-use studies testing 
the insulin-only 
configuration of its iLet 
bionic pancreas system 
in a series of ground-
breaking trials in adults 
and children with T1DM 
This automatic BG control system 
comprises two pumps which deliver insulin 
and glucagon respectively. The pumps 
connect with an iPhone app via Bluetooth 
enabling communication between the 
CGM device that help make automated 
dosing decisions about insulin and 
glucagon every five minutes based on the 












in glycaemic control has 
been achieved in 
diabetic rats and pigs. 
Human trials are still 
waiting to be 
commenced. 
The implantable insulin delivery device 
features a smart gel as part of the insulin 
reservoir that is responsive to changes in 
BG levels. When BG levels are elevated, 
the viscosity of this glucose-sensitive gel 
drops to enable a rapid release of insulin; 
during low BG levels, the gel remains 
intact to prevent insulin being released. 
The implantable system could be refilled 




Two of the artificial pancreas systems represented commercially and in clinical 
studies comprise an electronic sensor and pump for SC insulin delivery. 
However, the implantable artificial pancreas developed by Taylor et al. 
represents a different innovative system wherein the sensor and delivery 
system are principally the same component. This device, namely the INsmart, 
was developed based on a reservoir that insulin can deliver through a smart gel 
as a function of changing glucose environment. The smart gel is formulated to 
exhibit a fast gel-sol transition with a response specifically to glucose (detailed 
in chapter 5). The device is completely implantable in the peritoneal region 
between the lowest rib and the hip and can be refilled with insulin every few 
weeks via SC ports accessible on the skin surface. The closed-loop device is 
proposed to respond rapidly to the presence of glucose in the blood and allow 
accurate administration of insulin dose, providing that the fast equilibration 
between glucose from blood to peritoneal fluid and insulin from peritoneal fluid 
to blood is achieved. Other advantages of this device include no electronic or 
moving parts; simple to implant and easily refillable; without the need for 
additional immunosuppressant therapy; not visible externally therefore socially 
preferable over the external portable pump (Taylor et al., 2016; Jacob, 2015). 
The in-vivo performance of this intraperitoneal (IP) implantable artificial 
pancreas was first assessed in induced-diabetic rats using a simpler version of 
the device. The performance of this closed-loop insulin delivery system was 
compared over time in diabetic rats against a control system following a 
protocol that involves the introduction of several glucose challenges and daily 
assessments of blood glucose level and body weight. Following daily 
assessment and challenging with large glucose doses, successful glycaemic 
control was observed in the device containing active gel compared with an 
inactive gel analogue which served as a control. It was estimated that the 
outputting response every hour from the device was ~ 0.5 Unit/kg for basal level 
with 2 Unit/kg to match the demand of high glucose challenges.  Notably, this 
apparently high dose rate was tolerated because the metabolic rate in rats is 
higher than humans. Eventually, the device was exhausted of insulin, thus 




study, the rats were implanted and recover post-operatively with a low insulin 
output from the device when the diabetic stage had not yet been introduced, 
whereas insulin delivery should ideally start after recovery when the rats were 
rendered diabetic. However, since the rats would have normal BG which would 
not result in a significant drop in the gel viscosity to trigger high insulin release 
from the device (Taylor, Tanna and Sahota, 2010)  
Moving forward, it was necessary to scale up the device to apply to human 
trials. Consequently, the improved device engineered with filling circuit was 
surgically implanted to the IP region of domestic pig. In this case, the weight-to-
weight insulin requirement of the pigs was essentially the same as for humans. 
The surgery was developed and diabetes in pigs was induced using 
streptozotocin on day 4 of the observed period, and BG levels were ensured to 
reach at least 33 mmol/L on day 15 before filling the device in situ with insulin 
solution via the subcutaneous ports. There was normal access to food and 
water with the addition of several oral glucose challenges at weekly intervals 
while the animals were observed for over 60 days (Taylor et al., 2016).  
Preliminary data for insulin delivery to induced-diabetic pigs using IV multiple-
dose injection (MDI) in both fasted and fed state were initially collected to 
investigate the basal dose needed and the boost dose requirement for 60g oral 
glucose challenges. It was reported that a fasted pig of 35 kg would need a 
dose of 40–50 Unit/day (loading dose, then 2 Unit every hour) of soluble insulin 
to reduce BG from >30 mmol/L to between 5 and 10 mmol/L while exposing to 
hypoglycaemia before the glucose challenge.  Whereas in the freely fed pig, 60 
to 170 Unit/day doses (2.5–7 Unit/h) was insufficient for basal needs. An 
additional 3–5 Unit dose prior to the boost doses (in non-fasted animals) given 
before or at the time of the glucose challenge was insufficient to control the 
eventual glucose-induced surge, even in the higher basal dose (7 Unit/h) 
regimen. Furthermore, the timing was critical in which a 5 Unit boost dose given 
50min before glucose challenge produced profound hypoglycaemia, whereas a 
similar dose given immediately before the glucose aggravated a 
hyperglycaemic state. Despite much surgical practice, only one successful kick 




successful open-loop regimen with insulin. However, the same pigs were not 
used subsequently for the assessment of the closed-loop system (Taylor et al., 
2016).  
Meanwhile, the results from the implanted pig illustrated that BG levels were 
successfully reduced from over 33 to under 10 mmol/L within five and a half 
days after filling the device with regular HI (Humulin® R 500Unit). Glucose 
challenge responses also demonstrated progressively well glycaemic control in 
which the increased BG levels observed after introducing high oral glucose 
challenges (60g) were normalised within 35 min. It was also highlighted that 
hypoglycaemia was less likely with IP dosage compared to IV injection because 
of the short half-life in the peritoneal and hepatic environment. After the removal 
of residual insulin solution on day 11 of good glycaemic control, the occurrence 
of diabetic BG levels above 33mmol/L was observed only after a further 24 
days. This implies that a depot of insulin had remained after insulin reservoir 
removal, most likely due to insulin precipitation in the smart gel, which was 
released over time until complete exhaustion. Based on the assumption that 
about 3 Unit/h were delivered over the seven loading dose days, an average 
dose of ~ 62.5 Unit every 24h was required to control diabetes from day 21 to 
day 52, including the increased output necessary to meet the high demand of 
large oral glucose challenges. This highlights the successful performance of the 
automatic bolus system without the need for manual insulin injection 
intervention. The study showed that the implantable artificial pancreas 
adequately controlled the basal and bolus needs for more than four weeks 
without any manual insulin adjustment (Taylor et al., 2016; Jacob, 2015). It 
could be arguable that there was still some pancreatic input from the tested pigs 
to support their basal and bolus needs, not just from the exogenous insulin held 
in the device. This can be justified by doing a C-peptide test to confirm if there 
was any endogenous insulin produced. However, since the BG levels went 
soaring up again when the device was empty, it was confirmed that the pigs 
were indeed fully diabetic and would have to rely on the device to meet their 




1.4 Fluorescent labelling in bioanalytical applications 
1.4.1 Fluorescence process and detection 
Along modern technology evolution, there has been a wide range of analytical 
tools developed to gain an understanding of intracellular dynamics and function 
at a molecular level. Some analytical methods widely used in various 
applications include absorption spectrometry, fluorescence spectrometry and 
chemical luminescence. In particular, fluorescence spectrometry offers highly 
sensitive and straightforward analysis of non-fluorescent biological molecules of 
interest. Fluorescent probe has become an indispensable tool in biotechnology 
laboratories as it can offer high sensitivity and selectivity in the detection of 
specific components from complex bio-molecular assemblies, such as live cells 
(Suzuki and Yokoyama, 2015). Generally, fluorescent molecules can be used 
directly or labelled onto other molecules of interest to investigate the locations 
or structural changes of certain assemblies within the cells. They can also be 
used to visualise the presence of individual membrane constituents on the cell 
exterior for the identification purpose. Alternatively, they are also utilised for the 
verification of various cellular activities such as enzyme action (Crivat and 
Taraska, 2012; Yue et al., 2019; Wang et al., 2017; Prakash and Rajeswari, 
2014; Jensen, 2012). 
Fluorescence is usually described as an event where certain molecules referred 
to as fluorophores or fluorescent dyes absorb, then emit light.as a result of a 
three-stage process as demonstrated in Error! Reference source not found. 
 
 
Figure 1-8:Fluorescence process showing the energy difference of excitation state (1) when a 
molecule absorbs light as energy and remains as its excited state (2) then emits light in the form of 




Within the excitation stage, the fluorophore absorbs a photon of energy from an 
external source such as an incandescent lamp or a laser, thus raising the 
energy level of the fluorophore (its electron) to an excited state. Interestingly, 
this process enables the distinction between fluorescence and 
chemiluminescence, in which the excited state is stimulated by a chemical 
reaction. The excited state then exists for a finite time typically 1–10 
nanoseconds. During this short period, some of the energy gained from the 
fluorophore is dissipated by interactions with its molecular environment or 
transferred to a proximal molecule. A photon is then emitted from the remaining 
lower energy to bring the excited fluorophore back to its ground state. This 
associated energy release is known as fluorescence emission (Lakowicz, 2013; 
Bernard Valeur and Mario Berberan-Santos, 2012). Due to the higher energy 
relaxation mechanism, the energy of this emission photon is lower, and of 
longer wavelength than the excitation photon absorbed by the fluorophore in the 
first stage. For example, if the absorbed light was blue (shorter wavelength) 
then green light (longer wavelength) will be emitted. Fluorescence emission, 
therefore, represents the loss of energy from excited state back to ground state 
that accompanied by the output of radiation such as light. The resultant 
energy/wavelength difference between the excitation and emission states is 
described as Stokes shift, which affects the sensitivity of fluorescence detection. 
This is because it allows the detection of emission photons against a low 
background, distinct from excitation photons. Notably, a massive Stokes shift 
can prevent the reabsorption of emitted photons, allowing higher contrast in 
fluorescent imaging. (Haugland, 2002; Gan et al., 2020; Lakowicz, 2013; Fu and 
Finney, 2018). Principally, the same fluorophore can repeatedly be excited and 
detected (a cyclical fluorescence process) providing that it is not irreversibly 
destroyed (Detail in the next section). It is, in fact, the ability of a single 
fluorophore to emit numerous detectable photons through this cycle of 
excitation and emission that gives fluorescence detection its high sensitivity and 
repeatability in various research applications (Limpouchová and Procházka, 




Generally, fluorescence spectral data are shown as emission spectra (plots of 
the fluorescence intensity against wavelength or wavenumber). They can vary 
widely depending on the chemical structure of the fluorophore and the 
dissolving solvent (Lakowicz, 2013). Beside those definable factors including 
the intensity of excitation source and the instrument efficiency for fluorescence 
collection, the brightness (fluorescence output) of a given fluorophore is also 
affected by its chemical properties. These include the efficiency of how it 
absorbs and emits photons, as well as its ability to undergo repeated 
excitation/emission cycles. Absorption and emission efficiencies are therefore 
the most useful quantifications for determining fluorescence output. 
Fluorescence quantum yield (QY) presents the number of emitted photons by a 
fluorophore relative to the number of absorbed photons. Fluorophores with a 
large QY, approaching unity, such as rhodamine will display a bright emission 
(Wang et al., 2019; Lv et al., 2020; Lakowicz, 2013). The value of molar 
extinction coefficient (EC) for absorption efficiency indicates how effectively the 
fluorophore absorbs light, specifically at a single wavelength (usually the 
absorption maximum). It is defined by the Beer-Lambert law as A = EC•c•l, 
where A = absorbance, c = molar concentration, l = optical pathlength. Overall, 
fluorescent intensity/brightness of a given dye, which is an important feature for 
the selectivity of suitable fluorescent probes, is determined by the product of EC 
(at the relevant excitation wavelength) and fluorescence QY (Thorn, 2017; 
Villamena, 2017).  
1.4.2 Fluorescent labelling methods and choice of fluorescent probes  
Fluorescent labelling is a process in which biomolecules of interest such as 
proteins are covalently tagged by fluorescent probes so that they can be 
visualised by fluorescence imaging. Here, the fluorescent signal represents the 
position of the tagged molecules as the label is covalently bonded and does not 
detach easily. Nowadays, fluorescent labelling method is widely used for 
detection purpose in many bioanalytical applications and often supersedes the 
use of radiolabelling. This is because it can offer a more stable, highly sensitive 
(even at low concentrations), safer, easier and inexpensive alternative over 




same time (Santos et al., 2020; Man, Gawne and de Rosales, 2019; Fu and 
Finney, 2018). Furthermore, its additional properties such as sensitivity to the 
environment i.e. pH, visibility against a dark background and fluorescence 
lifetime also offer many more applications. One most significant advantage of 
fluorescent labelling over radiolabelling is that it does not damage the targeted 
molecule’s structure and is therefore preferable in many live-cell studies 
(Jameson and Ross, 2010; Wysocki and Lavis, 2011). 
Another key consideration is the brightness of the fluorescent tag, which is 
typically assessed based on its fluorescent intensity as detailed in section 1.4.1. 
In general, a larger value indicates a brighter fluorescence output. In addition, 
the fluorescent intensity can also be affected by the surrounding environment of 
the tagged protein (pH or salt concentration). It is well established that the 
fluorescent tag of many proteins is quenched at low pH, thus can cause 
problems when analysing in acidic environments (Shinoda, Shannon and Nagai, 
2018; Stoddard and Rolland, 2019; Thorn, 2017). Another related issue is the 
photo-stability of the fluorescent tag. All fluorescent molecules can undergo side 
reactions when repeatedly excited that may result in the destruction of a 
fluorophore, leading to loss of fluorescence over time, described as 
photobleaching. How rapidly this occurs is nonlinearly dependent on the 
excitation light intensity and the illuminated period of a fluorophore, thus the 
experimental design is equally important for consideration. Furthermore, the 
effects of the tag on the protein including size, solubility, biological activity or 
partition coefficient must also be considered to ensure the normal activity of 
native proteins is minimally affected. (Thorn, 2017). 
The first-ever used fluorophore synthesised in 1871 was fluorescein (FSC) 
which exhibits excitation at 490 nm and emission at 514 nm. It is made up from 
two xanthene moieties, each of which contains two benzene rings joined 
together by a pyran ring (Nishi et al., 2015; Ikeno, Nagano and Hanaoka, 2017). 
To improve its biological, chemical and fluorescent properties and especially its 
stability, various forms of FSC derivatives have been synthesised such as 
Oregon Green, FITC, fluorescein diacetate and carboxyfluorescein (Zheng et 




eosin Y, erythrosin and rose bengal (Zhang, Zhang and Liu, 2014). FSC and its 
derivatives have been the most commonly used reagents for covalently labelling 
proteins via their amine-reactive groups owing to their availability for several 
decades and relatively cheap and straightforward labelling methods. Another 
remarkable point for these labelling candidates is that their conjugates are not 
exceedingly susceptible to precipitation at physiological pH and can be 
prepared in high purity. However, in addition to their excellent water solubility 
and fluorescent quantum yield as well as relatively high absorptivity, FSC-based 
dyes and their conjugates are highly pH-dependent and prone to 
photobleaching. Regardless, their applications are broadly limitless in various 
bioassays/biomaterials and life science. These include cell assays such as flow 
cytometry or fluorescent microscopy, FRET-based assays, probing (fluorescent 
hybridisation) as well as microarray/biochip assays (Crivat and Taraska, 2012; 
Prakash and Rajeswari, 2014; Sahoo, 2012; Aderinto, 2020). 
Similarly, alternative fluorophores like rhodamine and its derivative such as 
tetramethylrhodamine isothiocyanate (TRITC) were also extensively used in 
various bioassays/biomaterials including cell assays (fluorescent cytomics), 
probing and microarray/biochip assays (Zheng et al., 2013; Nishi et al., 2015). 
To improve photo-stability and increase brightness, newer candidates such as 
AlexaFluor and DyLight Fluor dyes were also developed. In addition to having 
greater photostability and brightness, they are also more advantaged with lower 
pH sensitivity than conventional dyes while maintaining comparable 
excitation/emission profiles. However, they are relatively more expensive. 
These newly developed AlexaFluor dyes have been used in various 
bioassays/biomaterials, such as biosensing (magnetic modulation biosensing), 
probing (small molecule fluorochrome assay) and microarray/biochip assays 
(Kobayashi et al., 2009; Li, Tebo and Gautier, 2017; Sabnis, 2015). Overall, the 
availability of various fluorescent probes and improving properties of newly 
developed probes have enabled great flexibility in selecting a fluorophore of 
choice for specific bioanalytical applications which are increasingly growing 




1.4.3 The use of fluorescent probes for detection techniques in bioanalytical 
applications 
Fluorescence-based assays have become increasingly useful for the study of 
numerous biological processes down to single cellular level since the first use in 
the early 1900s to stain tissues, bacteria, and other pathogens for various 
biological investigations. The movement of individual proteins in real-time can 
also be visualised through the fluorescent assay. Nowadays, there have been 
numerous applications of fluorescence-based technology such as metabolic 
enzymes and DNA sequencing as well as investigation of biomolecule 
dynamics cell signalling and adaptation (Alam, Vedaei and Wahid, 2020; Khan, 
Fortunato and Leiknes, 2019). For example, the use of fluorescence in situ 
hybridisation (FISH) has enabled the identification of specific DNA sequences in 
cells to detect numerical and structural abnormalities of chromosome (Cui, Shu 
and Li, 2016) or the use of genetically encoded fluorescent probes (GEFPs) to 
investigate metabolic alterations in cancer (Depaoli et al., 2019). All of these 
have contributed greatly towards the understanding of various disease stages 
like in neurodegenerative diseases and liver metastasis, thus providing data to 
help with possible treatment (Zhou et al., 2020; Werner et al., 2019; Lavaud et 
al., 2020).The high selectivity of fluorescent probes to target specific organisms 
has also led to new paths for resolving many industrially and medically related 
problems in areas like public health, the safety of foods and environmental 
monitoring. For instance, fluorescence imaging is particularly useful in tracking 
drug delivery both in-vitro and in-vivo for advanced drug development as well as 
diagnosis of disease including cancer (Zavvar et al., 2020; Dong et al., 2020). 
Due to its preferably non-invasive approach, the use of fluorescent technology 
for molecular imaging is widely considered the future for medical imaging (Sano 
et al., 2012; Kobayashi et al., 2009; White and Errington, 2005; Thorn, 2017). 
Overall, the increasingly indispensable use of fluorescent molecule as a tool for 
detection techniques has become the standard in many bioanalytical 
applications especially those of interest in biomedical research. Table 1-7 





Table 1-7: Summary of some remarkable applications of fluorescent-based technology. 











Two-colour activable fluorescent probes administered as a 
cocktail enabled multi-colour target-specific fluorescence 
breast cancer imaging. The images have visualised a 
specific receptor expression in each breast tumour without 
post-image processing. It is useful for in-
vivo characterisation of breast cancers. 
(Sano et al., 
2012) 





dextran 70 kDa 
(HCD-70K) 
The development of a bright blue fluorescence dextran has 
been proven to be advantageous for stable vascular 
visualisation and detection of blood leakage, especially in 
combination imaging with red- and green-labelled pathogens 
and immune cells. 




FITC FITC-Ghrelin The use of FITC labelled ghrelin has enabled the 
visualisation of ghrelin uptake by cells of the blood-
cerebrospinal fluid (CSF) and the quantification of ghrelin 
diffusion onto the periventricular tissue of the brain where it 
can mediate rapid effects. 




processes at a 
molecular level in 
living cells 
Rhodamine B Rhodamine B-
pentacyclic 
triterpenes 
Achievement of a direct visualisation of the antiviral 
mechanism (by targeting influenza HA protein) of pentacyclic 
triterpenes and the confirmation of their accumulated 
location after being taken up by MDCK cells. 
 (Li, M. et 
al., 2020)  
In-vitro and In-vivo 
study of drug delivery 





ICG labelled aptamer 
(AS1441) 
ICG labelled AS1441-
C8 ligand conjugate. 
 
AS1441-ICG complexes were used as fluorescent tracers to 
track their accumulation in tumoral cells and a melanoma 
mouse model to investigate the biodistribution of anticancer 
C8 ligands. 
AS1441-ICG is promising drug delivery agents for targeting 
tumoral cells in melanoma cancer models. 
 (Lopes-












The use of FISH technology enabled the detection genetic 
disorders from chromosomal abnormalities to sub-
microscopic copy number variants (CNVs) and the extension 
of the cell-based analysis from metaphases to interphases 





1.4.4 The use of fluorescently labelled insulin in biochemical research and drug 
delivery 
Since the discovery of insulin over a century ago, insulin remains as one of the most 
intriguing molecules of interest and has been studied extensively owing to its 
indispensable role. It has a small molecular weight yet possessing the typical 
structural features of many larger proteins. Various approaches have been carried 
out worldwide to study insulin at molecular and cellular levels. These include insulin 
structural configurations, its synthesis and release from the pancreatic β-cells, the 
binding mechanism to its receptors, its biological activity as well as the delivery of 
exogenous insulin by various routes (Asthana et al., 2019; Wasko et al., 2020; 
Iannuzzi et al., 2017; Ferri et al., 2019). Fluorescently labelled insulin was used back 
in the 1960s to investigate the localisation of insulin in different tissues (Tietze, 
Mortimore and Lomax, 1962; Maggi, 1966). Up to now, it still plays an indispensable 
role in the study of insulin biodistribution and pharmacokinetics for advanced insulin 
delivery via various routes (Caprifico et al., 2020; Sudhakar et al., 2020). Moreover, 
in advanced drug development and delivery, fluorescence studies have clarified 
aspects such as biodistribution, stability and metabolism with respect to the 
complexities imposed by the biological systems. These include cell/tissue 
penetration, drug-target interaction, and the pharmacodynamic consequences, thus 
emphasising the usefulness of fluorescently labelled insulin in research and drug 
delivery (Sudhakar et al., 2020; Pandey et al., 2018; Lochhead et al., 2019). 
There have been several studies that use fluorescently labelled insulin to investigate 
the advanced delivery of insulin through various routes including oral, intranasal, 
transdermal and implanted artificial pancreas (Lee et al., 2020; Lochhead et al., 
2019; Chen, Shyu and Chen, 2018; Jacob, 2015). For instance, FITC- insulin was 
used to investigate the intracellular localisation of insulin in vitro through the delivery 
of bio-mineralised insulin nanoparticle (BINP) in a liver cell line. Interestingly, the 
intracellular delivery test showed that there was no detectable intracellular FITC 
signal in the control group (free FITC-insulin not formulated as bio-mineralised 
insulin nanoparticle) using insulin resistance induced human hepatoma (R-HepG2) 
cells, suggesting that free FITC-insulin in its molecular form was not able to enter 
cells. In contrast, intense green fluorescence was observed intracellularly when 




BINP were further quantified using flow cytometry and the result showed that 96% of 
the cells contained insulin within its intracellular fluid only after 30min of insulin 
stimulation. This value gradually reached 100% after 2h, suggesting that the cellular 
uptake of BINP in insulin-resistant cells was rapid and highly efficient. Although a 
therapeutic effect of BINP via the intraperitoneal route of delivery on long-term 
improvement of glucose metabolism was further confirmed in mice, it is still in 
question for the reason behind the inability of R-HepG2 cells to uptake any free 
FITC-insulin molecules despite showing 50% glucose metabolism of normal cells. 
Overall, the study offered an alternative strategy for T2DM treatment with insulin by 
introducing mineralisation of insulin with calcium ions to improve its intracellular 
delivery (Xiao et al., 2017).  
Lochhead et al.,2019 also used FITC-insulin to investigate the distribution of insulin 
in trigeminal nerve and brain via intranasal (IN) administration to rats. Although 
details in the production and identification of FITC-insulin species were not given, 
their fluorescent signal data suggested that insulin can be delivered to the brain via 
the nasal passages along the perineural spaces of the trigeminal nerve. Insulin 
distribution along cerebral perivascular spaces was also visualised after 30mins of IN 
administration. Their data suggested that insulin administrated via the IN route can 
reach the brain areas with high expression of insulin receptors (IR) like the cortex. 
Interestingly, the FITC-insulin conjugate used in the study was also confirmed by 
SDS-PAGE electrophoresis to be primarily monomeric, which is the biologically 
active form of insulin. However only native insulin was used to examine the 
activation of IR in brain cells and their Western Blot data illustrated significantly 
higher level of phosphorylated IR in the brains compared to the saline control. The 
study also indicated the uncertainty of using fluorescently labelled insulin to 
investigate the biological activity of insulin as certain modifications to the insulin 
molecule by the fluorophore may affect how labelled insulin bind to the IR. 
FITC-insulin has also been used to determine the different degree of labelling effect 
on the hydrophilicity and lipophilicity of the insulin molecule that may alter its 
permeability through a cell monolayer. They found that the unlabelled insulin and its 
mono-labelled conjugate with FITC demonstrated significantly higher transport than 
tri-labelled conjugate. It is proposed that the slight increase in permeation of mono-




decreased permeability of tri-conjugates may be contributed by the size increase by 
over 1000Da in molecular weight of tri-labelled FITC-insulin conjugate (Shah et al., 
2019). However, it is important to highlight that the low purity of the conjugates 
produced could jeopardise the interpretation of the results. 
Not only applied in insulin drug delivery, but a recent study also demonstrated the 
use of Alexa488- insulin to investigate the cellular behaviour and intracellular 
signalling properties of insulin with ageing. For the first time, the cellular journey of 
insulin has been fully explored in the liver cells of young and aged pigs from insulin 
signalling response, its internalisation dynamics (nuclear localisation), endocytosis 
pathway down to post-endocytic sorting of insulin and insulin receptor. It was justified 
from a medical point of view that pigs would be a better model to study the role and 
cellular biology of insulin compared to the rodent model, especially for insulin 
resistant with ageing. In addition, porcine insulin can also be used for human 
diabetes treatment and it only has one amino acid difference to HI. There are three 
key points highlighted in the study including the inability of insulin to enter the 
recycling endosome or translocate into the nucleus in aged pig hepatocytes, which 
suggested that their mechanism of insulin clearance is different compared to the 
young pig hepatocytes. The second point was the significant reduction in insulin 
signalling response with age. Lastly, there was a series of changes in the cell 
behaviour of insulin between the young pigs and the aged pigs, which could 
contribute to insulin resistance with ageing. The study has suggested a potential 
contribution to insulin resistance with ageing from a cellular level perspective (Li, S. 
et al., 2020). 
Overall, the use of fluorescently labelled insulin in research and drug delivery has 
become increasingly useful in the understanding of insulin kinetics profiles for 
advanced drug development because it can offer high sensitivity, ability to visualise 
high contrast image and reasonably inexpensiveness. Despite its numerous 
applications in advanced drug delivery development, there were very little studies 
addressing the quality and characterisation of the fluorescently labelled insulin being 
used. Chapter 2 covers important aspects of labelling modification to investigate the 
quality of FITC-insulin conjugate produced in-house. It is emphasised that the 
degree of labelling can affect the overall structure and activity of native insulin 
































In this chapter, the use of FITC as the fluorescent probe of choice for labelling 
insulin will firstly be discussed, followed by a general overview of insulin 
receptor structure and binding sites. Different commercial insulin products will 
also be presented with details about changes in their structure and formulation. 
There will also be a summary of key findings from previous studies on the 
synthesis of fluorescently labelled insulin conjugates. The practical work will 
involve screening most of the clinically used commercially available insulin 
preparations that have modifications in their amino acid sequences to select the 
best candidate for synthesising the desired Mono labelled FITC-insulin 
conjugate. The process of synthesis, purification and identification of FITC-
insulin conjugate will also be described. The objective is to modify specific 
reaction conditions such as molar ratio, reaction time and pH to produce the 
most biological active FITC-labelled insulin at the B1 position. 
2.1.1 FITC– the fluorescent probes of choice 
FITC is still the fluorophore of choice to label proteins and other biomolecules 
because of its relatively high absorptivity and excellent fluorescence quantum 
yield in aqueous media. Furthermore, its covalent conjugation with protein is not 
susceptible to precipitation. FITC is the derivative of FSC with an isothiocyanate 
(ITC) reactive group, which is reactive towards amine and sulfhydryl groups 
commonly found in biomolecules. FITC isomer I is more easily isolated in pure 
form and is, therefore, less expensive than the isomer II with the thiocyanate 
group on the 5-carbon atom of the benzene ring instead of 4 (Yan et al., 2017), 





Figure 2-1: Structure of Fluorescein isothiocyanate isomers (Taken from Fluorescent probes 
G.T. Hermanson 2013) 
FITC exists as a fine yellow-orange powder which is quite hygroscopic with a 
molecular weight of 389.4 Da. It is highly soluble in acetone (1mg/mL), in 
anhydrous dimethyl sulfoxide (DMSO) at 5 mg/mL and to a lesser extent at 9 
mg/ml in 2-methoxy ethanol and 20 mg/mL in ethanol. Although FITC is soluble 
in water at 0.1mg/mL, it rapidly decomposes; therefore, an organic solvent is 
preferable. Its ITC group reacts with amino-terminal and primary amines in 
proteins, forming covalently bonded conjugates (Figure 2-2) 
 
Figure 2-2: FITC reacts with amine-containing compounds (Taken from Fluorescent probes G.T. 
Hermanson 2013) 
FITC displays a maximum absorption excitation at 494 nm and emission at 519 
nm in the visible range of the spectrum. Owing to its closely matching maximum 
excitation with the 488 nm spectral line of the argon-ion laser, FITC is indeed an 
important fluorophore for flow cytometry applications and confocal laser-
scanning microscopy (Haugland, 2002; Johnson, 2019). It is widely applicable 




such as protein tracing and micro-sequencing of proteins. It is also used as a 
reagent in fluorescent antibody techniques for the rapid identification of 
pathogens as well as in medical practices like FSC angiography and FSC-
guided surgery (Rodríguez-Sáinz et al., 2013; Yeo et al., 2016; Lepore et al., 
2018; Acerbi et al., 2018). 
Despite being the most common fluorophore to covalently label proteins, FSC-
based dyes and their conjugates do have some drawbacks. Especially the high 
rate of photobleaching and pH sensitivity spectra between pH5 and pH8 could 
cause a problem to quantitative measurements. There have been no new dyes 
available that can completely solve photobleaching problems seen by FSC dyes 
although newer alternatives such as AlexaFluor 488 or Oregon green 488 are 
much more photostable and have less pH sensitivity in the physiological pH 
range. Nevertheless, FITC has remained as one of the most useful reactive 
dyes partly due to its well-established applications in research and medical 
practice but also because of the low cost and widespread availability of optical 
filter sets designed to efficiently excite and detect its fluorescence (Warrier and 
Kharkar, 2014; Yan et al., 2017). 
FITC conjugation with antibodies, proteins and clinical drugs have been widely 
used in many biological applications and research. However, their stability 
profiles have not been fully investigated and therefore it is difficult to establish 
how stable they are in various biological applications (Broadwater et al., 2019; 
Icha et al., 2017). So far, an extensive study by Reeves et al. 2012 was one of 
the very few that investigated the stability, safety and suitability of FITC-labelled 
conjugates using both in-vitro and in-vivo models. There was very little or no 
photobleaching (irreversible loss of fluorescent property) and phototoxicity 
(cellular damage caused by prolonged illumination with high laser power) 
observed in-vitro using their synthesised FITC-BSA conjugate compared to 
commercial products. A dorsal microcirculatory chamber implanted in rats was 
also used to examine whether varying the illumination duration and repeated 
administration of the synthesised FITC-BSA conjugate in conscious animals 
would lead to microvascular instability. The results showed that de-conjugation 




Repeated administration studies indicated that the FITC-BSA conjugate 
synthesised inhouse can be repeatedly administered to conscious animals at 
weekly interval without resulting in damage to the microcirculation. There was 
also no sight of long-term side effects reported (Reeves et al., 2012). 
Meanwhile, a more recent study by Salari et al. 2019 has examined the 
potential cytotoxic level of FITC-labelled nano-cellulose using a cellular gut 
epithelium model. The results showed that the FITC-tagged materials were not 
cytotoxic, and they also have comparable bioactivity to their native counterparts 
hence making them suitable for biological studies (Salari et al., 2019).  
Overall, the fluorophore probe of choice should ideally be small, stable, bright, 
non-toxic, reasonably inexpensive and do not interfere with the biological 
property of the tagged molecule. The chosen fluorophore should also be 
selectively specific, able to label multiple proteins at the same time and have no 
tendency to oligomerise (Toseland, 2013). However, it may not always be 
possible to achieve all criteria of an ideal label for a specific experiment. Despite 
some drawbacks in photobleaching and pH sensitivity, FITC is the best 
compromise for this project, considering it is relatively cheap and widely 
applicable in various studies, therefore providing adequate background 
information to its suitability. 
2.1.2 Insulin receptor structure and binding sites on the insulin molecule. 
Many studies of insulin analogues have enabled mapping of the interactive 
residues on the surface of the molecule. These demonstrated how the 
authenticity of insulin folding could affect its activity. It is necessary to highlight 
the importance of certain insulin residues involved in insulin-insulin receptor 
recognition and binding for understanding the impact of fluorescent labelling on 
specific sites of the insulin molecules and therefore affecting its activity. 
Insulin receptor (IR) belongs to a family of receptor- tyrosine kinases (RTKs), 
which phosphorylate their substrate proteins on tyrosine residues. There are 
primarily two subunits within an IR: the extracellular α-subunit containing the 
ligand-binding site where insulin molecules can bind to and the transmembrane 




monomers (αβ), also known as a homodimer that are linked together by 
disulphide bonds. The extracellular portion of each IR monomer consists of six 
domains, including the first leucine-rich repeat domain (L1), a cysteine-rich 
region (CR) followed by a second leucine-rich repeat domain (L2) and three 
fibronectin type III domains (FnIII-1, Fn-III2, and FnIII-3), with FnIII-2 containing 
a large (~120 residues) insert domain (ID). The ID contains the furin (α/β) 
cleavage site yielding the α-chain and β-chain (IDα and IDβ) of the mature 
receptor monomer. Ending the α-chain component of the ID is the carboxy-
terminal α-chain (α-CT) segment. The intracellular C-terminal region of the IR 
monomer contains the tyrosine kinase (TK) catalytic domain bordered by two 
regulatory regions of the trans- and juxta-membrane domains (TM/JM) and 
lastly the C-terminal tail region (Menting et al., 2013; De Meyts, 2016; Scapin et 
al., 2018). The layout of the IR domains (from the N-terminal α chain to the C-
terminal β chain) is illustrated in Figure 2-3. 
 
Figure 2-3: Insulin receptor homodimer domains layout showing the disulphile bonds in black, 
the α-CT segment in purple triangles, the first binding site pair in red stars (1 star for IR-site1 
and 2 stars for IR-site2) and the second binding site pair in orange diamonds (1 diamond for IR-
site1’ and 2 diamonds for IR-site2’). (Adapted from Menting et al,.2013) 
According to De Meyts et al. 2015 and Lawrence et al. 2014, the current model 




binding sites, located on separated regions of each alternate IR monomer. The 
first site also referred to as the low-affinity site (IR-site1), involves residues 
within the L1 domain of α-subunit and the α-CT segment on the other α-subunit’ 
(marked as red star in Figure 2-3). The second site (IR-site2) involves residues 
at the FnIII-1/ FnIII-2 junctions (marked as two red stars in Figure 2-3) of the α-
subunit’ opposite to that contributing to the L1 region of IR-site1 (they are 
distinguished by α-subunit and α-subunit’ in Figure 2-3). It is highlighted that 
within an IR homodimer, there are two pairs of IR binding site from each 
alternate IR monomer. One composes the IR-site1 of the α-subunit and the IR-
site2 of the opposite α-subunit’ and vice versa (the other pair is marked as 
orange diamond in Figure 2-3). Furthermore, the ectodomain IR homodimer is 
also understood to show a two-fold symmetric inverted "V" conformation. One 
strand of each monomer consists of the FnIII-1, -2, -3 modules extended in a 
linear arrangement from the cell membrane upwards and the L1-CR-L2 
modules folding over downwards. Within an IR dimer, the L1-CR-L2 modules of 
one monomer are packed against the FnIII-1, -2, -3’ modules of the alternate 
monomer (De Meyts, 2015; Diwanji, Thaker and Jura, 2019; Ye et al., 2017) as 
illustrated in Figure 2-4. 
 
Figure 2-4: Structure of the ectodomain IR homodimer in a two-fold symmetric inverted “V” 
conformation showing the binding site pairs in red stars (one star indicates IR-site1 and two 
stars indicate IR-site2) and orange diamond (one diamond shows IR-site1’ and two diamonds 





Menting et al. 2015 also described that there are two surfaces of an insulin 
molecule interacting with the two IR binding sites. The first surface mainly 
involves residues derived from insulin’s dimerised conformation that contact IR-
site1. While the residuals predominantly drew from insulin’s hexameric surface 
are proposed to interact with residues of IR-site2. Once insulin binds to the IR-
site1 on either side of the α-subunits, a second binding event occurs between 
the bound insulin and the IR-site2 of the opposite IR α-subunit. It is understood 
that two insulin molecules cannot bridge both IR-site1 and IR-site2 pairs on one 
side of the IR homodimer and the corresponding pairs on the alternate side 
simultaneously hence resulting in negative co-operativity. This is because high-
affinity binding can only occur between either single pair within one IR dimer or 
the corresponding pair of the alternate side (Xu et al., 2018; Weis et al., 2018; 
Menting et al., 2013; De Meyts, 2016).  
Figure 2-5 shows two surfaces of insulin molecule that involve in IR binding 
region. 
 
Figure 2-5: Two binding surfaces on insulin molecule: The red residuals represent binding site 1 
and residuals from binding site 2 are in blue. Note that binding site 1 is partially covered by the 





The classical binding surface, referred as site 1, comprises several residues in 
the dimer-forming surface including both A-chain residues A1(Gly), A5(Gln), 
A19(Tyr), A21(Asn) and B-chain residues B24(Phe), B25 (Phe), B26(Tyr), 
B12(Val), B16(Tyr) with some of the hydrophobic residues buried beneath the 
C-terminus of the B chain. Site 2 includes A12 (Ser), A13(Leu), A17(Glu), 
B10(His), B13(Glu) and B17(Glu) residuals which contribute to the hexamer 
surface of insulin molecule. Notably, the primary binding motif that links 
between site 1 and site 2 was the central helix of B-chain insulin. Upon receptor 
engagement of the insulin molecule to the ectodomain of IR, insulin would 
rearrange itself by displacing the C-terminal B chain residues B20-B30 from its 
helical core, thereby inducing structural changes in the β subunit of the IR 
intracellular domains. This change removes the inhibitory effect on the 
intracellular TK domains, thus allowing them to trans-phosphorylate each other 
and initiate the insulin signalling pathways (Uchikawa et al., 2019; Menting et 
al., 2013; De Meyts, 2016). The overall receptor binding and activation process 
highlights the importance of certain sites of the insulin molecule for the IR 
recognition and the receptor compatibility to initiate insulin response. It is 
stressed that the degree and position of FITC substitution at particular sites on 
the insulin molecule would affect its structural conformation as well at its 
interaction with the IR binding sites and therefore the biological activity of 
insulin. 
2.1.3 Different types of clinically used commercially available insulin 
preparations based on human insulin 
HI was successfully made using recombinant-DNA (rDNA) technology in the 
early 1980s. Nowadays, clinically used insulin preparations are either neutral or 
low-pH solutions. These insulin analogues have modified amino-acid 
sequences (except for Humulin® S and Actrapid® which are essentially the 
same as HI but do not originate from human) with improved pharmacokinetic 
properties according to general principles of protein folding and assembly. 
However, they all have the insulin hexamer as a typical structure unit (Berenson 
et al., 2011; Nagel et al., 2019). It is essential to recognise the primary structural 




of fluorescent labelling on specific sites of the insulin molecule. The production 
of short-acting insulin analogues (Humulin® S and Actrapid®) uses rDNA 
technology with the same structure as natural HI thus have similar absorption 
profile and mode of action (refer to Table 1-4). Apidra®, NovoRapid® and 
Humalog® containing insulin glulisine, insulin aspart and insulin lispro 
respectively have been produced with reduced self-association properties or 
accelerated hexamer dissociation properties leading to rapid absorption than 
regular insulin hence classified as rapid-acting insulin analogues (Danne, 
Heinemann and Bolinder, 2019; Jacob, 2015). Newer generation of rapid-acting 
insulin analogues include Fiasp® and Lyumjev®. They have the same active 
molecules as in NovoRapid® and Humalog® respectively. However, the 
formulation of Fiasp® also contain niacinamide (Vitamin B3) to increase the 
initial absorption rate of insulin aspart and L-arginine to aid in stabilising effect. 
Meanwhile, Lyumjev® utilises treprostinil and citrate excipients to accelerate the 
absorption of insulin lispro from the administration site. The improved 
formulation of Fiasp® and Lyumjev® to increase the absorption of their active 
molecules results in a faster insulin time-action profile and in earlier glucose 
lowering when compared to NovoRapid® and Humalog® (Davis, Kuriakose and 
Clements, 2019; Shiramoto et al., 2020).  Long-acting insulin analogues include 
insulin detemir (Levemir®), insulin glargine (Lantus®). They have been 
synthesised either by introducing changes in amino acid sequence that reduce 
its solubility at physiological pH (Lantus®) or by covalent acylation (Levemir®). 
Insulin glargine has asparagine at A21 position replaced by glycine (to prevents 
deamidation and dimerisation that would occur with acid-sensitive asparagine) 
and two arginines added to the C-terminus of the β-chain (Figure 2-6), resulting 
in a shift of isoelectric point to neutrality. After SC injection, the insulin glargine 
acidic solution (pH 4) is neutralised; leading to the formation of micro-
precipitates from which insulin glargine is slowly released. This results in a 
relatively constant concentration /time profile over 24hrs with no pronounced 
peak, allowing once-daily dosing as basal insulin (Nagel et al., 2019) . 
Meanwhile, insulin determir has threonine in position B30 omitted and replaced 




B29 (Figure 2-6). This modification allows a delayed absorption of insulin 
determir from the SC tissue due to increased self-association into hexameric 
form at the injection site and high degree of reversible albumin binding by a fatty 
acid chain. Slightly different to Lantus®, Levemir® can be administrated once or 
twice daily for basal insulin need (Noorden, Knopp and Chase, 2019). The ultra-
long acting insulin analogues including Tresiba® (insulin degludec) and 
Toujeo® (insulin glargine U300) have an extended duration of action of up to 42 
hours and 36 hours respectively. Insulin degludec has threonine at B30 position 
removed and the addition of 16-carbon fatty acid to lysine at B29 via a γ-L-
glutamic acid linker (Figure 2-6). It is formulated as a soluble di-hexamer which 
forms stable soluble multi-hexamers after SC injection. The gradual separation 
of degludec Monomers from the multi-hexamers enables a slow and continuous 
delivery of insulin degludec from the SC tissue into the circulation (Shimoda et 
al., 2016; Sharma et al., 2019). The glargine U300 formulation in Toujeo® has a 
more extended time‐action profile than Lantus® because it forms a more 
compact subcutaneous depot with smaller surface area and volume, thus 
achieving a prolonged dissolution from the SC tissue (Standl and Owen, 2016c; 
Hemmingsen, Richter and Metzendorf, 2019). 
 
Figure 2-6: Modifications of pharmaceutical insulin analogues compared to human insulin 
primary structure (taken from Nagel et al,.2019) 
Table 2-1 summarises the main differences of some insulin analogues that are 
used for FITC labelling in this study (the information was primarily taken from 



















Structurally identical to natural HI thus have similar absorption 





Colourless, clear aqueous solution. Each mL contains 100 Units 
of HI (produced by rDNA technology in a special non-disease-
producing laboratory strain of Escherichia coli bacteria,16mg 
glycerol, 2.5mg m-cresol, 0.005mg zinc oxide & Water for 




Neutral, clear, colourless solution containing 100 Units/ mL HI 
corresponding to 3.5mg of anhydrous HI /mL produced by rDNA 
technology using Saccharomyces cerevisiae; glycerol, m-cresol, 






Insulin aspart has proline in position B28 replaced by aspartic 
acid (Figure 2-6) creating charge repulsion and steric hindrance 
due to local conformational change at the B-chain C-terminus. 
Reduced tendency to self-associate due to electrostatic 
repulsion at the dimer interface resulting in rapid absorption→ 





Clear, colourless aqueous solution. Each mL contains 100 Units 
of insulin aspart produced by rDNA technology using 
Saccharomyces cerevisiae,16mg glycerol, 1.5mg phenol, 1.72 
mg m-cresol, 0.0196mg zinc chloride, 1.25mg disodium 
phosphate dehydrate, 0.58ng sodium chloride (NaCl) & WFI, pH 






The asparagine at position B3 is replaced by lysine while 
glutamic acid is substituted for lysine at position B29 which is 
involved in FITC covalently binding site.  
Glucose lowering activities of Apidra® & regular HI are 
equipotent when administered by IV route, however after SC 
administration; the effect of Apidra® is more rapid in onset & for 





Clear, colourless solution. Each mL contains 100 Units (3.49mg) 
of insulin glulisine produced by rDNA technology using a non-
pathogenic laboratory strain of Escherichia coli (K12), 3.15mg 
m-cresol, 6mg tromethamine, 5mg NaCl, 0.01 mg polysorbate 
20 & WFI, pH 7.3 (adjusted with HCl and/or NaOH). 
Insulin lispro  
Humalog® 
Eli Lilly 
The amino acid proline at position B28 and lysine at B29 are 
swapped over in insulin lispro (Figure 2-6) creating steric 
hindrance and reducing the ability to self-associate so is 
absorbed more rapidly than regular soluble insulin from SC 





Clear, colourless solution. Each mL contains 100 units (3.5mg) 
insulin lispro produced by rDNA technology using a non-
pathogenic laboratory strain of Escherichia coli 16 mg glycerol, 
1.88 mg dibasic sodium phosphate, 3.15 mg m-cresol, zinc 
oxide to provide 0.0197mg zinc ion, trace amounts of phenol & 






2.1.4: The synthesis of fluorescently labelled insulin conjugates from previous 
studies and key findings 
Initial work on the synthesis of FITC-insulin conjugates yielded mixtures with 
reduced biological activities (Maggi, 1966; Gök and Olgaz, 2004). 
Fluoresceinthiocarbamyl insulin derivatives of bovine insulin were first prepared 
in aqueous solution in 1967 by Bromer and his team. However, the products 
yielded mixtures of mono, di and tri substituted species where the mono-
labelled fraction only retained 40% of native insulin activity.  
The synthetic method described by Hentz et al. 1997 can be regarded as the 
seminal work in the production, separation and identification of FITC-labelled 
insulin but none of the commercially available insulin injections was studied. HI 
was labelled with FITC by employing four different reaction conditions. These 
comprised FITC: HI molar ratio of 3:1 and 1:1 at both pH7 and 8.5. These 
reactions were monitored at different time intervals by HPLC over 20h.The 3:1 
reaction carried out at pH 8.5 for 20h had the highest number of FITC-HI 
species so was chosen by Hentz for further characterisation. The four isolated 
species were labelled at A1(Gly), B1 (Phe), A1(Gly)B1(Phe) and 
A1(Gly)B1(Phe)B29(Lys) positions on the amino acid sequence. Figure 2-7 
illustrates the binding site of FITC molecule to insulin. 
 
Figure 2-7:Human insulin structure with yellow stars indicating possible positions for FITC label 





Based on their biological activity measurements using a TK phosphorylation 
assay, the FITC-HI conjugate labelled at B1(MonoB1) had an equivalent activity 
to native insulin while the rest showed a decreased biological activity.  Hentz 
proposed that the structure conformational changes and hence the activity of 
FITC-HI species differ concerning the degree and position of substitution. 
Consequently, he hypothesised that the B1 position was not considered to be 
involved in binding to the IR while the A1 site plays a role in forming part of the 
classical binding site for the receptor since the conjugates labelled at 
A1(MonoA1) and A1B1(di-labelled) show a ten-fold decrease in biological 
activity compared to native insulin. Furthermore, the conjugate labelled at 
A1B1B29 (tri-labelled) have almost 100-fold reduction in activity. This significant 
reduction suggested that the B29 site has a vital role in receptor binding in 
which the conformation of the tri-labelled molecules must be altered in such a 
way that the receptor-binding region on the insulin molecule is no longer 
recognisable therefore, reducing its biological activity. This work has formed the 
most fundamental research on the synthesis and characterisation of FITC-HI 
conjugates for bioanalytical analysis. However, their synthesis methods 
produced a mixture of mono-, di- and tri-labelled species which are not all the 
desirable due to the variation in their biological activity.  
A recent extended study on fluorescently labelled insulin with FITC by Jacob et 
al. 2015 built on Hentz synthesis method produced several mono-labelled and 
di-labelled products whose biological activity was not assessed. In Jacob’s 
work, the effects of varying reaction time and adding phenolic compounds to 
FITC-HI conjugate produced were studied and compared to the commercially 
available FITC-insulin product manufactured by Sigma Aldrich, which was found 
by Jacob to contain a mixture of conjugates, predominantly the biologically 
inactive tri-labelled species. The results showed that at a short reaction time of 
up to 5h, mono-labelled conjugate was successfully produced but the product 
also contained unlabelled HI. Besides, this work has not specified the labelling 
position of the mono-labelled species to be at A1 or B1 and their biological 
activity were not determined. Meanwhile, increasing reaction time over a 45h 




produced after 20h reaction time. Furthermore, there was a 10% decrease in 
the amount of mono-labelled species produced at a short reaction time of 2h in 
the presence of phenol or m-cresol. This observation could occur because the 
phenolic compounds promote the stable R-state of insulin monomer in which 
the A1 residue is in an extended form and is more readily available for labelling 
at both A1 and B1 positions. Commercially available insulin preparations 
ranging from short-acting, rapid-acting to long-acting were also fluorescently 
labelled with FITC by Jacob et al 2015 for future biomedical applications. This 
recent work produced a mixture of mono- and di-labelled conjugate whose 
biological activities were not examined. Despite trying a wide range of insulin 
preparations and adding phenolic compounds, Jacob et al 2015 still has not 
successfully synthesised FITC-labelled insulin conjugate at the desired B1 
position that showed by Hentz to have similar biological activity as native 
insulin. 
A more recent work on the development of a fully bioactive fluorescent-labelled 
insulin has been described by Williams et al. 2018. This study has greatly 
emphasised the indispensable role of fluorophores in contributing to the finding 
of how insulin from the interstitial fluid enters the skeletal muscle cell cytoplasm. 
This group successfully synthesised fluorescently labelled HI at the B1 position 
whose biological activity has also been fully confirmed via IR-binding assay and 
insulin tolerance test in-vivo. However, their fluorophore of choice was 
AlexaFluor 647 and only biosynthetic HI was used in the study. The use of tert-
butyloxycarbonyl (t-boc) protection chemistry to block the activity of free amines 
at the A1 and B29 position, consequently leaving the B1 position free for 
AlexaFluor 647 labelling has successfully produced the desired mono-labelled 
species. However, the lengthy process of synthesising the insulin protected t-
boc intermediates is very time-consuming. Furthermore, the intermediates also 
required purification by RP-HPLC before they could undergo another synthesis 
for the desired conjugates labelled at the B1 position, which also required 
further HPLC purification. Moreover, the high cost of materials used, and the 





Overall, the insulin binding sites including residues A1, A13, A21, B12, B17 and 
B-chain residues B20-B30 play an essential role in the binding of insulin to IR, 
therefore, are crucial for insulin biological activity. Meanwhile, the labelling of 
FITC to insulin involves A1, B1 and B29 residues. However, only FITC label at 
the B1 position could maintain the biological activity of insulin whereas the A1 
and B29 positions showed a reduction (~10-100 fold) in insulin activity, thus 
emphasising the importance of A1 and B29 in the binding of insulin to IR (Hentz 
et al., 1997; Jacob et al., 2016; Williams et al., 2018). The objective of this 
current study is to synthesis the desired biologically active FITC-insulin 
conjugate labelled at the B1 position merely by modifying certain reaction 
conditions including molar ratio, pH and reaction time. However, it is also 
understood that the use of protecting group on specific sites of the insulin 
molecules may be required to target B1 specific binding site in future research. 
 
2.2 Materials and Methods 
2.2.1 Chemicals and Reagents 
FITC isomer I (F-7250, CAS: 3326–32-7) and Sephadex TM-G25 were 
purchased from Sigma-Aldrich (St. Louis, MO). Actrapid®, NovoRapid® and 
Insulatard® manufactured by Novo Nordisk; Humalog® and Humulin S® by Eli 
Lilly and Apidra® by Sanofi-Aventis were used. HPLC grade acetone, HPLC 
grade acetonitrile (ACN), HPLC grade trifluoroacetic acid (TFA), sodium 
dihydrogen phosphate (NaH2PO4), disodium hydrogen phosphate (Na2HPO4) 
glycerol, m-cresol and zinc oxide were purchased from Fisher Chemicals 
(Loughborough, UK). Ethylenediaminetetraacetic acid disodium salt (EDTA) 
was from Hopkins & Williams. Milli-Q water obtained from a Milli-Q UF Plus 
water purification system was used throughout for all HPLC analysis while the 
use of distilled water was for other preparation processes such as the making of 
buffers; 0.1M NaOH and 0.1M HCl were used for pH adjustment. 
2.2.2 Synthesis of FITC-insulin analogues conjugates 
The protocol for the synthesis of clinically used commercially available insulin 




2.2.2.1 Preparation of FITC stock solution 
A 25mg/mL solution of FITC in acetone was freshly prepared just before use in 
a 5mL volumetric flask. It was protected from light by covering with foil and kept 
in the dark at 2-8°C until use.  
2.2.2.2 Preparation of 0.1M Sodium Phosphate buffer pH 7.0 
6.6g of NaH2PO4 and 10.27g of Na2HPO4 were dissolved in ~ 500mL of distilled 
water. After dissolution, the solution was made up to 1L in a volumetric flask 
with distilled water and pH was adjusted to 7.0 with 1M NaOH or 1M HCl. 
2.2.2.3 Synthesis of FITC-Actrapid® (Human Insulin) conjugate 
5mL of Actrapid® solution (equivalent to 17.5mg HI) was measured and 
transferred into a clean glass jar. This is equivalent to 0.003 millimoles of HI 
(Number of mole of HI=17.5mg/5808Da). For a 2:1 molar ratio, 0.006 millimoles 
of FITC is required, which is equal to 2.34mg of FITC (Mass of 
FITC=0.006x389.382Da). Therefore, 94 µL of 25mg/mL FITC stock solution is 
required for conjugation. 
0.44mg EDTA (200mM) was added to the Actrapid® solution. The volumes of 
FITC stock (25mg/mL) solution added according to each molar ratio of FITC 
and Actrapid® being synthesised are shown in Table 2-2 with the pH of the 
mixture being adjusted to pH7 to yield a bright yellowy-orange solution.  
Table 2-2: Volumes of FITC solution corresponding to each molar ratio of FITC and Actrapid® 
The molar ratio (FITC: Actrapid®) Volume of FITC stock solution 
(25mg/mL) added (µL) 
3:1 141  
2:1 94  
1.5:1 70  
1:1 47  
0.5:1 23  
 
The mixture was left to react in the dark on a magnetic stirrer for the allocated 
reaction time (For the molar ratio study, the reaction time was 4h; For the 
reaction time study at 2:1 molar ratio, the reactions were stopped after 




Similarly, to study the effect of pH on the synthesis of FITC-Actrapid® 
conjugates at 2:1 molar ratio and 2h reaction time, each set of FITC-Actrapid® 
preparations was adjusted to pH 7.5; pH8.5, pH9 and pH9.5  
2.2.2.4 Synthesis of FITC- Apidra® (Insulin glulisine)/ NovoRapid® (Insulin 
aspart)/ Humalog® (Insulin lispro)/ Humulin S® (Human insulin)/ Insulatar ® 
conjugates 
The protocol to label other commercially available insulin injections with FITC at 
pH7 using 2:1 molar ratio was following the synthesis of FITC-Actrapid ® 
conjugate as summarised in Table 2-3 
Table 2-3:The protocol to label other pharmaceutical insulin injections with FITC. 
 
2.2.3 Purification of FITC-insulin conjugates 
Once the allocated reaction time has been reached, the synthesised FITC-
insulin conjugates were separated by gel permeation chromatography (GPC). 
The GPC equipment consists of a Buchii apparatus chromatography pump B-
688, peak detector B-686, fraction collector B-684 and a gel permeation 
column, which was composed of a borosilicate plastic-glass column containing 
Sephadex™ G25. 
To pack the column, ~ 15g of dry Sephadex-G25 (bead size: dry 50–150 μm) 
was swollen with 100mL of distilled water for 3h at 20°C and the resulting slurry 
was packed vertically into the column to provide a continuous bed for 
separation. 




Volumes of  
pharmaceutical insulin 
injection used (mL)/ 
tradename 
FITC-Apidra® 93 5/ Apidra® 
FITC-NovoRapid® 94 5/ NovoRapid® 
FITC-Humalog® 94 5/ Humalog® 
FITC-Humulin S® 94 5/ Humulin S® 




2.2.4 Analytical procedures for identification of FITC-insulin conjugates  
The fractions collected from GPC were analysed using Reversed-Phase High-
Performance Liquid Chromatography (RP-HPLC) and Mass Spectroscopy (MS) 
to identify the species produced. 
RP-HPLC chromatographic analyses 
A Shimadzu Prominence HPLC system consisting of an in-line DGU-20AS 
Prominence degasser, LC-20 AD Prominence quaternary pump, SIL-20A 
Prominence autosampler, CTO-20 AC Prominence column oven and SPD-
M20A Prominence diode array detector was used to analyse the conjugation 
products. A Luna (3 μ) C18(2), 150 × 4.60 mm column from Phenomenex, 
Cheshire UK was used for the separation preceded by a 0.5 mm in-line filter 
and a widepore C18, 4 × 3 mm guard column. Elution was achieved using a 
gradient method with a flow rate of 1.0 mL/min, a column temperature of 40 °C 
and a sample injection of 50 μL. The following gradient was used in HPLC 
determinations: 0–15 min (85 % to 65% A), 15–25 min (65%to 35% A), and 25–
32 min (35% A) where A was mobile phase A containing 0.1 % trifluoroacetic 
acid (TFA) in Milli-Q water and B was mobile phase B containing 90% 
Acetonitrile, 10 % Milli-Q water and 0.1% TFA. SIL-20A Prominence 
autosampler performed the sampling and the sample volume used throughout 
was 50μL. The peaks were monitored by fluorescence detection where the 
excitation and emission wavelengths were set at 494 and 518 nm, respectively. 
The Photo Diode Array (PDA) detector was also set to scan from 190 to 400 nm 
and had a channel set at 215 nm to detect the presence of unlabelled native 
insulin. 
MS analyses 
MS to determine the mass and labelling position of FITC-insulin conjugates 
produced was performed using an MS-Orbitrap Fusion with UltiMate 3000 
RSLCnano System (Thermo Scientific) consisting of a TriVersa Nanomate 
nanospray source (Advion, NY) which was set to electrospray the samples 




pressure of 0.3 psi.MS analyses were performed by the Proteomics Research 
Technology Platform at the University of Warwick. 
2.2.5 FITC- insulin conjugate storage conditions and lyophilisation process 
All fresh FITC-insulin conjugates collected after GPC purification would be 
protected from light and kept at -20°C for lyophilisation no later than a week 
after being synthesised. The samples were placed inside a round bottom flask 
and sharp frozen using liquid nitrogen. The frozen flask was then placed on the 
Heto drywinner freeze dryer for 48h to ensure no aqueous solution remained in 
the flask. Once achieving the yellow powder of FITC-insulin conjugate, it is 
ready for storage at 4°C in an amber bottle until further use. 
2.2.6 Validation procedures for HPLC analysis 
The qualification parameters assessed for the validation of FITC-insulin RP-
HPLC methods were set out in Table 2-4 according to FDA guidance 
documents Q2B Validation of Analytical Procedure. 
Mono-labelled FITC-Actrapid® conjugate (Mono) synthesised inhouse was used 




Table 2-4: Validation Procedures 
Parameters  Samples Criteria 
Selectivity/specificity Milli-Q water and diluting fluid containing m-cresol, glycerol, zinc oxide 
excipients as present in Actrapid® both adjusted to pH7.0 with 0.1M NaOH 
There should be no peaks present in Milli-Q 
water or diluting fluid interfering with the 
peak area response from Mono. 
System suitability The integral system (including the equipment, electronics, analytical 
operations and sample to be analysed) suitability was assessed by a 
minimum of six replicate analyses of Mono at 1mg/mL 
An acceptance criterion of ±2% for 
percentage relative standard 
deviation(%RSD) for the peak areas and 
retention times (RT) of Mono 
Linearity and range A minimum 5-point curve generated over a range of 80-120% of the test 
standard. 
A series of 10 concentrations (0.07-0.08-0.09-0.1-0.11-0.12-1-2-3-4 mg/ml) 
of Mono standard solutions were analysed. 
Calibration plots from at least six replicate experiments were constructed 
R2 ≥0.990 
Achieving an acceptable degree of linearity 
within and at the extremes of the 
concentration ranges studied 
Accuracy Analysing three replicates of four different concentrations (0.05-0.1-0.5-1 
mg/ml of the standard Mono sample)  
Area under the peak (AUP) for each sample was recorded [mean AUP for 
3 replicates +/- SD] and the Recovery percentage was calculated using the 
regression equation. 
Determined concentration at each level 
must be 97.0%–103.0% of theoretical 
concentration 
Precision/repeatability 
intra-day and Inter-day 
The precision of the assay was determined by Intra-day (repeatability, 
testing the sample on the same day) and Inter-day (intermediate precision, 
testing the sample on different days with freshly prepared mobile phase 
and different FITC- Actrapid® standard) 
Data collected using three replicates of three different concentrations from 
low (0.01mg/ml) to medium(10mg/ml) and high(100mg/ml) of Mono. 




LOD and LOQ 
Limit of detection (LOD) and quantitation (LOQ) were calculated based on 
the standard deviation of the analytical response represented by AUP 
(lowest concentration used 0.5 %) and slope of the calibration curve. The 








Where SD is the standard deviation of the response and S is the slope of 
the calibration curve. The regression data obtained from the linearity 
studied were used.  




2.3 Results and Discussions 
2.3.1 Validation of RP-HPLC method used to analyse FITC-insulin for the 
determination of Mono 
Selectivity/Specificity 
The RP-HPLC method used to analyse FITC-Actrapid® conjugate under 
chromatographic conditions had a run time of 45min with elution of mono-
labelled species at 21.9min retention time (RT), di-labelled species at 22.6min 
RT and tri-labelled species at 23.7min RT as shown in Figure 2-8 
 
Figure 2-8: RP-HPLC fluorescence chromatogram of FITC-Actrapid conjugate in water 
showing peaks at RT 21.9min (mono-labelled species); 22.6min (di-labelled species) and 
23.7min (tri- labelled species) 
Comparisons of the fluorescent chromatograms for placebo (diluting fluid) and 
FITC-Actrapid® conjugates revealed no additional peak co-eluting with the 
peaks corresponding to each conjugated species. 
System suitability 
System suitability for FITC-insulin method with 1mg/mL Mono showed an RT of 
21.9min for mono-labelled species with a %RSD = 0.04 (n=6) and %RSD for 
peak areas was 1.57. Both results are within ±2% acceptance criteria indicating 
the suitability of the RP-HPLC system. The capacity factor and resolution were 
both >2 and the tailing factor was <2 within accepted criteria. The data 
suggested that the chromatographic system and conditions used in this FITC-






























Figure 2-9 shows the linear relationship of Mono concentrations over the range 
of 0.07-4 mg/mL and their AUP. The calibration curves constructed for the six 
replicate experiments were evaluated by their correlation coefficient where R2 
equal to 0.9997 and the Pearson correlation coefficient, r is 0.9998. 
 
Figure 2-9: Parameters of the regression equation for Mono against analytical response (AUP) 
using the RP-HPLC method for FITC-insulin. 
Range 
The linearity results demonstrated in Figure 2-9 suggest that the FITC-insulin 
analytical method provide an acceptable degree of linearity within and at the 
extremes of the concentration ranges studied. 
Accuracy 
The AUPs corresponding to four concentrations of 0.05,0.1,0.5,1 mg/mL of 
Mono from two different sets of four solutions were used to calculate the 
recovery percentage of each samples using the regression equation. The 
average recovery was 98.6 ± 1.02% which is within the acceptable range of 
theoretical concentration of 97-103%. 
Precision 
Table 2-5 shows precision data for Mono samples prepared at three different 
concentrations of 0.01,1 and 10 mg/mL during intra- and inter-day runs. The 




































%RSD for intra- and inter-precision was ≤1.0% except for the lowest 
concentration of 0.01mg/mL. 
 
Table 2-5: Precision of FITC-insulin method for determination of Mono. 
Standard 
concentrations 
Intra-day Inter-day Overall 
RSD % 









0.01 1594±60 3.73 1359±57 4.00 3.85 
1 148761±724 0.49 145206±1819 1.25 0.87 
10 1651035±9262 0.56 1636451±5319 0.33 0.45 
 
Precision studies demonstrated the repeatability and intermediate precision of 
the FITC-insulin method used for 1 and 10 mg/mL concentrations. The results 
suggest that 0.01 mg/mL concentration was below the limit of detection for the 
sample to be analysed because the %RSD for intra- and inter-precision was 
greater than 3. 
Detection and Quantitation limits (sensitivity)  
Limit of detection (LOD) and quantitation (LOQ) were calculated based on the 
standard deviation of the analytical response represented by AUP (lowest 
concentration of 0.07mg/mL used in the linearity study) and slope of the 
calibration curve shown in Figure 2-9. The calculated LOD and LOQ was 
0.055mg/mL (1.57 Units/mL) and 0.167mg/ml (4.77 Units/mL), respectively. The 
result showed the sensitivity of FITC-insulin analytical method used to 
determine Mono. 
2.3.2 Purification of FITC-insulin conjugates by GPC 
After the required reaction time, the FITC-insulin sample was injected directly 
onto the GPC to achieve three separated fractions as showed in Figure 2-10 . 
Band 1 showed the larger molecules of FITC-insulin conjugates, and Band 3 





Figure 2-10: Picture showing separated bands corresponding to FITC-insulin conjugates and 
unreacted FITC molecules purification by GPC. 
 
2.3.3 The screening of commercially available insulin preparations to select the 
desired mono-labelled conjugate. 
Before identifying which species of FITC-insulin was produced using PR-HPLC 
system; it is necessary to confirm complete removal of unreacted FITC by GPC 
from fluorescent conjugates as well as the presence of any unlabelled insulin in 
the final conjugated products. Figure 2-11 shows FITC peaks observed at RT 
of 13min, 24min and 28.1min.  
 
Figure 2-11: RP-HPLC fluorescence chromatogram of FITC in acetone showing peaks at RT 



































Figure 2-12 shows the PDA UV chromatogram detected at 215nm for 
Actrapid® with peaks at 16.8min RT and 20.4min RT corresponding to m-cresol 
and native insulin respectively. 
 
Figure 2-12: PDA UV chromatogram of native insulin (Actrapid®) showing peaks at 16.8min RT 
for m-cresol and 20.4min RT for Actrapid®  
The detection of these identified peak for FITC and insulin in subsequent 
chromatograms would indicate that unreacted FITC and unlabelled insulin are 
still present after GPC purification. 
The initial approach was based on previous findings by Jacob 2015 where the 
conjugates were produced with a 3:1 FITC: insulin ratio. In this work, the ratio 
was reduced to 2:1 and FITC conjugation with Actrapid®, Humulin S®, Apidra®, 
Humalog®, NovoRapid® and Insulatard® at pH 7 will be assessed after 2h and 
20h. The long-acting insulin analogues Levermir® and Lantus® were excluded 
from this study because of their distinct structural differences at the B29 
positions and low pH formulation that make it difficult for FITC conjugation 
following the usual synthesis method. The low yield achieved in Jacob 2015 
study using these two analogues also suggested that they are unsuitable  
Error! Reference source not found. summarises the overall yield of FITC-insulin c
onjugates as a percentage AUP corresponding to each insulin analouges 






























Figure 2-13:Charts showing various percentage AUP of Mono and Di produced at 2h and 20h 
reaction time for Actrapid®, Apidra®, NovoRapid®, Humalog®, Humulin S® and Insulatard® 
All conjugates synthesised at a reaction time of 2h had unlabelled insulin peak 
at 20.4 min (PDA). This peak was not present in those synthesised at a reaction 
time of 20h, suggesting that with a lower amount of FITC used, 2h is still not 
long enough to allow complete FITC-insulin conjugation. The absence of 
unreacted FITC was also confirmed from HPLC fluorescence chromatograms, 
indicating that GPC purification was successful in removing all the unreacted 
dye from the conjugated product. 
At a short reaction time of 2h, the FITC conjugates produced with the chosen 
insulin analogues were predominantly Mono with a considerably smaller amount 
of di-labelled FITC-insulin conjugate (Di). Actrapid® showed the highest Mono 
yield (100%) while the rest produced a mixture of Mono and Di. Apidra®, 
Humulin S® and NovoRapid® showed a similar yield of more than 93-98% 
Mono with less than 7% Di. Insulatard® and Humalog® had the lowest yield of 
Mono with only 80-86%.  
Meanwhile, at a longer reaction time of 20h, there was also a mixture of Mono 
and Di produced with a higher percentage yield of Di than the synthesis at a 
short reaction time. Actrapid® maintained the highest yield (96%) of Mono while 
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amount of Di being produced, the percentage yield of Mono was reduced to 
85% for Apidra® and 78% for NovoRapid®. Insulatard® and Humalog® showed 
a similar yield of 60% Mono while Humulin S® had the lowest amount of 54%. 
It was anticipated that the short-acting insulins such as Actrapid® and Humulin 
S® should have a similar production of conjugates with FITC because they 
share the same structure as HI. However, this similarity in the synthesis of 
FITC-insulin conjugates was only observed at a short reaction time of 2h while 
there was a 41% reduction in the yield of Mono at 20h reaction using Humulin 
S®. The longer reaction time of 20h did not seem to largely affect the synthesis 
of Mono using Actrapid®. It is possible that other excipients formulated in 
Actrapid® might contribute to the structural configuration of insulin in such a 
way that FITC labelling to more than one site is more challenging.  
Similar to Actrapid®, the rapid-acting insulin analogues including Humulin S®, 
Apidra® and Novorapid® also produced predominantly Mono. However, only 
Actrapid®, Humalog® and Novorapid® had a single peak in their fluorescent 
chromatogram that represented one species of Mono at 21.9min RT while 
Apidra® and Humulin S® had two mono-labelled peaks at 21.3min RT 
(although at a much lower percentage of less than 2% ) and 21.9min RT, which 
could indicate labelling at both A1 and B1 positions; refer to Error! Reference s
ource not found. and Error! Reference source not found. for illustrations of 





Figure 2-14: Combined Fluorescence (black) and PDA UV chromatograms (pink) of Actrapid®-
FITC synthesised at 2:1 molar ratio (FITC: Actrapid®) after 2h reaction showing a single Mono 
peak at 21.9min RT (100% AUP) and PDA peak at 20.4min RT for unlabelled insulin. 
 
 
Figure 2-15: RP-HPLC fluorescence chromatogram of Apidra®-FITC conjugate synthesised at 
2:1 molar ratio (FITC: Apidra®) after 2h showing two Mono peaks at RT 21.3min (1.8% AUP) 
and RT 21.9min (95.9% AUP) and one Di peak at RT 22.6min (2.3% AUP).  
It is possible that the modifications in the amino acid sequences of these 
analogues and the differences between the equilibrium of the R- and T- state of 
the insulin hexamer could both contribute to the production of two mono-
labelled species. This is because the B1 binding site for FITC is fully exposed 



























































































accessible for FITC binding. On the other hand, the A1 binding site is folded 
inward in the T-state and shielded from FITC by the -helix, whereas in the R-
state it is facing outward and more expose, hence enabling FITC binding at the 
A1 position (refer to Figure 2-16) (Kosinová et al., 2014). 
 
Figure 2-16: Structure of the T/R state transition (Taken from Kosinová et al., 2014) 
The production of two Mono at both B1 and A1 position using Apidra® is likely 
because it is formulated without zinc ions but still contains m-cresol. Therefore, 
the T/R transition would be subjected to the phenolic induced R-state in which 
the A1 is also exposed for FITC label. Notably, the slightly higher pH in Humulin 
S® formulation may have contributed to the higher production of Di at 20h 
reaction times. This observation could be due to the initial high pH formulation 
of Apidra favouring the R-state of hexameric insulin which allows more 
accessibility to the A1 position for FITC labelling. Although there was 13-15% 
reduction in Mono production using Apidra® and NovoRapid® at 20h reaction 
time; this was only a quarter of the reduction observed for 3:1 molar ratio at 20h 
reaction time by Jacob 2015. The results indicated that excessive amount of 
FITC in addition to longer reaction time could result in a higher production of Di 
and possibly tri-labelled FITC-insulin analogue conjugate (Tri) produced. 
Interestingly, Insulatard® containing HI with prolonged duration of action 
produced the lowest yield of Mono at both short and long reaction time. This is 




sulphate, which precipitate the insulin at its isoelectric point. The results 
suggested that HI formulated for protracted action like Insulatard® would have a 
higher tendency to produce a mixture of conjugates that is undesirable. 
Considering the lower yield of conjugates synthesis at 3:1 ratio reported by 
Jacob 2015 for long-acting insulin including Lantus® and Levermir® in addition 
to the observed data for Insulatard®, it is concluded that insulin analogues 
formulated for protracted action are not suitable for FITC label. 
The overall results showed that reducing the amount of FITC is beneficial in 
lowering the production of Di at both long and short reaction time of 2h and 20h 
and so far, Actrapid® is the best analogue for producing the highest yield of 
Mono.  
2.3.4 Molar ratio study using Actrapid® after 4h reaction time and at pH7 
Table 2-6 summarises the synthesis of FITC-Actrapid ® conjugates at pH7 
using various mole of FITC to 1 mole of Actrapid® analysed by RP-HPLC after 
4h reaction. Two main species Mono and Di were identified with their 




Table 2-6: Molar ratio study between FITC and Actrapid® showing the synthesis of different FITC-Actrapid® conjugates and their corresponding AUP 
percentages analysed by RH-HPLC and the presence of unlabelled insulin identified from their PDA chromatogram. 
Molar ratio 
FITC: Actrapid®  
RP-HPLC 




(No of FITC) 
Identity of conjugates 
0.5:1 20.4 (PDA 6.4%) 5807.6(0) Unlabelled Actrapid® 
21.9 (100%) 6197.0(1) Mono-labelled species 
1:1 20.4 (PDA 4.8%) 5807.6(0) Unlabelled Actrapid® (Confirmed by MS raw data 
peaks at 1162.3354 z5 and 1452.6674 z4) 
21.9 (100%) 6197.0(1) Mono-labelled species (Confirmed by MS raw data 
peak at m/z 1555.4228 z4) 
1.5:1 20.4 (PDA 3.2%) 5807.6(0) Unlabelled Actrapid® 
21.9 (100%) 6197.0(1) Mono-labelled species 
2:1 20.4 (PDA 1.7%) 5807.6(0) Unlabelled Actrapid® (Confirmed by MS raw data 
peaks at 1162.3364 z5 and 1452.9185 z4) 
21.9 (100%) 6197.0(1) Mono-labelled species (Confirmed by MS raw data 
peaks at m/z 1244.7402 z5 and 1555.6726 z4) 
3:1 20.4 (PDA 0.5%) 5807.6(0) Unlabelled Actrapid® 
21.3 (2.88%) 6197.0(1) Mono-labelled species 
21.9 (94.69%) 





As anticipated from previous studies by Jacob 2015, synthesis using 3:1 molar 
ratio produced a mixture of two mono-labelled species in addition to Di while 
other lower molar ratios yielded 100% Mono. Unfortunately, unlabelled insulin 
was still present in all conjugates despite the increase in reaction time from 2h 
to 4h. However, the PDA peaks detected for unlabelled Actrapid® was highest 
for 0.5:1 (6.4% AUP) and lowest for 3:1 (0.5%) molar ratio, suggesting that 
having FITC in excess could enable complete labelling of insulin but also 
increase the chance of producing more Di and Tri. The higher amount of 
unlabelled insulin presence from the synthesis at a lower molar ratio indicated 
that longer reaction time is necessary for achieving complete labelling of 
Actrapid® with FITC. However, increasing reaction time may lead to the 
production of other undesired conjugates as previously reported by Jacob et al 
2015.  
Overall, the synthesis of FITC-Actrapid® requires a compromised reaction 
condition between choosing a suitable molar ratio and appropriate reaction 
time. Ideally, if choosing 2:1 molar ratio then the reaction time should not be 
longer than 20h because this resulted in the production of Di. However, the 
reaction time should also not be shorter than 4h due to the presence of 
unlabelled insulin. Labelling at longer reaction time than 20h may be necessary 
for lower molar ratios of 1.5:1 or 1:1 in which the availability of FITC molecules 
could be limited for selective labelling at a single site on each insulin molecule 
while there still is sufficient time for achieving a complete conjugation and 
leaving no unlabelled insulin left. 
2.3.5 The effect of pH on the conjugation of FITC and Actrapid®  
Hentz et al. 1997 demonstrated that the synthesis of FITC-insulin conjugates at 
pH8.5 would result in a mixture of two mono-labelled species at both A1 and B1 
positions. It was also found from their study that the mono-labelled at the A1 
position had an RT of 22.6min while the one labelled at the B1 position 
exhibited a slightly longer RT of 23.1min, i.e. MonoA1 would elute from the RP-
HPLC column first. Although there are several factors governing the degree of 
labelling, the nucleophilicity of the amino acid side chains and thus their pKa 




insulin molecule. For instance, at a neutral pH of 7, the ITC reactive group of 
FITC would have a tendency to react more readily to the α-amino groups of 
insulin having a similar pKa range around 7 rather than the ϵ-amino groups that 
have pKa value >9. Notably, several findings also reported that the pKa of the 
two N-terminal α-amino groups on insulin molecule was 8.4 for the aliphatic 
neutral Glycine at the A1 position and 7.1 for the aromatic hydrophobic neutral 
Phenylalanine at the B1 position while the ϵ-amino group of Lysine with a polar 
hydrophilic charge at the B29 position had a pKa above 9.8 (Wong, 1991; 
Bothelho and Gurd,1989; Hentz et al. 1997). It is therefore of interest to 
investigate the effect of changing pH on the labelling selectivity towards a 
particular amino acid group of Actrapid®, preferably where it can retain the 
biological activity of FITC-Actrapid® conjugate as well as native insulin. 
Error! Reference source not found. shows the combined RP-HPLC fluorescence c
hromatograms of FITC-Actrapid® conjugates produced with changing pH from 
pH7-9.8 at a 2:1 molar ratio of FITC: Actrapid® after 2h and Table 2-7 
summarises the identification of each conjugate according to their RT and the 
corresponding percentage AUP. 
 
Figure 2-17: RP-HPLC Fluorescence chromatograms showing the effect of pH on the synthesis 
of FITC-Actrapid® conjugates at 2:1 molar ratio after 2h at pH7(black), pH7.5(orange), 
pH8(grey), pH8.5(yellow), pH9(blue) and pH9.8(green). The first and second peak at 21.3min 





































Table 2-7: The peaks identified by RP-HPLC analysis for FTIC-Actrapid® conjugates and their corresponding yield in percentage AUP from the above 
fluorescence chromatograms. 
pH  RP-HPLC fluorescence  
Peaks RT (min) 
(AUP %) 
Theoretical molecular mass (Da) 
(No of FITC) 
Identity of conjugates 
7 21.9 (100%) 6197.0(1) Mono-labelled species (Confirmed by MS raw data peak 
at m/z 1555.4228 z4) 
7.5 21.9 (100%) 6197.0(1) Mono-labelled species  
8 21.4 (3.2%) 6197.0(1) Mono-labelled species  
21.9 (94.9%) 
22.6 (1.9%) 6586.3(2) Di-labelled species 
8.5 21.4 (4.9%) 6197.0(1) Mono-labelled species (Confirmed by MS peak at m/z 
6198) 21.9 (89.2%) 
22.6 (5.9%) 6586.3(2) Di-labelled species (Confirmed by MS peak at m/z 6586) 
9 21.6 (60.2%) 6197.0(1) Mono-labelled species 
22.5 (39.8%) 6586.3(2) Di-labelled species 
23.2 (Trace) 6975.6(3) Tri-labelled species (Confirmed by MS peak at m/z 
6972) 
9.8 21.6 (73.8%) 6197.0(1) Mono-labelled species 
22.5 (Trace) 6586.3(2) Di-labelled species 





Although it was not possible to collect all the mass spectra data for each FITC-
Actrapid® conjugate synthesised from different conditions, Figure 2-18 illustrates the 
confirmation of three conjugated species identified by MS analysis according to their 
corresponding MS peaks at m/z 6198 ;6586 and 6972 for Mono, Di and Tri 
respectively.   
 
Figure 2-18: Mass Spectrum of FTIC-Actrapid conjugate mixture synthesised at pH9 shows a peak at 
6198 m/z corresponding to mono-labelled species; peak at 6586 m/z for di-labelled species and peak 
at 6972m/z for tri-labelled species. 
The reactions at pH7-7.5 successfully produced 100% Mono identified by a single 
peak at 21.9 min RT (refer to Error! Reference source not found.). Notably, as the pH i
ncreased to 8.0 and 8.5, there was a mixture of two different mono-labelled species 
(peaks at 21.4min RT and 21.9min RT) as well as Di, however the predominant 
species was still the mono-labelled peak at 21.9min RT. Based on previous 
chromatographic data obtained from Hentz et al. 1997, the detection of another 
mono-labelled peak with slightly shorter RT from the conjugation at pH8-8.5 highly 
suggested that the 100% Mono (peak at 21.9min RT) produced at pH7-7.5 was 
labelled at the B1 position and the earlier peak at 21.4min RT observed for pH8-8.5 
would indicate MonoA1. The reaction at pH 8.5 also yielded the highest mixture of 
Mono and Di while pH>9 showed a considerably lower production of Mono. 




range of pH9-9.5, and the general protocol for FITC labelling of protein, particularly 
immunoglobulins also recommends that the reaction should occur at pH9 for 
maximal labelling (Hermanson, 2013). However, this pH study illustrated that FITC 
labelling of insulin was best optimised at pH7-7.5 rather than the highly alkaline pH 
of 9-9.8. Although the change in pH alone was not successful in selectively labelling 
FITC at a single site of the insulin molecule, increasing the pH to ≥8 produced a 
mixture of FTIC-Actrapid® conjugates (MonoA1, monoB1 and Di); while keeping the 
pH at 7-7.5 has achieved only one mono-labelled species. This observation could be 
due to the microenvironmental effects of Actrapid® where there may be overlap in 
the nucleophilicity of the two N-terminal α-amino groups on insulin molecule at pH>8 
thus allowing covalent coupling to occur at both groups (A1 and B1 positions). 
Besides, the structural conformation of the insulin molecule may enable the 
exposure of one N-terminal α-amino group, proposed to be the phenylalanine at the 
B1, more than the other. Therefore, the production of Mono identified by the peak at 
21.9min RT was predominant at pH7-8.5. Similarly, reaction condition at pH 9.8 
could not selectively target the labelling at the ϵ-amino group of lysine (B29) possibly 
due to competitive covalent coupling of other preferable amino acid groups at the B1 
and A1 position. However, it is anticipated that by increasing the reaction time (as 
observed in Jacob,2015 study) or having twice the amount of FITC, the production of 
Di and Tri could have increased.  
Despite having some degree of selectively labelling for all three amino acid targeting 
sites with increased pH, pH7-7.5 offers the best compromise for achieving only one 
mono-labelled species. Meanwhile, the distinct difference in the pKa of Glycine at A1 
position (8.4) and Phenylalanine at B1 position (7.1) in addition to a single mono-
labelled species produced at pH7 compared to two species at pH8.5 also supported 
the hypothesis that the Mono predominantly synthesised so far was labelling at the 
B1 position. According to Hentz et al. 1997, the FITC-insulin conjugate labelled at B1 
is the most biologically active species.  However, the presence of unlabelled insulin 
in the final conjugated product is still suggesting that either optimised labelling 
conditions would require more adjustment perhaps at a higher temperature for short 




2.3.6 Reaction time study 
As explained, some pH conditions with short reaction times at 2:1 molar ratio could 
produce a single species of Mono. However, the presence of unlabelled insulin in the 
FITC-Actrapid® conjugates is still undesirable. It is, therefore, necessary to further 
investigate at which time point there will be no unlabelled insulin left while still 
achieving only the desired Mono. Observation from the previous study indicated that 
for 2:1 molar ratio (FITC: Actrapid®) at pH7, a 4h reaction time was not long enough 
to achieve this while at a 20h reaction time although there was no unlabelled insulin 
left, 5% of Di was also produced. The synthesis of FITC-Actrapid® conjugate at 2:1 
molar ratio and pH7 was further investigated at a reaction time of 17h,18h and 19h to 
determine the balance of producing only Mono without any Di or unlabelled insulin. 
Error! Reference source not found. shows the combined fluorescence c
hromatograms of FITC-Actrapid® conjugates analysed by RP-HPLC for the effect of 
4h,17h,18h,19h and 20h reaction times on achieving only the desired Mono. 
 
Figure 2-19: Fluorescence chromatograms showing the effect of reaction time on the synthesis of 
FITC-Actrapid® using 2:1 molar ratio at pH7 for 4h(black); 17h (orange);18h(grey);19h (yellow) and 



















































Notably, the cut-off points for producing Di seemed to occur at the 19h reaction time 
in which Di accounted for ~ 3% of the total conjugates produced; however, there was 
also a trace amount of unlabelled insulin detected from the PDA chromatogram at 
this reaction time, suggesting that reaction times of shorter than 20h would result in 
under-labelling of FITC to Actrapid®. Furthermore, any reaction time of ≤18h could 
achieve 100% Mono production. However, unlabelled insulin is also present, 
suggesting that further purification is necessary. In general, mono-labelling of 
Actrapid® with FITC is still achievable at longer reaction time (≥20h) to ensure 
sufficient time for all insulin molecules to become covalently coupled to FITC. 
However, this would produce a mixture of conjugates (predominantly Mono and 
some Di). To achieve the desired balance, a reaction time of 18-19h is needed but 
further synthesis development necessary. 
To examine the biological activity of the desired conjugate, it is necessary to ensure 
there is no unlabelled insulin or any other conjugated species. The isolation of FITC-
Actrapid® conjugate using RP-HPLC has been successful in achieving a 100% yield 
of the desired Mono without any unlabelled insulin. Mono was pooled from its 
synthesis of 2:1 molar ratio at pH7 and 18h reaction time. The resultant lyophilised 





Figure 2-20: RP-HPLC fluorescence chromatogram (A) of the isolated FITC-Actrapid® conjugate 
showing Mono peak at 21.9min RT and the PDA chromatogram (B) indicating the absence of 





Figure 2-21 shows the mass spectrum data for the isolated Mono sample identified 
by HPLC, confirming its molecular mass of 6192.7Da and the absence of unlabelled 
insulin. 
 
Figure 2-21: Mass Spectra for the isolated FITC-Actrapid® conjugate showing peak corresponding to 
Mono at m/z of 1240.34/5 and the absence of insulin molecular mass of 5808Da 
 





Both HPLC and MS analyses confirmed the isolated Mono was in its purest form. To 
further confirm its labelling position on the insulin molecule, an additional HCD MS2 
fragmentation spectrum of 1240.40 (5+) was also obtained. Figure 2-23 indicates 
that FITC (peak at 390.0427/1 m/z) was labelled at the B1 position (peak at 
537.1112/1 m/z which is the amino acid Phe). 
 
Figure 2-23: HCD MS2 fragmentation spectrum of 1240.40 (5+) with red dots indicating FITC 
containing fragments. Noting that the m/z peak at 390.0427/1 for FITC was present at the first amino 
acid of the -chain which is B1(Phe) 
Generally, a quick and robust synthesis protocol by merely adjusting specific 
reaction conditions to achieve the desired MonoB1 production would be preferred 
without having to consider the use of protecting group, involving multiple steps of 
synthesis and purification of intermediates. Modification of pH, molar ratio and 
reaction time have been successful in producing a single species of mono- labelled 
FITC-insulin conjugate. However, it is necessary to compromise a balance between 
obtaining the highest degree of labelling that is consistent with the preservation of 




binding that can result in labeling of other species with reduced activity. Despite the 
production of a single entity (MonoB1) using 2:1 molar ratio (FITC: Actrapid®) at pH7 
with all reaction time lower than 18h, the compromise leaves unlabelled insulin in the 
final conjugated products and this is undesirable. However, this problem was 
overcome by further removal of unlabelled insulin using RP-HPLC method to isolate 
only the desired MonoB1 from the synthesis with the highest yields. 
2.4 Chapter summary 
The need to synthesise fluorescently labelled insulin inhouse was first because 
commercially available FITC-insulin was expensive and not readily available. 
Secondly, labelling insulin randomly may result in insulin losing its biological activity 
and thus is not practically ideal for studying the cellular activity of insulin. In our 
particular work, large amounts of fluorescently labelled insulin will be necessary for 
further in-vitro diffusion experiments to investigate the release profile of insulin from 
the closed-loop insulin delivery (INsmart) device developed within our group. FITC-
bovine insulin and FITC-HI available from Sigma Aldrich were both found to contain 
a mixture of Mono, Di and Tri as analysed by Jacob 2015. The commercial FITC-
bovine insulin also contained unlabelled bovine insulin and unreacted FITC while Tri 
were the main products identified in the commercial FITC-HI. Each of these is 
undesirable for representing the in-vitro rate of insulin release from our INsmart 
device since the diffusion rate of FITC alone compared to FITC-HI gives an 
overestimate due to the big differences in molecular weight. In addition, unlabelled 
insulin cannot be analysed by fluorescence detection, therefore the diffusion rate 
analysed from FITC-HI alone may represent only a fraction of the total insulin 
released from the INsmart device. Moreover, fluorescence detection offers highly 
sensitive and specific quantification at significantly lower concentration compared to 
UV absorbance of insulin alone, which could be compromised by the protein 
absorbance of the smart gel components in the device. Therefore, FITC-labelled 
insulin was chosen as an improved analytical tool for fluorescence quantification to 
understand the release profile of insulin from the INsmart delivery device. 
The synthesis protocol according to previous studies by Hentz et al.1997 and Jacob 
2015 was adopted and further developed to produce the most biologically active 
FITC-Actrapid® conjugate, which is mono-labelled at the B1 position. Previously, the 




molar ratio of 3:1 after 25h reaction. This conjugate was predominantly di-labelled 
species (75%). However, the synthesis was successful in confirming the absence of 
unlabelled insulin. It is anticipated that using further modification of these reaction 
conditions, it would be possible to synthesise only MonoB1. This desired conjugate 
is ideal for retaining the biological activity of native insulin as well as offer a more 
realistic release of insulin from the closed-loop insulin delivery device. The following 
summaries key findings and achievements: 
➢ Clinically used insulin analogues synthesised for commercially available 
insulin injections often have modifications to their amino acid sequences 
which may be of interest to selectively target FITC labelling at a certain site.  
Screening of short-acting, rapid-acting and intermediate-acting insulin 
preparations for the production of FITC-insulin conjugates using 2:1 molar 
ratio at both short and long reaction time has selected Actrapid® as the best 
candidate for achieving the desired mono-labelled species. Besides, the quick 
onset of action exhibited by Actrapid® also makes it the most preferable 
product for future biological applications in tracing and receptor binding essay 
using both in-vitro and in-vivo study. 
➢ Reducing the molar ratio of FITC/insulin to 2:1 has successfully prevented the 
production of Tri while minimising the yield of Di at a reaction time of 20h 
however the conjugates synthesised at a shorter reaction time than 20h 
always contain some unlabelled insulin. The result suggested that having a 
high amount of FITC would increase the chance of producing more di- and tri-
labelled species, especially at a long reaction time of ≥ 20h. In another way, 
lowering the molar ratio of FITC has selectively inhibited the labelling of FITC 
at the B29 position that results in the production of Tri, however, reducing the 
amount of FITC also limits the degree of insulin labelling and therefore there 
would be a higher amount of unlabeled insulin at shorter reaction time. A fine 
balance of FITC: insulin molar ratio and sufficient reaction time are therefore 
required to achieve optimal labelling. 
➢ Having a low amount of FITC as in 0.5:1 molar ratio (FITC/Actrapid®) also 
produced only Mono. However, there was more unlabelled insulin present in 
the conjugates. Longer reaction time at this low molar ratio was not studied in 




unlabelled insulin however it might be of interest to find out if the production of 
Di can be prevented even at longer reaction time than 20h using this low ratio. 
Overall, 2:1 molar ratio has been chosen for further synthesis to produce the 
desired Mono  
➢ Adjusting the pH of the reaction mixture close to the pKa of the individual 
amino acid at A1 (pKa of 8.4); B1(pKa of 7.1) and B29 (pKa>9.8) could not 
selectively target labelling to a specific amino acid. There was some degree of 
selective labelling at pH≥8 which resulted in the production of two mono-
labelled species at A1 and B1 positions with some Di (6%) even at a short 
reaction time of 2h. Reaction at pH≥9 resulted in a mixture of conjugates 
including Mono, Di and Tri. Meanwhile, only the reactions at pH7 and 7.5 
have successfully produced a single Mono (100%). However, unlabelled 
insulin was also present at 2h reaction time. Based on the chromatographic 
data presented by Hentz et al., the production of mixed conjugates at pH≥8 
highly supported the hypothesis that the Mono produced at pH7-7.5 could be 
labelling at the B1 position, which according to Hentz et al. is also the most 
biologically active species. 
➢ Several reaction times of less than 19h at pH7 using 2:1 molar ratio 
(FITC/Actrapid®) are capable of producing only the desired Mono. However, 
optimise labelling of FITC to Actrapid® is not yet achieved due to the 
presence of unlabelled insulin in the final conjugated product. Further HPLC 
purification of the highest Mono yield produced at 2:1 molar ratio, pH 7 after 
18h has successfully removed any unlabelled insulin to achieve 100% pure 
Mono. This was confirmed by RP-HPLC and MS to only contain mono-
labelled species labelled at the B1 position. Further examination of this 










 . The biological activity study of FITC-insulin 
species synthesised in-house 
 
3.1 Introduction  
The experimental work presented here provides one of the first investigations 
into the biological activity of four different FITC-Actrapid® conjugates 
synthesised inhouse using HUVEC. The insulin signalling pathway for the 
regulation of glucose metabolism has been well studied both in-vitro and in-vivo 
using insulin-responsive models such as skeletal muscle, adipose and liver cells 
(Karlsson et al., 2005; Titchenell et al., 2016; Honka et al., 2018). The use of 
HUVEC has also been used as a model for insulin signalling studies, however 
the specific effect of insulin stimulation on glucose metabolism has not yet been 
investigated (Maeno et al., 2012). Besides, there is also very little research on 
the expression of insulin-dependent glucose transporter (GLUT4) in HUVEC. 
More investigation into the regulation of insulin, especially glucose transport, in 
HUVEC is, therefore, necessary to address this gap in the existing literature. 
This chapter covers a basic overview of the insulin signalling pathway; its 
specific role for glucose uptake; introduction to endothelial cells and their use to 
investigate the biological effect of insulin. The main objective is to assess the 
biological activity of Actrapid® and its fluorescent labelled conjugate with FITC 
by measuring the level of serine/threonine AKT phosphorylation and GLUT4 
translocation via the insulin signalling pathway in HUVEC and skeletal muscle 
cells C2C12 respectively. The outcome of the study would confirm if the mono-
labelled FITC-Actrapid® conjugate synthesised inhouse has similar or 
equivalent biologically activity as native insulin. 
 
3.1.1 Insulin signalling pathway overview 
Principally, cells communicate and function via a specific biochemical signalling 
pathway which involves three essential elements: the substrate/stimuli, a 
receptor type on the cell membrane and a cascade of events that triggers series 
of cellular activities once the substrate/stimuli binds to its receptor. The insulin 
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signalling pathway is one of the most important mechanisms of biological 
action, which regulates many fundamental functions of the cells. Cellular 
responses to insulin involve regulation of glucose homeostasis, stimulation of 
glycogenesis, lipogenesis and protein synthesis, modification of gene 
expression leading to cell proliferation, cell differentiation and apoptosis (Kolb et 
al., 2020; Hatting et al., 2018). The signalling pathway of insulin is also one of 
the most attractive research areas not only because of its fundamental roles in 
cellular activity but also due to its complex yet impressive cascade of cellular 
events that help maintain normal cell functions. Besides, these cascades of 
events stimulated by insulin are also famous as a targeting site for the treatment 
of diabetes mellitus and other related diseases (Kerru et al., 2018; Artasensi et 
al., 2020; Yaribeygi et al., 2019b). Although the activity and function of insulin 
involve complex signalling cascades, one keynote is that these series of events 
would occur in a chronicle cascade, most of which is via phosphorylation of 
several substrate proteins and disruptions to these events would result in 
abnormal cell function or disease (Di Camillo et al., 2016).  
Initially, insulin hormone released to the bloodstream by beta cells from the 
islets of Langerhans in response to high blood glucose level arrives at the 
extracellular fluid and are recognised by its insulin receptor (IR) on the cell 
surface of target tissues. As detailed in chapter 3, IR is a glycoprotein dimer 
consisting of two extracellular (α) and two transmembranes (β) subunits that 
also project inside the cell. The signalling begins when insulin, the primary 
messenger, binds to the alpha subunit of IR of target cells on the extracellular 
membrane, resulting in dimerisation of the receptor to form the α2β2 complex in 
the cell membrane. This complex, in turn, activates the beta subunit of the IR by 
auto-phosphorylation of its activating loop. Here, the three tyrosine kinase 
residues on each beta subunits are phosphorylated (Figure 3-1), leading to the 
phosphorylation of several substrates that provide specific docking sites for the 
recruitment of other downstream signalling proteins (Hall, Yu and Choi, 2020; 




Figure 3-1: Initial activation of the insulin receptor. Insulin binds to insulin receptors triggering its 
dimerisation (1) and intracellular autophosphorylation of their tyrosine residues (2) (Adapted 
from Chapman 2013) 
The subsequent result from a fully activated IR then leads to the activation of 
two major signalling cascades of events: the mitogen-activated protein kinases 
(MAPK) pathway and phosphatidylinositol 3 kinase (PI3K)/ AKT pathway. The 
MAPK pathway which is also known as the extracellular signal-regulated kinase 
mainly involves in the regulation of genes expression and therefore has a role in 
mitogenic functions of cell growth (Hall, Yu and Choi, 2020; Zhao and Zheng, 
2017). Meanwhile, the PI3K/ AKT pathway is regulated exclusively by the 
insulin receptor substrate (IRS) and is responsible for the metabolic action of 
insulin throughout the body (Madhunapantula, Mosca and Robertson, 2011; Rai 
et al., 2019; Świderska et al., 2018)  
The metabolic action of the insulin-dependent cascade is carried out by most 
cell types in the body yet is more specific to cells of the muscle tissue, vascular 
endothelium, heart, adipose tissue and liver. Initially, glucose metabolism via 
glucose uptake into cells of adipose tissue, skeletal muscle, and the heart is 
one of the essential responses generated by insulin’s effects to maintain 
glucose homeostasis (Zatterale et al., 2020; Chadt and Al-Hasani, 2020; Rai et 
al., 2019). In the liver, insulin exerts its metabolic effect on the reduction of 
gluconeogenesis (production of glucose) and increases in glycogenesis 
(conversion of glucose to glycogen). Insulin also stimulates the synthesis of fat 
as a source of energy storage and protein synthesis as well as conversely 
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inhibits lipolysis and protein degradation. Vasodilation via the production of nitric 
oxide (NO) is also observed in the vascular endothelium and heart as a result of 
insulin stimulation (Bahadoran, Mirmiran and Ghasemi, 2020; Vargas and 
Carrillo Sepulveda, 2019). 
Although the full pathway of insulin signalling is far too complex to be discussed 
in detail as it involves several signal-transduction steps and consequential 
series of responses. The need to understand the effect of insulin stimulation 
that leads to the phosphorylation of AKT is important for the investigation of 
insulin biological activity in fluorescently labelled insulin candidates. A more 
detailed account for the mechanism of insulin action through the PI3K/AKT 
signalling pathway is discussed in the next section. 
3.1.2 Insulin stimulates PI3K/AKT signalling pathway 
The following description mainly focuses on the mechanisms of PI3K/AKT 
signalling that regulates metabolism in normal physiology in response to insulin 
stimulation (refer to  Figure 3-2).  
 
Figure 3-2: Summary of Insulin stimulates PI3K/AKT signalling pathway: (1) Phosphorylated 
IRS-1 leading to activation of PI3K (2), resulting in the formation of PIP3 (3) as a second 
messenger. (4) PDK1 is then activated, subsequently leading to activation of AKT to its 
phosphorylated form (5), which leads to the phosphorylation of AS160 (6), causing translocation 
of GLUT4 vesicle to the cell membrane (7). GLUT4 facilitates the influx of glucose, leading to 




The PI3K/AKT pathway starts when one of the phosphorylated tyrosine kinase 
residues of the IR attracts the IRS-1. This adaptor protein IRS-1 is one of major 
substrates of the IR along with IRS-2 and IRS-4, usually described as a platform 
for the signalling complex. Upon binding, the IRS-1 is phosphorylated by the 
insulin receptor kinase. The phosphorylated IRS-1 now acts as an attachment 
point for PI3K, a lipid kinase. Once the regulatory region of PI3K attached to the 
phosphorylated residues of IRS-1, it causes the active site of PI3K to move in 
close proximately to the membrane where phosphatidylinositol 4,5- diphosphate 
(PIP2) is found. Here, the active PI3K attaches a phosphate group from an ATP 
molecule onto PIP2, creating phosphatidylinositol 3, 4, 5 triphosphates (PIP3) – 
the second messenger. This PIP3 travels along the membrane to activate the 3-
phosphoinositide-dependent protein kinase 1 (PDK1). This activated PDK1 
subsequently activates AKT (also known as protein kinase B or PKB) via two 
mechanisms: PDK1 can directly phosphorylate AKT at Threonine 308 
phosphorylation site or it can indirectly activate mTOR complex, which then can 
phosphorylate AKT at Serine 473 phosphorylation site. The activated AKT then 
consequentially leads to phosphorylation of AS160 (AKT substrate of 160kDa). 
Under normal physiology without insulin stimulation, AS160 substrate protein 
acts as an inhibitor of GLUT4 translocation, preventing its localisation to the 
membrane. However once phosphorylation of AS160 occurs, translocation of 
GLUT4 from the cytoplasmic vesicles onto the cell membrane surface will be 
stimulated (Khorami, Movahedi and Sokhini, 2015; Huang et al., 2018; 
Sugiyama, Fairn and Antonescu, 2019). The resultant GLUT4 translocation to 
the cell membrane thereby increases the insulin-dependent transport of glucose 
into the cell, leading to glycolysis. 
One important point to consider is that under normal physiology, both receptor 
tyrosine kinase and G-Protein coupled receptor can lead to the activation of 
AKT (Law, White and Hunzicker-Dunn, 2016; Sugiyama, Fairn and Antonescu, 
2019; New et al., 2007). AKT is a well-known target for multiple pathways 
however under basal conditions, AKT activation is relatively low therefore it is of 
interest to investigate the enhanced AKT activation in the presence of insulin. 
Beside AS160 substrate protein, the activated AKT also plays a vital role in the 
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cell signalling mechanisms that regulate the activity of many other major 
proteins (such as mTOR, FOXO) for cell metabolism, cell survival and 
proliferation (Nitulescu et al., 2018; Revathidevi and Munirajan, 2019). Noting 
that these responses from activated AKT were not illustrated in Figure 3-2 
since the key focus is to simplify the insulin signalling cascade leading to AKT 
phosphorylation only. However, to facilitate the study behind the biological 
activity of fluorescently labelled insulin candidates, the insulin action on GLUT4 
translocation will be detailed in the following section. 
 
3.1.3 Insulin regulation of glucose transporters 
Glucose is an essential carbohydrate and primary energy resource within most 
cells, especially mammalian cells. Since most living cells use glucose for their 
energy production, glucose transport across the cell membrane is therefore 
critical for life. However, because of its relatively large size and polar nature, 
glucose molecules cannot cross the cell membrane by simple diffusion due to 
the impermeable property of the lipid bilayer to polar carbohydrate.  Instead, the 
entry and exit of glucose molecules across the cells are mainly achieved by 
glucose transporters (Stringer, Zahradka and Taylor, 2015; Yaribeygi et al., 
2019; Navale and Paranjape, 2016). Under basal conditions, the initial supply of 
energy is from the breakdown of endogenous glycogens which are stored in the 
liver for whole-body usage. These stores are replenished by glucose from diet. 
Following carbohydrate digestion and glucose absorption in the circulation, 
insulin secretion from the pancreatic β-cells is stimulated, leading to the 
distribution of glucose among various tissues in the body (Gonzalez and Betts, 
2019b; Chadt and Al-Hasani, 2020). In order to achieve rapid uptake of glucose, 
the brain, muscle and adipose tissues have to adapt with highly specialised 
glucose- transport system (Chadt and Al-Hasani, 2020; Wasik and Lehtonen, 
2018; Koepsell, 2020). This system is not only crucial for insulin-dependent 
glucose storage in muscle and adipose tissues after a meal to maintain normal 
blood glucose levels consistently but also particularly important during exercise 
to meet rapidly high metabolic requirements of skeletal muscles (Sayem et al., 
2018). Meanwhile, although the brain is also highly equipped with specialised-
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glucose transporters, it is understood that glucose uptake in most brain cells is 
not dependent on insulin (Gray, Meijer and Barrett, 2014; Koepsell, 2020). 
Glucose distribution throughout the body is performed by a family of glucose 
transporter proteins which act as vehicles to carry glucose across the cell 
membrane. Sodium-glucose linked transporters (SGLTs) and facilitated 
diffusion glucose transporters (GLUTs) are two main types of glucose 
transporters that have been identified. SGLTs are also known as secondary 
active transporters that use the sodium concentration gradient generated by the 
sodium-potassium ATPase as a source of chemical potential to drive glucose 
uptake (Mueckler and Thorens, 2013; Stringer, Zahradka and Taylor, 2015). On 
the other hand, GLUTs are classed as facilitative glucose transporters that 
transport glucose across the plasma membrane using a facilitated diffusion 
mechanism as its class suggested. Here, glucose molecules diffuse down their 
concentration gradient across the cell membrane via GLUTs protein channels to 
enter the cells. Both types of transport are equally essential and can be found 
across different tissues and organs. SGLTs express mainly on the luminal 
surfaces of cells lining the small intestine where they absorb glucose from diet. 
They are also known to facilitate the reabsorption of glucose from the 
glomerular filtrate and are therefore present in renal tubules. While SGLTs are 
responsible for reabsorption of glucose into the circulation, GLUTs are essential 
for the transport of glucose into the cells where it can be utilised as energy or 
stored as glycogen and fat. GLUTs are proteins containing 12 membrane-
spanning regions with intracellularly located amino and carboxyl terminals. 
According to recent researchers, 14 mammalian facilitative GLUTs have been 
identified until now. Each of them has distinct substrate affinity, specificity, and 
tissue distribution (Navale and Paranjape, 2016; Long and Cheeseman, 2015; 
Klip, McGraw and James, 2019). They are subdivided into three classes based 
on their protein sequences and structural similarity as summarised in Table 3-1. 
The information listed below is mainly collected from reviews by Calvo et al., 
2010 and Navale and Paranjape, 2016. 
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Tissue distribution Function 
Class I GLUT1 Red blood cells present in all 
human tissue, blood-brain barrier, 
heart (lesser extent) 
Insulin independent- primary vehicle for transport of glucose from the blood into 
the brain as well as across other blood and tissue barriers to ensure that both 
brain and RBC receive the appropriate level of glucose.  
GLUT2 Beta cells of the pancreas, liver 
and kidney. 
Insulin-independent 
Act as glucose sensor of the insulin‐secreting β‐cells  
GLUT3 
(GLUT14) 
Brain, Neurons  Insulin-independent 
Transfer glucose into the cells that have a higher requirement of glucose 
GLUT4 Heart, brain, skeletal muscle, 
adipose tissue 
Insulin-dependent  
Increase glucose uptake into the cells from circulation. 
Class II GLUT5 Cells of the small intestine, testes 
and kidney 
Primary transporter of fructose 
GLUT7 Cells of the small intestine, colon, 
testis and prostate 
High-affinity transporter for glucose and fructose 
GLUT9 The proximal tubule of the kidney, 
in the liver and placenta 
major transporter for uric acid reabsorption by the kidney 
GLUT11 Heart, placenta, skeletal muscle, 
kidney and pancreas cells, adipose 
tissue 
Facilitate the transport of both glucose and fructose 
Class III GLUT6 Brain, spleen cells and peripheral 
leukocytes 
low-affinity glucose transporter 
GLUT8 Brain and testis cells Not regulated by insulin, facilitate glucose transport through the intracellular 
membrane such as mitochondria membrane 
GLUT10 Heart, brain, placenta, skeletal 
muscle, lung, kidney, liver and 
pancreas cells 
maintaining redox homeostasis 
GLUT12 Adipose tissue, small intestine, 
skeletal muscle, pancreas. 
Insulin-dependent but influenced by protons. 
Facilitate transport of glucose in a similar mechanism as GLUT4 
GLUT13 Brain, Blood-brain barrier, Adipose 
tissue 
specific transporter for myoinositol 
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As emphasised on the fundamental role of insulin in maintaining glucose 
homeostasis, GLUT4 also plays a vital role as the only source of insulin-
sensitive glucose transport. It is expressed mainly in skeletal muscle and 
adipose tissues and to a smaller extent in heart tissues. (Klip, McGraw and 
James, 2019; Chadt and Al-Hasani, 2020) Under basal state, GLUT4 resides in 
intracellular cytoplasmic vesicles called GLUT4 storage vesicles (GVS). In 
response to increased BG level, insulin stimulates glucose uptake via GLUT4 
by efficiently deposing of glucose bulk from the circulation into skeletal muscle 
and other target tissues. Upon insulin stimulation, GLUT4 vesicles would 
undergo exocytosis to enable GLUT4 translocation to the plasma membranes. 
GLUT4 exocytosis can be described as a process involving the generation of 
GLUT4 vesicles moving from the trans-Golgi network region to the plasma 
membrane and finally fusion of these vesicles to the plasma membrane (Hou 
and Pessin, 2007; Stöckli, Fazakerley and James, 2011; Vargas and Carrillo 
Sepulveda, 2019), refer to Figure 3-3. Here, GLUT4 acts as a protein channel 
allowing the influx of glucose across the plasma membrane into the cells. After 
uptake, glucose can either be stored as glycogen or undergo oxidation in the 
mitochondria for energy conversion (Bahari et al., 2020; Son and Wu, 2019) 
 
Figure 3-3: Trafficking of GLUT4 exocytosis:(1) Movement of GVS from the Trans-Golgi network 
toward the plasma membrane (2) Tethering;(3) Docking and (4) Fusion of GVS with the 




Another model of GLUT4 exocytosis is understood to involve the initial 
approach of GVS by specialised microtubules on the cell membrane, followed 
by tethering of these vesicles mediated by large multi-subunit complexes. 
Further docking and fusion of GLUT4 vesicles to the cell membrane allow 
GLUT4 to exert its action. This sophisticated model falls beyond the objective of 
this biological activity study to be discussed in detail. In fact, the underlying 
process involving tethering, docking and fusion of the GLUT4 vesicles to the 
plasma cell membrane is only partially understood to involve complex 
interactions between various proteins and several regulatory factors  (Stöckli, 
Fazakerley and James, 2011; Jaldin-Fincati et al., 2017; Vargas, Podder and 
Sepulveda, 2019) 
Over the past few decades, more information has become available from the 
extensive study of GLUT4 trafficking to establish that GLUT4 is a continuously 
recycling membrane protein. This cycling process of GLUT4 involves its 
exocytosis movement from the endosomal origin towards the plasma 
membrane and its endocytosis movement from the membrane back to the 
endosomal sorting system (Jaldin-Fincati et al., 2017; Tunduguru and 
Thurmond, 2017; Klip, McGraw and James, 2019). Endocytosis of GLUT4 
involves the budding of clathrin-coated vesicles of GLUT4 on the plasma 
membrane then upon internalisation, GLUT4 becomes a part of the early 
endosomes and re-sorted back into intracellular vesicles (Figure 3-3) (Hou and 
Pessin, 2007; Vargas, Podder and Sepulveda, 2019). A detailed process of 
GLUT4 vesicles budding and internalisation will not be illustrated here. 
However, reviews by Hou and Pessin, 2007 and Antonescu et al., 2009 have 
discribed the activity of some protein complexes contributing to GLUT4 
endocytosis. Nevertheless, GLUT4 exocytosis has been studied to a larger 
extent because insulin is well established to rapidly stimulate the rate of GLUT4 
exocytosis in adipose and skeletal muscle cells while there is inadequate 
literature to support the regulation of GLUT4 endocytosis by insulin (Jaldin-
Fincati et al., 2017; Elhassan et al., 2018; Brewer et al., 2014; Watson and 
Pessin, 2007). Interestingly, as suggested by Gonzalez and McGraw, 2006 the 
 
 109 
primary regulator of GLUT4 exocytosis, which is AKT, is not required for insulin 
regulation of GLUT4 endocytosis. 
PI3K/AKT pathway is a major insulin signalling that leads to GLUT4 
translocation, through phosphorylation of the AS160 substrate as described in 
the previous section. AS160 is a GTPase-activating protein that when 
phosphorylated activates small G proteins called Rabs, which are important for 
the organisation of intracellular membrane trafficking (Tan et al., 2012; Homma, 
Hiragi and Fukuda, 2020). The switching between the active form by GTP 
loading and inactive forms via GTP hydrolysis of Rabs is catalysed by guanine 
nucleotide exchange factors (GEFs) and GTPase-accelerating proteins (GAPs). 
Here, during unstimulated conditions, Rabs are maintained in their GDP-loaded 
inactive form by the active AS160, retaining GLUT4 stored as GSVs within the 
intracellular space. Once insulin stimulates phosphorylation of AS160 via 
activated AKT, the activity of AS160 is inhibited. The overall effect leads to the 
activation of a Rab protein which then regulates docking and fusion of GSVs 
with the plasma membrane hence resulting in GLUT4 translocation (Jaldin-
Fincati et al., 2017; Brewer et al., 2014). It was evidenced that insulin-stimulated 
GLUT4 translocation could be inhibited by the expression of mutant AS160 that 
missing AKT-specific phosphorylation site or the knockdown of AS160 in 
specific tissues (Tan et al., 2012; Sano et al., 2003). 
Meanwhile, other pieces of evidence also suggested that the proto-oncoprotein 
c-Cb1 tyrosine phosphorylation is also stimulated by insulin, initiating another 
signalling cascade which is independent of the PI3K pathway. Although this 
cascade of events has not been studied extensively, the key finding is that this 
insulin-dependent stimulation process would also subsequently lead to GLUT4 
translocation to the plasma membrane (Liu et al., 2009; Vargas and Carrillo 
Sepulveda, 2019) .  
Besides insulin, exercise and physical activity causing muscle contractions also 
stimulates glucose transport via GLUT4 translocation in skeletal muscle through 
an AMK -dependent mechanism, which is independent of the insulin-stimulated 
pathway. Skeletal muscle contraction triggered by membrane depolarisation 
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results in increased intracellular calcium ion (Ca2+) and reduced intracellular 
ATP concentrations. This change, in turn, leads to activation of 5’-AMP-
activated protein kinase (AMPK) which is believed to contribute to exercise-
responsive GLUT4 vesicles translocation to the plasma membrane. Here, 
GLUT4 mediate glucose transport into the cells to meet the increased energy 
demands of skeletal muscle during exercise  (Knudsen et al., 2020; Sylow et al., 
2016; Richter and Hargreaves, 2013) 
 
Many recent reviews related to insulin activity and signalling pathways have a 
rise in complexity and cascade of events in addition to increasing number of 
protein complexes involved and other chemicals contributing to the 
accomplishment of insulin functions. Understanding many intricate steps in 
GLUT4 translocation is essential to investigate the nature of defects in insulin 
resistance so that improved strategies and specialised treatment choices can 
be designed to tackle complications of diseases affected by insulin resistance. 
However, it is beyond the scope of this study to discuss in detail, the overall 
objective of this review is to assist a basic understanding of insulin signalling 
pathways yet simplify the key regulation of insulin biological activity involved in 
the phosphorylation of AKT and GLUT4 translocation to the plasma membrane, 
thus the consequence effect in maintaining glucose homeostasis as described 
in section 1.1.1. 
 
3.1.4 The Role of Insulin signalling in Human Endothelial Cells. 
In addition to its metabolic roles, insulin also has vasodilator actions in the 
production of NO from the vascular endothelium (Luse et al., 2020; Walsh et al., 
2019). Functional insulin receptors are also expressed on endothelial cells, thus 
enabling intracellular signalling responses to insulin stimulation (Kolluru, Bir and 
Kevil, 2012; Escudero et al., 2017). Many studies have demonstrated that 
insulin induces this vasodilator response via the PI3K-AKT pathway (Mammi et 
al., 2011; Jiang et al., 2014; Muniyappa et al., 2020). Following insulin 
stimulation as detailed in section 3.1.2, the Serine/Threonine protein kinase 
AKT will be activated which leads to the enhancement of endothelial nitric oxide 
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synthase (eNOS) phosphorylation, resulting in NO production. NO is one of the 
most important signalling molecules in endothelial cells due to its potent 
vasodilator action as well as a powerful anti-platelet activity, preventing platelets 
from sticking to vessel walls and anti-leukocyte factor to reduce inflammation. 
Production of NO is essential for mediating dilation and improve blood flow 
hence ensuring sufficient nutrient supply to tissue (Janus et al., 2016; 
Strembitska et al., 2018; Luse et al., 2020). More importantly, it has been 
reported that inhibition of insulin via the PI3K/AKT pathway could lead to 
impaired NO availability and loss of NO function, which is one of the earliest 
indicators or markers of CVD(Zeng et al., 2000; Jiang et al., 2014; Ormazabal et 
al., 2018). Additionally, a decrease in NO bioavailability is well observed in 
patients with type 1 and type 2 diabetes and also in cardiovascular disorders 
such as hypertension and atherosclerosis associated with insulin resistance 
(Salt et al., 2003; Tessari et al., 2010; Assmann et al., 2016).  
Generally, HUVECs which originate from the vein of the umbilical cord, are one 
of the most popular model systems used to study the regulation of endothelial 
cell function in-vitro because of their relatively high availability compared to 
other types of blood vessels. Their common applications in physiological and 
pharmacological investigations include macromolecule transport, blood 
coagulation, angiogenesis, and fibrinolysis (Cao et al., 2017). In addition, there 
are many important endothelial markers such as selectins expressed in 
HUVECs, as well as signalling molecules associated with vascular physiology 
like NO (Caniuguir et al., 2016; Choi et al., 2018).HUVECs, like other ECs, 
could produce NO through the activity of eNOS to regulate the function of blood 
vessels (Karbach et al., 2014; Gimbrone Jr and García-Cardeña, 2016). 
Although there is still a lack of evidence for the expression of GLUT4 in 
HUVECs, some studies suggested that mainly GLUT1, GLUT3 and GLUT4 are 
expressed in endothelial cells. However, GLUT1 is said to more predominant 
(Al Mamun et al., 2020; Li, J. et al., 2020; Yazdani et al., 2019). It is of interest 
to investigate the translocation of GLUT4 in response to insulin stimulation in 
HUVECs since GLUT1 is independent of insulin as detailed in Table 3-1. 
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There have been several studies examining the effects of insulin stimulation 
using HUVEC, none of which explicitly investigates the GLUT4 translocation. 
However, it is well established that insulin resistance is one of the key 
contributors to many complications of CVD and HUVECs have been used as an 
endothelial model to investigate the treatments of insulin resistance. In 
particular, Mammi et al., 2011 used HUVECs to study the effect of sildenafil, a 
phosphodiesterase 5 (PDE5) inhibitors, in insulin resistance conditions. Here, 
HUVECs were treated with insulin in the presence of glucose 30 mM and 
glucosamine 10 mM with or without sildenafil. In insulin resistance conditions, 
the activation of AKT and eNOS was found to be impaired to a certain extent 
depending on the level of resistance, leading to reduced vascular functions in 
patients with diabetes. AKT phosphorylation is one of the most crucial steps 
within insulin signalling cascade for the regulation of glucose homeostasis, 
glycogenesis, lipogenesis and protein synthesis. In the case of HUVEC, pAKT l 
enhances the activation of eNOS, leading to NO production. The level of AKT 
phosphorylation and NO production were the two main measurements in 
Mammi’s study to assess the potential therapeutic use of sildenafil in restoring 
the activation of AKT and eNOS in insulin resistance conditions. Promisingly, 
the data has indicated that sildenafil might help restore the level of AKT and 
eNOS activation in insulin resistance conditions (Mammi et al., 2011). 
 
Another study by Yang et al., 2016 also used HUVECs to evaluate the effect of 
atorvastatin- a vessel protective drug that is used to reduce blood cholesterol on 
insulin resistance-associated endothelial dysfunction. In Yang’s study, HUVECs 
were pre-treated with different glucose concentrations with, or without insulin for 
24 h, following treatment with atorvastatin. Interestingly, a wide range of 
phosphorylation products derived from the insulin signalling pathways were all 
assessed during this experimental study. These measurements included the 
tyrosine phosphorylation of IR and IRS-1, the production NO, the activity and 
phosphorylation level of eNOS on serine1177 although not the phosphorylation 
level of AKT. This study not only illustrated certain key steps within the insulin 
signalling pathways using HUVECs but also demonstrated that high 
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concentrations of glucose and insulin for 24 h would result in an insulin 
signalling impairment and lead to endothelial dysfunction. The data also showed 
promising result of atorvastatin used in a dose-dependent manner under insulin 
resistance state to enhance the protein expression of phosphorylated IR, IRS-1 
and eNOS as well as increased activity of eNOS and the production of NO 
primarily via the PI3K/AKT/eNOS pathway (Yang et al., 2016). 
Many other studies have also investigated HUVEC response to insulin primarily 
via the IRS/PI3K/AKT/eNOS pathways and mostly analysed by the level of IRS 
or AKT phosphorylation; the activity of eNOS or the production of NO. These 
studies are designed either by inhibition of insulin signalling or mimicking insulin 
resistance state in order to investigate the potential therapeutic use of certain 
medicines or chemicals in CVD related to insulin resistance (Maeno et al., 2012; 
De Nigris et al., 1; Choi et al., 2018).The use of HUVEC is therefore supported 
in this particular study to investigate the insulin signalling pathway of PI3K/AKT 
in response to both insulin and its FITC-labelled conjugates stimulation.  
Meanwhile, it is without question that skeletal muscle is one of the major target 
tissues for insulin activity and plays an essential role in insulin-induced glucose 
uptake since most studies used skeletal muscle or adipose tissue as a model 
for in-vitro testing to investigate the GLUT4 translocation response to insulin 
stimulation (Brewer et al., 2014; Coughlan et al., 2016; Vazirani et al., 2016). 
Nevertheless, evidence is still lacking in supporting GLUT4 translocation in 
response to insulin stimulation in HUVEC; therefore, this specific study design 
will make a novel contribution to this field. The objective of this study is to 
confirm if our Mono-labelled FITC-insulin conjugate synthesised inhouse is as 
biological active as native insulin based on the levels of AKT phosphorylation 
and GLUT4 translocation as the key criteria in the insulin signalling pathway. 
 
3.2 Materials and Methods 
3.2.1 Chemicals and Reagents 
Table 3-2 includes chemicals and reagents used in this biological activity study.  
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Table 3-2: List of chemicals and reagents used 
Chemical and Reagents Origin 
HUVEC Sigma-Aldrich (UK) 
GibcoTM Medium 200 and Medium DMEM Fisher (Loughborough UK) 
Sterilised phosphate buffer (PBS) Fisher (Loughborough UK) 
Fetal bovine serum (FBS) Fisher (Loughborough UK) 
GibcoTM Low Serum Growth Supplement 
(LSGS) 
Fisher (Loughborough UK) 
Semi-skimmed milk powder Tesco 
Rabbit Phospho-AKT (Ser473) (193H12) 
primary antibodies 
Abcam (UK) 
Goat AKT primary antibodies Abcam (UK) 
Anti-goat (IgG) secondary antibodies Abcam (UK) 
Anti-rabbit (IgG) secondary antibodies Abcam (UK) 
Rabbit GLUT-4 primary antibodies (ab654) Abcam (UK) 
Alexa Fluor 546 goat anti-rabbit IgG (H+L) Fisher (Loughborough UK) 
Protein marker  Sigma-Aldrich (UK) 
HPLC graded Methanol Fisher (Loughborough UK) 
Sodium orthovanadate Sigma-Aldrich (UK) 
Dithiothreitol (DTT) Sigma-Aldrich (UK) 
Acrylamide/Bis-acrylamide (Acry/Bis), 30%  Fisher (Loughborough UK) 
EDTA Sigma-Aldrich (UK) 
Bromophenol blue Sigma-Aldrich (UK) 
Sodium Dodecyl Sulphate (SDS) Sigma-Aldrich (UK) 
Ammonium persulfate (APS) Sigma-Aldrich (UK) 
N, N, N′, N′-Tetramethyl ethylenediamine 
(TEMED) 
Sigma-Aldrich (UK) 
Tris base Sigma-Aldrich (UK) 
NaCl Sigma-Aldrich (UK) 
Bovine Serum Albumin (BSA) Fisher (Loughborough UK) 
Triton-X100 Sigma-Aldrich (UK) 
p-coumaric acid MP Biomedicals (Solon,USA) 
Luminol  Sigma-Aldrich (UK) 
DMSO Sigma-Aldrich (UK) 
Hydrogen peroxide Sigma-Aldrich (UK) 
FITC-Actrapid conjugates Produced in house 
Stripping buffer(10X) Sigma-Aldrich (UK) 
 
C2C12 skeletal muscle cells were kindly donated to us from Loughborough 
University, UK. Milli-Q water was used throughout for all HPLC analysis and 
FITC- Actrapid® conjugates preparation. Distilled water was used for all other 
preparative processes such as the making of buffers. 0.1-1M NaOH and 0.1-1M 
HCl were used for pH adjustment. 
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3.2.2 Preparation of FITC-insulin conjugate for cell stimulation 
Four species of FITC-insulin produced inhouse were used in this study to 
investigate the resultant level of phosphorylated AKT in HUVEC compared to 
insulin stimulation. However, as discussed in chapter 2, certain reaction 
conditions will affect the degree of labelling; therefore, three batches of FTIC-
insulin conjugates from different reaction conditions were further purified by 
HPLC to isolate each species as summarised in Table 3-3 
Table 3-3: Four species of FTIC-insulin produced from different reaction conditions and isolated 
by HPLC. 
Species of FITC- insulin  Reaction conditions Isolated peaks  
Mono-labelled FITC- 
insulin at the A1 position 
(MonoA1) 
1h reaction time at pH8.4 
and 2:1 molar ratio 
Sample elutes at 
21.3min RT  
Mono-labelled FITC- 
insulin at the B1 position 
(MonoB1) 
18h reaction time at pH7 
and 2:1 molar ratio 
Sample elutes at 
21.9min RT  
Di-labelled FITC- insulin 
(Di) 
72h reaction time at pH7 
and 3:1 molar ratio 
Sample elutes at 
22.6min RT 
Tri-labelled FITC- insulin 
(Tri) 
72h reaction time at pH7 
and 3:1 molar ratio 
Sample elutes at 
23.7min RT 
 
Once separated, each species was lyophilised then confirmed by HPLC and MS 
analysis as detailed in chapter 2. Prior to cell stimulation, four stock 
concentrations of each FITC- insulin species were prepared by diluting 3.5mg of 
its lyophilised powder (equivalent to 100Unit per mL insulin injection) in 1mL of 
Milli-Q water, pH7. 
 
3.2.3 Passage of HUVEC from Frozen (P0) 
HUVEC (P0) were cultured in T-75 flash using Medium 200 (Fisher), containing 
5% FBS and 1% LSGS at 37°C in humidified 5% CO2 air. Media was changed 
every two days until the cells were fully confluent (80-100%) for passaging. 
Cells from P4 were used throughout this study. 
Once cells from P4 reached confluency as observed in Figure 3-4, they would 





Figure 3-4: Microscopic image of 80-100% confluent HUVEC P4 
 
3.2.4 The stimulation of HUVEC by Actrapid® and the fluorescently labelled 
Actrapid® conjugates.  
To investigate the activity of the insulin variants, HUVEC were stimulated with 
or without Actrapid® and its FITC-labelled conjugates. Prior to stimulation, 
HUVEC were starved with serum-free media for 24h.The stimuli stocks of 
100Unit /mL Actrapid®, four species of FITC-Actrapid® conjugate and FITC 
(3.5mg/ml) were added to each well accordingly in 1:1000 dilution (~0.1Unit of 
insulin), then left to incubate for 15mins at 37°C. 
After 15min of stimulation, media was removed and cells washed with cold 
PBS, and cells lysed with 60µL of Laemmli buffer (62.5mM Tris buffer pH6.8; 
87.6mM SDS;10% Glycerol; 5mM EDTA pH6.8; 0.004% Bromophenol blue; 
3%w/v DTT and 8mM Sodium orthovanadate). The adherent cells were then 
scraped off, then transferred to mini centrifuge tubes labelled accordingly to 
each stimulus. The samples then underwent processes of sonication for 15 
seconds then heating for 5 minutes at 95°C and finally centrifugation for 1 
minute at 179xg. 
Each experiment set was triplicated using cells from different batches. 
 
3.2.5 Electrophoresis of protein lysates. 
Formulation for preparing 10% SDS-PAGE is shown in Table 3-4 
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Table 3-4: The preparation of two 10% SDS-PAGE gels 
Reagents Volume added for resolving gel  Volume added for stacking gel  
30% Acry/Bis 6.7 mL 3.3 mL 
2M Tris pH 8.8 3.7 mL 2.5 mL 
Distilled water 9.6 mL 13.7 mL 
10% SDS  200 µL 200 µL 
10% APS 134 µL 200 µL 
TEMED  14 µL 20 µL 
Standard protein marker and protein lysate samples were loaded on 10% SDS-
PAGE gel and electrophoresed in electrophoresis buffer (190mM Glycine; 
25mM Tris-base; 0.1%w/v SDS). Gels were electrophoresed at 120V for 1.5h  
The blotting cassettes were prepared according to Figure 3-5. The assembled 
cassettes were then placed in blotting tank and electrophoresed for 1.5h at 70V 
in blotting buffer (190mM Glycine; 25mM Tris-base; 20%v/v Methanol) 
 
Figure 3-5: Preparation of stack for Western blot analysis 
The visual appearance of protein standards as shown in Figure 3-6, confirmed 
the transfer of proteins to the nitrocellulose membrane was successful. 
 
Figure 3-6: Illustration of proteins transferred to the nitrocellulose membrane. 
Proteins transferred on to nitrocellulose membrane were blocked in blocking 
solution (5% w/v semi-skimmed milk powder in TBST (25mM Tris; 15mM NaCl 
;0.1%v/v Triton-X, pH7.5)) for 1h.  
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5ml of primary antibody (phospho-AKT) prepared in Table 3-5, was then added 
to one blot and incubated overnight at 4°C. 
Table 3-5: Preparation of phosphor-AKT primary antibody solution. 
Reagents Final concentration or volume 
BSA 5% w/v 
Rabbit Phospho-AKT primary antibody 1 in 1000 
TBST 5 mL 
After 24h, the pAKT antibody solution was removed, and the blots were washed 
three times with TBST before adding the secondary antibody as prepared in 
Table 3-6 
Table 3-6: Preparation of secondary antibody solution. 
Reagents Final concentration or volume 
Semi-skimmed milk powder 5% w/v 
Anti-rabbit or goat IgG secondary antibody 1 in 2000 
TBST 5 mL 
The secondary antibody was added to the washed blot for 1h at room 
temperature. Agitation was also applied to ensure adequate homogenous 
covering of the membrane and prevent uneven binding. The washing process 
was further repeated. Once completed, the blot was emerged in ECL solution 
as prepared in Table 3-7, then analysed using the GeneGnome 
Chemiluminescence imaging from Syngene (discontinued model). 
Table 3-7: Preparation of ECL solution used in processing for acquiring the image 
Reagents Amount added 
1M Tris-HCl pH8.5 1 mL 
Distilled water 9 mL 
90mM p-coumaric acid in DMSO 22 µL 
250mM Luminol in DMSO 50 µL 
Hydrogen peroxide 3 µL 
 
Once imaged, the blot could be stripped for 15 minutes using a stripping buffer 
to remove the antibodies. 
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After stripping, the blot was briefly rinsed with TBST, and the blocking solution 
was applied and the whole process begun again for total AKT antibody as 
prepared in Table 3-8. 
Table 3-8: Preparation of AKT primary antibody solution 
Reagents Final concentration or volume 
Semi-skimmed milk powder 5% w/v 
Goat AKT primary antibody 1 in 1000 
TBST 5 mL 
Similarly, the secondary antibody was added then the images were acquired. 
 
3.2.6 The immunofluorescence of GLUT4 translocation  
Cells were stimulated with insulin or Mono as described in section 3.2.4  
Once the course of stimulation was completed and cells washed with PBS 
(pH7.4), the fixation process was applied by incubating the cells in freshly 
prepared 4% paraformaldehyde in PBS at room temperature for 15 mins, 
following three washes with PBS for 2 mins each. 
Permeablisation of the cell membrane was applied using Tris-buffered saline 
pH7.5 (TBS)-0.5% TritonX at room temperature for 15mins then cells rinsed in 
TBS-0.1% TX (3 changes in 3-5 mins).  
Blocking in 2% BSA prepared with TBS-0.1% TritonX (blocking solution) for 1h 
at room temperature, was necessary to reduce the background fluorescence. 
1mL of 1:200 GLUT4 primary antibody (ab654) prepared in blocking solution 
was then added to each well except for one blank well of the two controlled 
wells and incubated for 90 mins at room temperature. Once the incubation 
period was completed, cells were then washed at least five times in TBS-
0.1%TX. 
The AlexaFluor 546 labelled secondary antibody (1:500) was prepared in 
blocking solution and applied to each corresponding well for an incubation of 60 
mins, following repeat washes with TBS-0.1%TritonX. Before imaging, cells 
were rinsed with PBS before serum-free media was added to each well. 
Images were captured using the EVOS cells imaging system (Thermo Fisher 




3.2.7 Data analysis 
The intensity of pAKT and AKT level for each blot and the integrated density of 
GLUT4 cell membrane level for fluorescence images corresponding to each 
experimental set were quantified using ImageJ software. Data were obtained 
from the average of three readings for each set of samples then used to 
calculate the ratio of pAKT/AKT. The mean value of pAKT/AKT from three 
experimental sets would be presented as the final result. A paired T-test was 
performed across two sets of result to establish the difference in activity for 
each FITC-Actrapid® conjugates compared to native Actrapid®. 
 
3.3 Results and Discussions 
3.3.1 Determination of AKT phosphorylation and GLUT4 translocation in 
HUVEC stimulated by insulin and its fluorescently labelled conjugates 
The initial investigation into the biological activity of FITC-insulin conjugate 
synthesised in-house was to determine the level of phospho-AKT (pAKT), which 
is a central signalling mediator in the insulin stimulated cascade. AKT 
phosphorylation then leads to GLUT4 translocation to the plasma membrane to 
facilitate glucose influx, thus maintaining homeostasis. 
Figure 3-7 and Figure 3-8 present the western blot analysis of pAKT; AKT, and 
the corresponding ratio of pAKT/AKT respectively, in relation to the basal state 
of HUVEC and each stimulation with insulin, MonoA1, MonoB1, Di, Tri and 
FITC. The graph shows the mean ratio of pAKT/AKT calculated from three 
repeats and the p-value calculated from the paired t-test for each FITC-insulin 
species compared to native insulin. 
 
Figure 3-7: Western Blot analysis of AKT phosphorylation observed in HUVEC after 15mins at 





Figure 3-8:The ratio of phospho-AKT (pAKT) and total AKT levels as the mean of three repeats 
observed in HUVEC after 15min at basal state (control) and stimulation by insulin, four species 
of FITC-insulin conjugate and FITC. Noting the p-value of <0.05 for each conjugate compared to 
insulin indicates a significant difference in pAKT level. 
The paired t-test reveals that upon 15mins stimulation, there was no significant 
difference in the level of pAKT (pAKT/AKT) observed in insulin and its FITC 
single label at A1 and B1 (MonoA1 and MonoB1) while Di and Tri showed 
considerably reduced levels. Notably, the pAKT/AKT ratio of ~ 0.3 was equally 
observed under basal cell activity and in those stimulated by Tri, which could 
indicate that there was no further cellular response from Tri stimulation. 
Meanwhile, cell stimulation by MonoA1 and Di has resulted in ~ 14% and 31% 
reduction in pAKT level respectively compared to the activity observed by 
insulin and MonoB1 stimulations, which resulted in the same level of pAKT. 
Figure 3-9 presents the biological activity percentage of the four FITC-insulin 
species compared to native insulin calculated from the ratio of pAKT and total 


























Figure 3-8:The ratio of phospho-AKT (pAKT) and total AKT levels as the mean of three repeats 
observed in HUVEC after 15min at basal state (control) and stimulation by insulin, four species 
of FITC-insulin conjugate and FITC. Noting the p-value of <0.05 for each conjugate compared to 
insulin indicates a significant difference in pAKT level. 
  
Figure 3-9: The biological activity percentage of insulin compared to its conjugates with FITC. 
Overall, the biological activity of insulin was best preserved ranking from 
MonoB1> MonoA1> Di > Tri. This trend is in broad agreement with previous 
data reported by Hentz et al., 1997, where the biological activity of four FITC- 
insulin derivates were measured by a TK phosphorylation assay. Their results 
revealed that the B1 derivative was as biologically active as unlabelled human 
and pork insulin standards while the highest reduction in activity was observed 
in Tri. Notably, the decrease in biological activity observed in MonoA1 and Di 
has suggested that the A1 position may play an important role in the binding 
and IR activation dynamics. Meanwhile, the equivalent measurements in the 
biological activity of insulin and MonoB1 would indicate that the B1 position is 
less likely to involve in the insulin-IR binding. However, the dramatic decrease 
in biological effect of Tri suggested that the B29 position could play a key role 
for the binding of insulin to its IR and multiple substitutions on the insulin 
molecule could mean that three FITC molecules on the insulin are sufficiently 
big enough to cause a change in the 3D structure of insulin in such a way that 
the receptor-binding site of the insulin molecule is no longer recognisable by its 
IR. This observation was also supported by Pullen et al., 1976 and SchÄffer, 
























binding site of insulin toward its receptor. Their studies suggested that the 
degree (number of substitution) and position of insulin modification with FITC 
could significantly alter the structural conformation of the fluorescently labelled 
insulin. The overall changes would then influence the binding of insulin to its 
receptor and therefore affecting its biological activity to a certain extent ranging 
from fully active as observed in MonoB1 (99.5%) down to having a significantly 
low biological effect as reported in Tri (0.06%). This study agrees with other 
published data to highlight the important of A1 and B29 residues for the binding 
of insulin to IR, modifications to these positions would result in alterations to the 
IR binding site, thus affecting insulin biological activity. Meanwhile, B1 residue is 
not crucial for IR binding, therefore, FITC labelling at the B1 position would not 
affect the receptor binding site of insulin molecule thus maintain insulin 
biological activity. 
 
3.3.2 The immunofluorescence study of GLUT4 translocation in response to 
insulin stimulation using C2C12 skeletal muscle cells 
In order to confirm the biological activity of the most active FITC-insulin 
candidate (MonoB1), the cellular response from the insulin signalling pathway 
that finally results in GLUT4 translocation was further investigated. 
Unfortunately, GLUT4, which is the only type of insulin-dependent transport, 
could not be found in HUVEC from the pre-scanning western blot analysis and 
immunofluorescence study. Although the presence of other GLUT types would 
be essential for glucose transport in HUVEC, the lack of GLUT4 expression in 
HUVEC could indicate that intracellular uptake of glucose in HUVEC is not 
regulated by insulin. Because GLUT4 was not found in HUVEC, C2C12 skeletal 
muscle cells were chosen as the well-known model for GLUT4 expression. 
C2C12 was stimulated with MonoB1 and insulin to examine the biological 
response that further results in GLUT4 translocation. Similar GLUT4 
translocation levels resulting from both stimulations observed by fluorescent 
image would confirm that the biological activity of this most active form of FITC-
insulin is equivalent to native insulin. Figure presents the immunofluorescence 
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images of GLUT4 obtained at 20x magnification after 15min stimulation 
with/without insulin and MonoB1 stimulation in C2C12.
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Figure 3-10 above shows very few cells surface level of GLUT4 captured in the 
control while the expression GLUT4 were fluorescently visualised all around the cell 
membrane of those stimulated by insulin and MonoB1. The overall observation was 
also consistent for all three repeats. 
Figure 3-11 presents the integrated density and the correct total cell fluorescence 
(CTCF) quantified using ImageJ as the mean of three readings from each of the 
above fluorescence images that were further presented in each bar-chart by the 
mean from 3 repeats. Additionally, the p-values obtained from the paired t-test of the 
integrated density and corresponding CTCF for insulin and MonoB1 were also 
indicated. 
 
Figure 3-11: The integrated density and CTCF quantified for the GLUT4 immunofluorescence 
observed in C2C12 after 15min stimulation with/without Actrapid® and MonoB1 showing the p-value 
of >0.05 for both data comparing insulin and MonoB1. 
(CTCF=Integrated density- (Area of selected cells*Mean fluorescence of background readings)) 
 
The present study reveals that the level of GLUT4 translocation in C2C12 as a result 
of Actrapid® and MonoB1 stimulations is considerably higher with more than 80% 
increase in CTCF than the limited cell surface level of GLUT4 under the basal state. 
Notably, the integrated density quantified for each fluorescence image shows a 
significant difference (p=0.006) in the cell surface level of GLUT4 visualised under 
the basal state comparing to the stimulated conditions, which have a similar 
observation of GLUT4 translocation for both insulin and MonoB1. The increased 


























cellular response to insulin occurred via the activation of PI3K/AKT signalling 
pathway. Once the IRs have been activated, a cascade of events would occur inside 
the cell resulting in phosphorylation of AKT. The resultant pAKT then leads to the 
phosphorylation of AS160, which then allow the translocation of GLUT4 from the 
cytoplasmic vesicles onto the cell membrane surface for glucose intake, hence the 
observed increase in GLUT4 cell surface level.  
There was no significant difference (p=0.47) in the increased cell surface GLUT4 
levels after stimulation by insulin and Mono B1, suggesting that their biological 
activity would be equivalent. Besides, the additional data of pAKT levels quantified 
from western blot analysis as reported in section 3.3.1 for insulin and MonoB1 
revealed the similarity in activation dynamics of the insulin signalling pathway. 
3.4 Chapter summary  
Four different species of FITC-insulin conjugates including MonoA1, MonoB1, Di and 
Tri were synthesised inhouse, isolated and confirmed by RP-HPLC and MS. The 
biological activity of each species in comparison to native insulin was assessed in 
HUVECs and C2C12 skeletal muscle cells via the insulin signalling pathway by 
examining the levels of pAKT and cell surface GLUT4. It is understood that once the 
IR is activated as a result of insulin binding to its receptor site, there would follow a 
cascade of events causing the phosphorylation of AKT. The resultant increase in 
pAKT level consequently leads to the translocation of GLUT4 from the cytoplasmic 
vesicles onto the cell membrane via the phosphorylation of AS160, thus allow the 
insulin-dependent transport of glucose into the cell.  
The main findings are summarised as follow: 
➢ Fully confluent HUVECs in 6-wells plate were subjected to 15mins stimulation 
with 0.1 Unit of insulin and its FITC-labelled conjugates including MonoA1, 
MonoB1, Di and Tri. The level of pAKT was measured by Western Blot 
analysis to compare the cellular effects of each stimulus. The most prominent 
finding to emerge from this study is that the biological activity of native insulin 
was best preserved with MonoB1 while the rest had a reduced effect of 
exhibiting 78% down to 51% of the insulin activity with MonoA1 and di-
labelled species respectively. The significantly low activity (0.06%) observed 
with Tri highly indicated a complete loss of biological activity possibly due to 
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the inability of IR to recognise the receptor-binding site of this tri-labelled 
insulin. 
➢ The screening test for GLUT4 translocation in HUVEC could not confirm the 
presence of GLUT4, indicating that the intracellular uptake of glucose in 
HUVEC would occur via other types of GLUT which is independent from 
insulin stimulation such as GLUT1. 
➢ The use of C2C12 skeletal muscle cells to further confirm the biological effect 
of the most active FITC-insulin conjugate (MonoB1) on GLUT4 translocation 
by immunofluorescent showed no significant difference in the GLUT4 cell 
surface level, suggesting that the singly labelled FITC-insulin at B1 produced 
inhouse is as biologically active as insulin and could potentially be used for 














































The work presented in this chapter reviews some aspects of insulin stability and 
solubility to investigate the effect of FITC labelling on the stability and solubility 
profiles of fluorescently labelled insulin (Actrapid® and Novorapid®) conjugates. 
Like many proteins, the stability of insulin is primarily affected by changes in pH 
and temperature that might result in physical and chemical saturation of the 
insulin structure, thus affecting its biological activity. Pharmaceutical insulin 
preparations clinically used as injections or MDI have a well-established stable 
shelf-life providing their storage conditions are within the recommended 
temperature range typically at 2-8°C with the addition of stabilising excipients. 
The solubility of insulin is one of the key parameters in determining its rate of 
absorption and therefore, its ability to exert a biological effect. As FITC labelling 
on certain sites (A1 and B29) of the insulin molecule has been found to affect its 
biological activity, it is also of interest to find out if the FITC-insulin conjugates 
would share similar properties of insulin stability and solubility. Although 
fluorescently labelled insulin conjugates have been widely used in various 
applications, very few has focused on investigating their long-term stability and 
solubility profiles. The objective of this study is to examine the stability and 
solubility profiles of FITC-insulin conjugates prepared in their working dilutions 
with or without excipients which are typically found in most insulin formulations. 
 
4.1.1 Stability of insulin 
Generally, the stability aspect of insulin typically refers to its stability in 
pharmaceutical formulations in terms of biological potency. In fact, according to 
Brange 1994, many studies into the influence of different storage conditions on 
insulin stability for many years were based on the estimation of its biological 





(Pingel and Volund, 1972) examined a whole range of acid and neutral insulin 
formulations from rapid-, intermediate- to long-acting preparations during 
storage at various temperatures. The result after five years of storage at 4°C 
showed that all preparations retained virtually full biological activity, thus 
exhibiting a remarkably high biological stability within the recommended storage 
conditions. Notably, the biological potency of insulin dropped dramatically for 
every 10°C increase in temperature above 25°C. It was also reported that 
neutral insulin preparations are generally more stable than those prepared in 
acidic solution probably due to the enhanced stability effect by insulin hexamers 
(Brange, 1994; Landreh et al., 2012; Ohno et al., 2019). 
Principally, in order for therapeutic insulin to exert its biological effect, it is 
essential to maintain the structural integrity of insulin and thus its stability within 
the pharmaceutical formulation. Insulin stability is critically dependent on the 
conformational flexibility within the insulin molecules itself, and the resultant 
dimeric and hexameric formation. However, it is equally important to note that 
only the insulin monomer can exert the biological activity of insulin (Nagel et al., 
2019; Fu, R Gilbert and Liu, 2013; Mukherjee et al., 2018b).  The structural 
alterations of insulin during storage and usage are usually classified by changes 
in the conformation of secondary to quaternary structure (physical instability) or 
covalent modification of the primary structure leading to bond formation or 
cleavage (chemical instability). The overall changes have a mutual influence on 
the susceptibility of the molecule for chemical attack or vice versa (Manning et 
al., 2010; Brange et al., 1997).                  
The physical modifications of insulin’s primary and secondary structure involve 
denaturation, adsorption, precipitation, fibrillation, and aggregation. 
Denaturation (unfolding) is the loss of the physical native three-dimensional or 
globular structure without alteration to their chemical composition, owing to 
changes in temperature or binding of chaotropes (such as urea and 
guanidinium hydrochloride). Insulin adsorption either to the materials within its 
container or by the presence of 0.1-1% albumin, can both result in insulin loss. 
This effect is inversely proportional to insulin concentration (negligible for higher 





adsorption by hydrophobic than hydrophilic surfaces. Formation of amorphous 
or crystalline precipitates in insulin solution results from pH changes within its 
isoelectric precipitation zone of pH 4.5-6.5 or introduction of zinc ions (or other 
divalent metal ions), leading to a reduction in insulin solubility (Brange et al., 
1997; Landreh et al., 2012; Gradel et al., 2018a). Meanwhile, under the 
influence of high temperature and exposure to hydrophobic surfaces, insulin 
tends to undergo dissociation of its hexameric structure and conformational 
changes of monomers, resulting in successive linear aggregation and insoluble 
insulin fibrils formation. Notably, insulin fibrillation has been one of the most 
extensively studied phenomena concerning insulin stability. It was well 
established that there is a robust reverse relationship between the fibrillating 
tendency of insulin and its content of insulin-related impurities, including 
covalent insulin dimer and proinsulin. Importantly, neutral solutions containing 
low concentrations of hexameric insulin are more prone to fibrillation. However, 
this effect is less problematic since all clinically used insulin pharmaceutical 
preparations are at a high concentration with the addition of zinc ions, which 
together can improve the physical stability of insulin (Akbarian et al., 2020; 
Phillips et al., 2012; Brange et al., 1997). 
In contrast to the changes from physical instability, changes in amino acid 
sequences (primary structure) from chemical modifications or covalent 
alteration in insulin structure are irreversible and may result in the formation of 
insulin derivatives with less activity and potential immunogenicity (Yang et al., 
2017; Akbarian et al., 2018). In addition to the enzymatic degradation, various 
chemical reactions can also degrade proteins in general and insulin in 
particular. Deterioration of pharmaceutical insulin preparations during storage is 
mainly due to hydrolysis and insulin intermolecular transformation reactions. 
These two categories of chemical reactions usually lead to the production of 
higher molecular weight transformation (HMWT). Predominantly, hydrolysis 
reactions of insulin involve deamination of Asn residues which occur at the A21 
position in acidic solution and the B3 position in a neutral and alkaline 
environment. On the other hand, intermolecular aminolysis between the N-





mainly leads to the formation of covalent insulin dimers (CID). Also, 
intermolecular disulphide exchange between different insulin molecules can 
result in the formation of covalent insulin oligomers (CIO) and polymers, 
observed during the storage of neutral insulin solutions as well as preparations 
containing amorphous insulin at ambient and higher temperatures (Brange, 
1994; Akbarian et al., 2018; Jacob, 2015). Furthermore, changes in pH can also 
influence the chemical instability of insulin. Optimisation of CID and oligomers 
formation was reported around pH 4, whist the deamination of Asparagine 
residues due to different hydrolysis reactions was minimised at around pH 6.5. 
Meanwhile, in alkaline solution, the formation of CIO and polymers due to 
intermolecular disulphide interactions was mainly observed with increased pH> 
9. Other types of insulin formulations also exhibited similar chemical stability 
profiles, however formation of B3 residues deamination products was more 
predominant in neutral and slightly alkaline pH  (Brange, 1994; Manning et al., 
2010; Hjorth et al., 2016b).  
In summary, the stability of insulin in pharmaceutical preparations is highly 
complex and dependent on the formulation of each product. However, the need 
to understand insulin stability is critically important for designing an insulin 
formulation as well as producing its fluorescently labelled conjugates to 
maintain their efficacy. The rate of spontaneous structural transformation within 
the insulin molecule is determined mainly by its conformational and segmental 
flexibility, thus playing a crucial role in insulin stability. Notably, the 
combinations of physical and chemical factors contributing to the instability of 
insulin during storage are numerous and governed by the capacity of the B-
chain terminals to undergo the structural changes that allow physical 
interactions and chemical reactions to take place. In current insulin 
pharmaceutical preparations formulated at neutral pH, there must be less than 
10% transformation and degradation products formed during their shelf life if 
stored as recommended at 2-8°C, while the formation of the covalent HMWT 
which are potentially immunogenic must be less than 2% (Ohno et al., 2019; 
Donner and Sarkar, 2019b; Brange, 1994). Currently, isotonicity-adjusting 





can affect the stability of insulin preparations by their influence on deamination 
and covalent insulin dimers. It was investigated among preservatives that the 
stabilising effect gradually increases from methylparaben to m-cresol to phenol. 
For isotonicity agents from glucose to glycerol to NaCl, most are present in 
clinically used insulin preparations. Notably, the addition of glycerol and some 
polysaccharides can significantly increase the physical stability of insulin 
solutions. However, the chemical and biological stability will considerably 
decrease with these agents since the rate of CID formation was reported to be 
faster in glycerol-containing preparations (Brange, 1994; Jacob et al., 2019; 
Modi et al., 2019). Therefore, the need for compromise composition of these 
agents within each insulin formulation is equally important. 
 
4.1.2 Insulin solubility 
Principally, the solubility of a compound/ drug in water or organic solvents is 
equally essential for critical decisions throughout the entire process from the 
initial drug discovery stage to development and final formulation. The solubility 
of a drug is generally considered as one of the most important parameters in 
achieving the desired concentration of drug reaching the systemic circulation for 
the anticipated pharmacological response. Because water is well established as 
the solvent in all body fluids and for any drug to be absorbed, it must be present 
in the form of an aqueous solution at the site of absorption. Therefore, all drugs 
must exhibit at least limited aqueous solubility for therapeutic efficiency 
regardless of their administration methods (Magbool et al., 2017; Cantrill et al., 
2020). For instance, in all pharmaceutical insulin preparations, the rate-limiting 
step of insulin activity is indeed its absorption into the bloodstream after SC 
administration. Insulin glargine in Lantus® formulation is less soluble at neutral 
pH than HI in Actrapid® thus, it precipitates in the SC tissue post-injection, 
slowing its absorption and extending its duration of action for up to 24h; 
whereas short-acting Actrapid® is formulated in neutral pH solution, enabling 
rapid absorption and therefore exhibiting quick onset of action within 30mins. 
In general, several factors can govern the solubility of insulin, including pH, 





concentration of divalent metal ions and salts. Additionally, the species, purity of 
insulin, and the nature of its surface in contact with the solvent environment 
could also affect its solubility. Principally, the solubility of insulin refers to the 
maximum amount of crystalline insulin (solute) that can be dissolved in a given 
amount of solvent at specified conditions to achieve a homogeneous system. 
The extent of solubility can range widely, from very soluble in which less than 
one part of solvent is required per part of solute to give homogenous system, to 
practically insoluble in which more than ten thousand parts of solvent requiring 
per part of solute (McPherson and Gavira, 2014; Landreh et al., 2012; Gradel et 
al., 2018b).  According to Frederiq and Neurath 1950, insulin is practically 
insoluble in water at its isoelectric point of pH 5.4, but it is easily soluble at pH 
lower than 4. Notably, insulin tends to precipitate at a pH interval of pH5.3-5.4 in 
an aqueous medium, and this precipitation zone is broadened towards higher 
pH values with increasing zinc ions concentration. Practically, insulin can be 
well solubilised at 2 mg/mL in dilute acetic or hydrochloric acid, pH 2–3. 
Although insulin is usually less soluble in neutral pH and alkaline conditions, the 
solubility is strongly dependent on the concentration of zinc ions and the 
species of insulin. Insulin is also soluble in homogenous mixtures of water and 
organic solvents, for instance, in 50-70% (v/v) ethanol. Depending on the 
solvent type, temperature, pH, and salt content, the solubility of insulin tends to 
decrease with a high content of the organic solvent in the mixture (Zhou et al., 
2012; Pitt et al., 2020; Magbool et al., 2017).  
Generally, soluble HI comprises different oligomers, including insulin 
monomers, dimers, and hexamers in chemical equilibrium. It is well-established 
that insulin monomers and dimers are readily absorbed by blood capillaries 
post- SC injection whereas, insulin hexamers are not well absorbed into the 
capillaries but can to some extent be absorbed by the lymphatic system due to 
their larger size. The rate of insulin absorption found to be fastest for monomers 
followed by dimers and hexamers respectively is therefore determined by its 
oligomeric equilibrium (Gast et al., 2017b; Pitt et al., 2020; Gradel et al., 2018).  
For all clinically used insulin preparations nowadays, in addition to the insulin 





hexamers, the association state/ oligomeric equilibrium of soluble insulin is also 
dependent on its concentration. High insulin concentration can shift the 
oligomeric equilibrium towards hexamer formation while dilution will favour 
monomers and dimers state. Furthermore, upon SC administration, the 
subsequent dissociation rate of insulin hexamers into dimers and monomers 
before trans-capillary transport is dependent on the dispersion of lipophilic 
excipients such as phenol or meta-cresol as well as zinc from the insulin SC 
depot into the adipose tissue, thus contributing to faster absorption (Brange and 
Volund, 1999; Donner and Sarkar, 2019; Akbarian et al., 2018). Nowadays 
pharmaceutical insulin products are formulated at relatively high concentrations 
(100-500Unit/mL) for storage purpose, and therefore mainly exist as insulin 
hexamers in a clear, colourless solution at a specified, usually neutral pH range, 
except for Lantus® at pH4. Depending on their mechanism of action ranging 
from rapid-, intermediate and long-acting, these insulin analogues have 
chemical modifications to their amino acid sequences, in which for long-acting 
insulin analogues, insulin will precipitate in the SC tissue post-injection to 
achieve a slow rate of absorption. Rapid-acting insulin analogues have minor 
alterations in their amino acid sequence relative to HI so that in the absence of 
zinc and phenol or meta-cresol, these modifications reduce self-association of 
insulin monomers into dimers and hexamers compared with HI; therefore, a 
more significant fraction of insulin monomers would generate in the SC tissue. 
The resultant event leads to more rapid absorption from the SC tissue with a 
faster onset of action than HI (Savjani, Gajjar and Savjani, 2012; Gradel et al., 
2018; Brange and Volund, 1999). 
 
4.1.3 Studies on the stability and solubility profiles of fluorescently labelled 
insulin conjugates  
Fluorescently labelled insulin preparations have been widely used for several 
decades to support numerous studies into the activity of insulin, its interaction 
with receptors, its existence and localisation at cellular levels as well as its 
release profiles in drug development both in-vitro and in-vivo. However, the data 





aqueous solution and at specified conditions is limited.                                                       
Experimental data to establish the solubility of FITC-insulin conjugates at 
specified conditions such as at controlled temperature and pH are still not 
understood. Unlike all pharmaceutical insulin preparations whose stability 
profiles during long-term storage have been well-established in relation to their 
biological activity as well as physical and chemical instability, the stability 
aspects of fluorescently labelled insulin preparations would also be dependent 
on the properties of the fluorescent label itself. There are several factors to 
consider for the stability determination of the conjugated products such as 
whether the dyes remain conjugated in the solution or even in lyophilised 
powder form during long-term storage and the rate of photobleaching during the 
experimental procedure (Natarajan, Northrop and Yamamoto, 2017; Wakankar 
et al., 2010; Uchio et al., 1999). Theoretically, a fluorophore can repeatedly 
undergo the fluorescence process and emit light, but long-time exposure to 
high-intensity illumination can cause structural changes to the fluorophore, 
making it no longer fluoresce, a process known as photobleaching. For 
instance, a recent study by Williams et al., 2018 has examined the photostability 
of HI labelled with AlexaFluor 647 (INS-647) and according to their experimental 
imaging conditions, ~ 5-8% minimal loss in INS-647 fluorescent intensity during 
an experiment was due to photobleaching. Their results indicate that after 
30min in circulation, 90% of the fluorescent dye remained conjugated to insulin. 
However, this study did not exclusively indicate beyond what point 
photodamage may be detected, and all the dye would become un-conjugated 
from insulin. The observation seemed to suggest that the course of their 
experiment lasted for no more than 30mins which is usually sufficient for insulin 
transport studies. Another study by Yang et al., 2017 also supported this time 
course in their stability test using BSA labelled with RBITC for injection into 
rabbits. The study highlighted the use of BSA-RBITC conjugates as a tracer 
molecule for the study of protein transportation and vascular permeability based 
on the findings that they are highly specific, sensitive, and stable during 30min 
in-vivo experiment. Similar to FITC, RBITC has the ITC reactive group that 





form a dye-protein complex. Another study established that dextran products 
labelled with FITC are stable at 37°C in rabbit plasma, muscle homogenate, 
liver homogenate and urine for at least three days during which there was no 
significant data indicating changes in the molecular weight or the release of 
FSC moieties. Previous reports also concluded that FITC-dextran are stable for 
at least one day at physiological conditions. Using 6% trichloroacetic acid also 
enhanced the stability of FITC-dextran at room temperature for three days. 
Although FITC-dextran was found to be stable at pH 4 for over one month at 
35°C, there was a considerable loss of up to 24% in fluorescence at pH 9. 
Overall, the stability of FITC-dextran in-vitro and in-vivo is considered as 
excellent; however, there is a risk for hydrolysis of the FSC label only at 
elevated pH (>9) and high temperatures (>50) (De Belder and Granath, 1973; 
Kurtzhals, Larsen and Johansen, 1989; Wu et al., 2020; Thorball, 1981). 
Principally, to measure the solubility of a compound, there are several 
requirements, including accurate control of temperature and composition in the 
liquid and solid phase, preferably with the capability to collect a vast amount of 
data in a short time. A widely accepted and accurate method for measuring the 
solubility is through equilibration of a suspension, followed by concentration 
determination of the solution and assessing its composition. The method 
involves establishing a known concentration calibration curve for the tested 
compound in a given solvent at specified conditions and sampling from highly 
concentrated solution over a period of time followed by filtration to remove the 
solids then measuring the concentration using a gravimetric, spectroscopic or a 
chromatographic method like HPLC. This test enables the determination of the 
maximum solute amount that is soluble in a defined amount of solvent at 
specified conditions. However, one disadvantage is that this simplified 
Equilibrium Concentration (EqC) or the shake-flask method can be quite 
laborious and time-consuming. Alternative approaches for determining solubility 
include the Temperature Variation (TV) method and the Solvent Addition (SA) 
method, in which respectively the temperature of the suspension and the 
composition of the suspension are gradually changed until achieving a complete 





solubility line of a compound in a solvent, performing the TV method is the most 
suitable. Whereas SA is usually the method of choice for solubility data required 
at a constant temperature as in the case for multicomponent mixtures whose 
solubility is not strongly dependent on temperature. Although these methods 
have shown to achieve reliable and reproducible data in a short time, they 
require specialised instruments with built-in particle viewer cameras to monitor 
the presence or disappearing of crystals formed (Alsenz and Kansy, 2007; Di, 
Fish and Mano, 2012; Savjani, Gajjar and Savjani, 2012). Based on the 
intended testing conditions and the availability of validated HPLC method for 
detecting fluorescently labelled insulin, the shake-flask method offers the most 
suitability and reproducibility for the determination of FITC-insulin solubility. 
To date, there are no studies that investigate the stability and solubility profiles 
of insulin labelled with FITC product, especially in their working dilutions. The 
objective of this study is to investigate the effect of phenol, m-cresol and diluting 
fluid (containing m-cresol, glycerol and zinc oxide) on the stability profiles of 
FITC-insulin conjugate formulated in solution subjected to a change in 
temperature over time. In particular, the degree of de-conjugation (the presence 
of free FITC) which could interfere with fluorescent data in diffusion studies of 
FITC-insulin conjugate will be analysed by HPLC. The solubility profiles of 
FITC-Actrapid® conjugate will be assessed using the shake-flask method. Here, 
HPLC is the chosen analytical method to determine the maximum concentration 
of FITC-Actrapid® conjugate at neutral pH and ambient temperature to produce 
a homogeneous system. 
 
4.2. Materials and Methods 
4.2.1 Materials 
Mono-labelled FITC-Novorapid® and FITC-Actrapid® conjugates (both refer to 
as Mono) produced in house as described in chapter 2. HPLC grade ACN, 
HPLC grade acetone and TFA, 0.1M NaOH, NaH2PO4, Na2HPO4, 0.1M HCl 
and buffer salts were purchased from Fisher Chemicals (Loughborough, UK). 
Ethylenediaminetetraacetic acid (EDTA) disodium salt was from Hopkins & 





Aldrich Chemical Company Ltd (UK). Milli-Q water obtained from a Milli-Q UF 
Plus water purification system were used throughout. 
4.2.2 Preparation of FITC-Novorapid® and FITC-Actrapid® solutions in Milli-Q 
water for the stability test 
5mL stock solutions of 100 Unit/mL Mono were prepared by dissolving 17.5mg 
of lyophilised FITC-Novorapid® and FITC-Actrapid® individually in 5mL with 
Milli-Q water adjusted to pH7. 
Figure 4-1 shows 0.1mL of each stock solution added to individual 
chromatography vials and marked accordingly to the day of HPLC analysis in 
the first five consecutive days then several weeks after storing at specified 
temperatures (2-8°C, 20°C and 37 °C) 
 
Figure 4-1: Serial samples from 100 Unit/mL FITC-Actrapid® stock solution for stability test 
allocated by day of HPLC analysis over 56 days period. 
4.2.3 Preparation of FITC-Actrapid® serial dilutions for the solubility test 
1mL stock solution of 3,000 Unit/mL Mono was prepared by dissolving 105mg 
of FITC-Actrapid® powder in 1mL diluting fluid (0.0005%w/v zinc oxide;1.6%w/v 
glycerol; 0.25%w/v m-cresol; pH7.0). 
3mL of 300 Unit/mL Mono solution was made by diluting 0.3mL of 3,000Unit/mL 
Mono stock solution with 2.7mL of diluting fluid. 
The resultant dilution of 300 Unit/ml Mono was used to prepare five further 









Actrapid® stock solution 
of 300 Unit/mL (mL) 
Diluting fluid 
(mL) 
50 Unit/mL 0.167 0.833 
100 Unit/mL 0.333 0.666 
150 Unit/mL 0.500 0.500 
200 Unit/mL 0.667 0.333 
250 Unit/mL 0.833 0.167 
 
A standard calibration graph was constructed in the range of 50Unit-3000 
Unit/ml for FITC-Actrapid® (n=2)  
4.2.4 Preparation of 100Unit/mL FITC-Novorapid® solution in 0.2% phenol and 
0.25% m-cresol for the stability test  
Two solutions of 100Unit/mL Mono in 0.2% phenol and 0.25% m-cresol was 
prepared by dissolving each 35 mg of lyophilised FITC-Novorapid® in freshly 
prepared 0.2%w/v phenol and 0.25%w/v m-cresol, pH adjusted to 7 respectively 
and made up to 10mL volumetrically. 
4.2.5 Preparation of 100Unit/mL FITC-Actrapid® solution in diluting fluid for the 
stability test 
35mg of lyophilised FITC-Actrapid® was dissolved in freshly prepared diluting 
fluid (0.0005%w/v Zinc Oxide;1.6%w/v glycerol; 0.25%w/v M-cresol; pH7.0) and 
made up to 10 mL volumetrically. 
4.2.6 Preparation of 100Unit/mL Mono solution in buffers for the pH-dependent 
study 
Table 4-2 shows the preparation of buffers (pH4-9) used to dissolve Mono  
Table 4-2: Preparation of Acid/Base buffers pH ranging 4.0-9.0 (DeLloyd, 2000) 
pH Salt Addition of acid or base 
4 1.021g potassium hydrogen phthalate 0.1mL of 0.1M HCl  
5 1.021g potassium hydrogen phthalate 2.26mL of 0.1M NaOH 
6 0.681g potassium dihydrogen phosphate 5.6mL of 0.1M NaOH 
7 0.681g potassium dihydrogen phosphate 2.91mL of 0.1M NaOH 
8 0.681g potassium dihydrogen phosphate 4.67mL of 0.1M NaOH 






10mL of 100Unit/mL FITC-Actrapid® solutions were freshly prepared by 
dissolving 35mg of lyophilised mono-labelled FITC-Actrapid® in each buffer at 
pH ranging from 4 to 9 and made up to 10 mL volumetrically. 
4.2.7 Solubility test of Mono by Shake-flask method  
Method for the solubility equilibrium determination of FITC-Actrapid® was set 
out following eight basic steps as illustrated below: 
 
 
4.2.8 Analysis by RP-HPLC methods 
Serial dilutions of fluorescently labelled insulin analogues prepared in different 
solvents subjecting to storage at specified temperature were then analysed by 






4.2.9 Fluorescence intensity measurement for the pH-dependent study 
A fluorescence plate reader (SpectraMAX, model GeminiEM) was used to 
determine the fluorescence intensity of Mono conjugates prepared at different 
pH ranging from 4-9. 
The excitation and emission wavelengths were set at 494 and 518 nm, 
respectively and the fluorescence intensity was recorded as the mean of three 
readings from different samples. 
 
4.3 Results and discussions 
4.3.1 The effect of phenol and m-cresol on the stability of FITC-insulin in 
solution during storage at different temperatures 
The need to understand the stability profiles of fluorescently labelled insulin 
conjugates at 37°C is essential for the application of any in-vivo or in-vitro 
experiment especially where the course of studies may last over 24h. Generally, 
it may not always be practical to freshly prepare samples before the 
experimental start-up, therefore fluorescent conjugates sometimes need to be 
made up in solution and stored at specified temperatures. In addition to their 
role as anti-microbial preservatives, phenolic compounds are commonly used in 
insulin pharmaceutical formulation as allosteric effectors owing to their well-
established stabilising effect on the hexamer conformation of insulin. It is 
therefore of most interest to investigate the stability enhancement effects of 
phenol and m-cresol on fluorescently labelled insulin formulated in solution 
during storage at 4°C, 20°C and 37°C.  Generally, unlike insulin whose stability 
usually refers to its biological activity in relating to its structural transformation 
resulting from physical and chemical alterations, the stability aspects of its 
fluorescently labelled conjugate are typically discussed in relation to the 
maintenance of fluorescent dye conjugated to insulin throughout the 
experimental process. Depending on the method of analysis, the degree of 
FITC remaining conjugated to insulin can be quantified by the presence of free 
dye cleaving off the insulin molecules or the amount of native insulin formed. 





could also affect the experimental outcome, especially for biological activity 
study and therefore should be taken into consideration when investigating the 
stability of FITC-insulin conjugates. 
Figure 4-2 shows a reduction in the percentage AUP representing Mono 
conjugate analysed by RP-HPLC for 21 days period with respect to increased 
temperature from 20°C (A) to 37°C (B).  
 
Figure 4-2: Changes observed for the original FITC-Novorapid conjugate formulated in 
solution during storage at 20°C (A) and 37°C (B) showing the stability-enhancing effect of 
phenol and m-cresol. 
The stability-enhancing effect of phenol and m-cresol was illustrated by a much 
slower loss in the percentage of the original Mono conjugate comparing to water 
alone at both 20°C and 37°C. During storage at 20°C, there was a rapid 
reduction of ~50% Mono formulated in water after two days and down to 0% by 
day 21. Meanwhile, the reduction rate was much slower for phenol in which 





dropped down to 50% by day 21. Notably, the Mono formulated in m-cresol was 
maintained at 100% throughout 21 days observation at 20°C. Previous studies 
have established that the rate of degradation will increase with elevated 
temperature. However, unlike FITC-dextran which was reported to be stable for 
at least one day at physiological conditions (Natarajan, Northrop and 
Yamamoto, 2017), only 10% of Mono was lost after one-day storing at 37°C 
using Milli-Q water as a solvent. The reduction occurred quite rapidly after 4 
days when there was no conjugate detected from HPLC analysis. In the 
presence of phenol, the original conjugate was stable for one day then gradually 
reduced by more than 10% to 40% from day 2 to day 7, and by day 21 there 
was only 20% of Mono remained, thus suggesting that phenol can enhance the 
stability of Mono but only to a certain extent. Notably, the original conjugate 
(100%) was maintained for up to seven days in m-cresol then reducing to ~70% 
on day 14 with a further 30% loss by day 21. 
Meanwhile, the original Mono samples also contained a trace amount of 
unlabelled insulin identified by a peak at 20.4min RT from the PDA detector at 
215mn as detailed in section 2.3.3. The HPLC method used to analyse FITC-
insulin conjugates is unfortunately not compatible with identifying any degraded 
products such as insulin deamination from insulin itself. However, it is 
questionable that any of the denatured insulin products (if any) throughout this 
study would fluoresce since the appearing of other unidentifiable peaks were 
detected in the fluorescent mode, prompting that these other peaks could be the 
degradable products from FITC itself or the conjugate.  
More importantly, the data collected from RP-HPLC analysis did not only 
demonstrate the percentage loss in the original Mono but also identified the 
amount of free FITC cleaving off as well as the formation of other conjugated 
species such as Di and Tri. Table 4-3 and Table 4-4 present different species 
identified by RP-HPLC other than the original conjugate owing to the stability 




Table 4-3: Species identified by RP-HPLC showing the changes of FITC-Novorapid® conjugate formulated in Millipore water, Phenol and m-Cresol 
during storage at 20°C 















(23.4 min RT) 
Free FITC 
(13 min RT; 
16 min RT  





Day 0-2 Trace 100% None None None None 
Day 3 Trace 55.36% 20.13% 24.51% None Trace 
Day 4 Trace 25.39% 25.63% 48.98% Trace Multiple 
peaks/Trace 
Day 7 Lost 10.72% 10.78% 78.50% Trace Multiple 
peaks/Trace 
Day14 Lost Trace Trace 41.23% 36.81% Multiple 
peaks/Trace 




Day 0-2 Trace 100% None None None None 
Day 3 Trace 93.62% 6.38% None None None 
Day 4 Trace 92.27% 7.73% None None None 
Day 7 Trace 87.18% 12.82% None Trace  Trace 
Day14 Lost 61.10% Trace None 38.91% Trace 
Day 21 Lost 50.90 Trace None 49.10% Trace 
In 0.25% 
m-Cresol 
Day 0-7 Trace 100% 100% None None None 
Day 14 Trace 100% Trace None Trace None 




Table 4-4: Species identified by RP-HPLC showing the changes of FITC-Novorapid® conjugate formulated in Millipore water, Phenol and m-Cresol 
during storage at 37°C 


























Day 0 Trace 100% None None None None 
Day 1 Trace 92.24% 7.76% None None None 
Day 2 Trace 34.67% 13.25% 51.83% None Trace 
Day 3 Trace 7.82% Trace 92.18% None Trace 
Day 4 Lost Trace Trace 100% Trace Multiple peaks/Trace 
Day 7 Lost Trace 10.09% 17.10% 67.10% Multiple peaks/5.71% 
Day14 Lost Trace 12.98% 13.40% 70.09% Multiple peaks/3.53% 
Day 21 Lost Trace 5.0% 7.97% 87.03% Multiple peaks/Trace 
In 0.2% 
Phenol 
Day 0-1 Trace 100% None None None None 
Day 2 Trace 88.93% 11.07% None None None 
Day 3 Trace 73.43% 26.57% None None None 
Day 4 Trace 69.58 30.42% None None None 
Day 7 Trace 57.66% 42.34% None Trace  Trace 
Day14 Lost 36.59% 42.57% 6.72% 14.12% Multiple peaks /Trace 
Day 21 Lost 20.28% 36.10% 9.46% 34.16% Multiple peaks /Trace 
In 0.25% 
m-Cresol 
Day 0-7 Trace 100% None None None None 
Day 14 Lost 69.19% 16.55% None 14.26% Trace 




During three weeks of storage at 20°C, the stability of Mono was best enhanced 
in m-cresol then phenol and least in water. Based on the preservation of 100% 
of the original conjugate, it was therefore concluded that the presence of m-
cresol could enhance the stability of Mono in a solution for up to three weeks. 
The appearance of Di and free FITC peaks observed in day 14 indicated that 
change in the original conjugate may have started but occurred at a much 
slower rate. However, the considerably low amount of these products did not 
reach concentrations suitable for quantification by HPLC analysis and therefore 
was marked as trace. Interestingly, the loss of original conjugate in water from 
day 3 to day 7 was correlated to the formation of Di and Tri rather than free 
FITC. By day 14, deconjugation also occurred as there was ~ 40% of free FITC 
detected, which was further increased to 80% after 21 days as more FITC was 
released. It was anticipated that a complete deconjugation of Mono in water 
would have occurred after 28 days storage at 20°C. Meanwhile, changes in the 
original conjugate occurred at a much slower rate in phenol as there was only ~ 
13% of Di formed without any Tri detected in day 7. Unlike the case in water, 
the increased loss of Mono observed in day 14 and 21 using phenol was 
directly correlated to FITC cleaving off. This result suggested that in the 
presence of phenol although the loss of Mono occurred at a much slower rate 
than in water, it would lead to the appearance free FITC rather than the 
formation of Di and Tri. 
As anticipated, an elevated temperature of 37°C had a higher impact on the 
stability of Mono. The formation of Di, Tri and denatured products also occurred 
at a faster rate than compared to storage at 20°C. Especially, the fast forming of 
Di and Tri observed in water seemed to result in the rapid appearance of free 
FITC and other degraded products. After one day, there was nearly 10% 
reduction of Mono in water and rapidly by day 4, further Mono loss resulted in 
the complete formation of Tri. As deconjugation started to occur, there was 
nearly 70% of free FITC detected by day 7, which comparing to the 
deconjugation rate at 20°C was much faster. In the presence of phenol, Mono 
loss occurred at a slower rate than in water with a slower formation of Di and 




was also detected but at a much lower amount than in water. Although similar 
rate of deconjugation also occurred using m-cresol after 14 days, its ability to 
preserve 100% Mono for up to seven days at 37°C comparing to almost 50% 
lost by day 7 using phenol indicated that m-cresol was the most suitable solvent 
for enhancing the stability of FITC- insulin conjugates in solution during storage 
at high temperature (37°C).  
Overall, the stability of lyophilised Mono conjugates in solution is best enhanced 
using 0.25% m-cresol for all conditions ranking best at 2-8°C for more than 8 
weeks > 20°C for up to 4 weeks > 37°C for seven days. Even though the data 
was only collected until week eight, it is possible that the Mono samples 
prepared in m-cresol could have been stable for more than eight weeks if stored 
at 2-8°C. It is, therefore, necessary to determine at which time point insulin will 
start losing their fluorescent label to avoid storing samples in their working 
dilution for longer than needed. Notably, the stability of Mono conjugates in 
solution remained unchanged regardless of the solvent used for up to seven 
weeks if stored at 2-8°C. This study showed which conditions FITC-insulin 
conjugates can be formulated and stored until it is no longer suitable to use. 
The most appropriate solvent was also necessary to prepare FITC-insulin 
solution in the INsmart device for diffusion study set at room temperature and 
run at 37°C for several days.  
 
3.3.2 The stability enhancement effect of diluting fluid on FITC-insulin during 
storage at 2-8°C, 20°C and 37°C  
It is of interest to know whether the hexamer structure of insulin can be 
reformed after conjugation with FITC since during the labelling the process, the 
insulin-zinc hexameric structure was altered by the addition of chelating agent 
EDTA. Although the removing of zinc content was not necessary, it may be lost 
during the purification process owing to the disappearing of the phenolic content 
observed from FITC-insulin product. It is, therefore, necessary to investigate the 
labelling effect of FITC on the stability of insulin and the use of diluting fluid 
containing m-cresol, glycerol and zinc oxide as formulated in pharmaceutical 




Brange 1987, at a concentration equal to or higher than 2mM, the hexamer can 
be formed at neutral pH without the assistance of zinc ions. The standard 
concentrations formulated in most pharmaceutical insulin preparation is 
100Unit/mL which is equivalent to 0.6mM; therefore, it is proposed that the 
addition of zinc oxide to both pharmaceutical insulin preparations and their 
fluorescently labelled conjugates is still necessary for the formation of insulin 
hexamer to enhance their stability.  
Figure 4-3 illustrates the changes in percentage AUP of Mono in diluting fluid 
analysed by RP-HPLC during storage at 20°C and 37°C  
 
Figure 4-3: Changes in the original FITC-Actrapid® conjugate during storage at 20°C and 37°C 
for 56 days period showing the stability-enhancing effect of diluting fluid. 
 
As expected, the stability of Mono was better enhanced at 20°C than at 
elevated temperature of 37°C. In the presence of both zinc and phenolic 
compound, the original conjugate was well preserved even at high temperature 
since the percentage AUP of Mono was maintained for up to seven days at 
37°C and 56 days at 20°C. Whereas by day 7, the percentage AUP of Mono 
has dropped down to 80% and almost 50% at 20°C and 37°C respectively in 
water alone. Unlike FITC-Novorapid® samples, the purer form of FITC-
Actrapid® conjugate without any unlabelled insulin maintained the original 



























































Mono in water was not observed until day 14 at 37°C and day 56 at 20°C 
whereas in the case of FITC-Novorapid® this loss was observed by day 4 and 
14 respectively. Notably, the presence of zinc oxide did not seem to enhance 
the stability of Mono for any longer than seven days at 37°C as observed using 
m-cresol alone. However almost 60% of the original conjugate in m-cresol has 
been lost by day 21. Meanwhile, in the case for diluting fluid containing zinc 
oxide, Mono loss at 37°C was much slower in which 97% of the original 
conjugate was still maintained by day 21, and there was more than 60% of 
Mono remained after 56 days. This observation suggested that the stability of 
Mono can be best enhanced using diluting fluid containing m-cresol, glycerol 
and zinc oxide as formulated in pharmaceutical insulin products. 
Table 4-5 and Table 4-6 summarise different species identified by RP- HPLC 
other than the original conjugate as a result of changes in FITC-Actrapid® 






























16min RT  
and 28min RT) 
Others 
In milli-Q water Day 0-3 100% None None None None 
Day 4 96.80% None None None 3.20% 
Day 7 79.75% None None 20.25% Trace 
Day 14 73.31% Trace None 20.34% 6.35% 
Day 21 59.59% Trace None 40.41% Trace 
Day 28 57.25% Trace Trace 42.75% Trace 
Day 56 None None None 100% None 
In diluting fluid Day 0-28 100% None None None None 
Day 56 100% None None Trace None 




Table 4-6: Species identified by RP-HPLC showing the changes of FITC-Actrapid® conjugate formulated in diluting fluid during storage at 37°C 











16min RT  
and 28min RT) 
Others 
In milli-Q water Day 0-1 100% None None None None 
Day 2 98.2% None None 1.8% None 
Day 3 88.01% None None 11.99% None 
Day 4 70.03% None None 29.97% None 
Day 7 52.31% None None 47.69% Trace 
Day 14 None None None 100% Trace 
Day 21-56 None None None None Multiple peaks-100% 
In diluting fluid Day 0-7 100% None None None None 
Day 14 98.09% Trace None None 1.91% 
Day 21 97.05% Trace None None 2.95% 
Day 28 85.20% Trace None None 14.80% 
Day 56 62.09% Trace None 8.18% 29.73% 
Day 70 None None None 100% Multiple peaks- trace 
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During storage at 20°C, the initial detection of other degradants was thought to 
be accountable for more than 3% loss of the original conjugate formulated in 
water after four days. The majority of Mono loss in water seemed to correlate 
with FITC cleaving off insulin molecule rather than the formation of other 
labelled species as observed in FITC-Novorapid® conjugate. However, it is 
possible that the presence of unlabelled insulin in FITC-Novorapid® samples 
may have contributed to the formation of Di and Tri while FITC-Actrapid® 
samples contain no unlabelled insulin owing to further HPLC purification. As 
free FITC was detected by day 7 in FITC-Actrapid® samples, it was also of 
interest whether unlabelled insulin would be present. However, since there was 
no observation of any insulin peak, it is concluded that despite losing its FITC 
labels as observed by an increase in free FITC from 20% to 100% detected by 
day 7 to day 56 respectively, the deconjugated insulin molecules cannot be 
restored to their native insulin form. In the presence of unlabelled insulin as in 
the case for FITC-Novorapid®, the loss of original conjugate resulted from the 
formation of Di and Tri would occur at a faster rate within three days in water. 
Unlike for FITC-Actrapid® the loss due to FITC cleaving off was much slower as 
free FITC was gradually released over seven weeks. The results suggest that 
unlabelled insulin remained in the conjugated product may lead to a quicker 
formation of other FITC-insulin species during storage in their working 
formulations rather than the deconjugation process of breaking the covalent 
bonds between FITC and insulin molecules. Notably, compared to the effect of 
m-cresol alone, the diluting fluid illustrated better enhancement effects on the 
stability of FITC-insulin, which was stable for up to 56 days at 20°C.  
On the other hand, during storage at 37°C, loss of the original conjugate 
formulated in water by day 2 was found to correlate with the rapid formation of 
free FITC which reached nearly 50% by day 7 and 100% by day 14. After 21 
days, the samples became completely degraded owing to the presence of 
multiple peaks which were not identified previously from their fluorescence 
chromatogram. In contrast, in diluting fluid this loss seemed to relate to the 
slower formation of other fluorescently degradant products, which were 
observed from day 14 to 56, accounting for 2%-30% respectively of the total 
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fluorescent peaks. It was not until nearly 40% of the original conjugate was lost 
that almost 10% of free FITC was detected in day 56, suggesting that the 
presence of diluting fluid had slowed down the deconjugation process for at 
least 28 days even at high temperature of 37°C. However, the conjugates are 
still prone to degradation at high temperature. Rapidly after further observation 
of 14 days (day 70) a complete loss of Mono was seen in diluting fluid with the 
detection of 100% free FITC and a trace amount of other fluorescently 
degraded products. 
Overall, there is the capability of diluting fluid to maintain 100% of the original 
conjugate for up to 56 days (although peaks for free FITC also started to 
appear) at 20°C. It is, therefore, the solvent of choice for the preparation of 
FITC-insulin in its working formulations. However, at 37°C, daily analysis 
between day 7 to day 14 may be necessary to conclusively confirm at which 
day the loss of original conjugate starts because there was only 2% reduction of 
Mono by day 14, suggesting that the sample could last longer than seven days. 
Meanwhile, the stability of Mono in water and diluting fluid was best maintained 
during storage at 2-8°C for up to three months and six months respectively after 
which the 100% yields of original conjugates started to reduce owing to the 
formation of free FITC and other fluorescently degraded products. However, the 
complete loss of Mono has not been observed (Chromatograms for storage at 
2-8°C are shown in the appendix). 
In conclusion, the stability of FITC-insulin formulated in solution is best 
enhanced using diluting fluid containing m-cresol, glycerol and zinc oxide at 2-
8°C for six months > 20°C for two months> 37°C for seven days. Although the 
original conjugate was best maintained in diluting fluid for all studied 
temperatures the results also highlighted the impact of unlabelled insulin 




4.3.3 The fluorescence stability profiles of FITC-insulin with respect to pH 
changes.  
Figure 4-4 represents an increase in the fluorescence intensity of Mono in 
response to increased pH from 5 to 8 at which maximum fluorescence was 
recorded then reduced by 20% at pH 9. Furthermore, after seven days of 
storage in its working formulations at room temperature, there was a shift in 
fluorescence profile. However, the trend of increased fluorescence intensity with 
respect to increased pH has remained unchanged despite the shift.  
 
Figure 4-4: Fluorescence intensity (Emission 519mm) of FITC-insulin in the range pH 4-9 
prepared in water, measured in day 1 (blue) and day 7 (orange), showing a fluorescence 
maximum at pH8.0 and fluorescence intensity best preserved at pH4-5 
Notably, upon 24 hours standing, Mono solution formed a suspension at pH 4, 5 
and 6 as illustrated in Figure 4-5 however after thorough shaking the 
suspension re-dissolved to form a clear solution. 
 
Figure 4-5: Observation of FITC-Actrapid® conjugate in solution after 24h showing Mono 
































Principally, FITC is well established to be highly sensitive to pH and therefore 
has been used as a pH indicator in biological material for intracellular and 
extracellular pH measurement.  According to a study by (Breen, Raverdeau and 
Voorheis, 2016), the response to changes in pH observed from the 
fluorescence intensity of FITC demonstrates that the FSC moiety of FITC itself 
irreversibly loses fluorescence at elevated pH above 7, while FITC-methylamine 
exhibits reversible loss of fluorescence at high and low pH and has a 
fluorescence maximum at pH 8.0. Similarly, FITC-insulin sample manufactured 
and used in this study also demonstrated a fluorescence maximum at pH 8 
(Figure 4-4). However, it is uncertain that FITC-insulin could exhibit best 
detection capacity at pH 7-8 if formulated in water for an extended period at 
room temperature. Notably from the previous stability test, FITC-insulin was 
reported to be stable in water for only four days at 20°C. Therefore, the 
decrease in fluorescence measured in this pH study could be due to the free 
FITC detaching from insulin after seven days storage at 20°C. Meanwhile, it 
was also well established that insulin can precipitate out in solutions due to pH 
changes within its isoelectric precipitation zone of pH 4.5-6.5; therefore, the 
precipitations of Mono observed at pH 4, 5 and 6 after 24h were expected. In 
general, fluorescently labelled insulin should be best formulated at pH 7-8 and 
ideally avoiding pH ≥9. 
4.3.4 The equilibrium solubility of FITC-insulin using the shake-flask method 
It is understood that FITC-insulin conjugates are more soluble than native 
insulin in water. This could be due to the effect of FITC modification on the 
hexameric structure of insulin, making it easily dissolvable but the actual 
reasons are beyond the scope of this study. From a practical point of view, 
1,000Unit/mL (35mg/mL) of FITC-insulin could be easily formulated in water 
(pH7) without forming any precipitation for several weeks storing at 2-8°C. It is 
proposed that a starting concentration of 3,000 Unit/mL could be used to 
determine the maximum concentration of FITC-insulin for its working 
formulation. From the previous findings, it was noted that FITC-insulin could 
precipitate in aqueous solution at pH6 and below. Besides, the need to observe 
the solution for several days suggests that the use of diluting fluid (pH7) to 
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ensure its stability would be more appropriate for this study. Initially, 1mL of the 
starting concentration of 3,000 Unit/mL FITC-insulin was prepared in a 1.5mL 
Eppendorf tube as described in 4.2.7. Within a few seconds of gentle mixing a 
uniform solution was achievable however it appeared opaque as illustrated in 
Figure 4-6, suggesting that compete dissolution might not be achieved at 3,000 
Unit/mL. 
 
Figure 4-6: An opaque solution of 3,000 Unit/mL FITC-insulin observed immediately after gentle 
mixing in diluting fluid. 
The resultant mixture was then left mixing for 24h at 200 rpm followed by 2h 
standing at room temperature, after which there was visible precipitation formed 
as showed in Figure 4-7 
 
Figure 4-7: The precipitation of 3000 Unit/mL FITC-Actrapid® conjugate observed after a cycle 
of 24h mixing and 2h standing at room temperature. 
From the calibration curve (R2=0.999) constructed directly using the HPLC 
analysis software (LC lab solution), the concentration of the first supernatant 




Figure 4-8: Mono concentration determined by HPLC at 490Unit/mL for the first supernatant 
collected from 3,000Unit/ml starting concentration. 
 
Notably, this EqC of FITC-insulin is half the preliminary data observed for 
1,000Unit/mL but is equivalent to the highest concentration in commercially 
available insulin injections One possible explanation for this could be due to the 
small volume of diluting fluid (1mL) used to dissolve such a large amount of 
lyophilised FITC-insulin (105mg). Principally, the surface area of any solute that 
can come into contact with its solvent to achieve a complete dissolution is 
affected by the volume of solvent available and the size of solute. The smaller 
amount of solute will enable more surface area contact with the same volume of 
solvent used than any bigger amount where contact will be considerably limited 
by the large particle sizes. In another way, like many other solutes, the smaller 
amount of lyophilised FITC-insulin (35mg) will have a higher chance of 
achieving complete dissolution. 
Meanwhile, the resultant pellet resuspended in 1mL of diluting fluid had a 
concentration of ~ 2,470Unit/mL as showed in Figure 4-9.  
 










Figure 4-9: Mono concentration determined by HPLC at 2,470 Unit/mL for the first collected 
pellet of 3,000Unit/mL staring concentration after centrifugation then being resuspended in 1mL 
diluting fluid. 
Interestingly, Figure 4-10 shows that the resuspended pellet has remained in 
equilibrium as a clear solution for another cycle of 24h mixing. 
 
Figure 4-10: A clear solution of the resuspended pellet (determined at 2,470Unit/mL) observed 
after a further cycle of 24h mixing. 
This observation suggested that the maximum concentration of FITC-insulin at 
equilibrium solubility can be as high as 2,400Unit/mL. However, it could be 
understood that the resultant pellet from 3,000Unit/mL FITC-insulin solute was 
pre-dissolved and exposed to diluting fluid for more than 24h subject to being 
resuspended in another mL of diluting fluid thus there is a higher chance for this 









pre-wetted pellet to remain in dissolution compared to the equivalent amount of 
lyophilised sample. In fact, a starting concentration of 2,000Unit/mL FITC-insulin 
was similarly tested. However, precipitation still occurred after 24h-mixing cycle, 
suggesting that the amount of FITC-insulin was still too high to be completely 
dissolved. To further determine the maximum concentration of FITC-insulin in 
diluting fluid (pH>7) that would remain in equilibrium, another starting 
concentration of 1,500 Unit/ml was similarly tested as described in section 
4.2.7.  
Figure 4-11 shows a clear yellow solution of 1500 Unit/mL FITC-insulin 
formulated in diluting fluid after two cycle of 24h mixing and 2h standing.  
 
Figure 4-11: A clear solution observed after 24hour mixing then centrifugation at room 
temperature of the freshly prepared FITC-insulin at 1500Unit/mL. 
Based on the observation of a clear uniform solution without any precipitation 
following two cycle of 24h mixing then centrifugation, it is therefore concluded 
that the equilibrium solubility for FITC-insulin formulated in diluting fluid (pH7) is 
at a maximum concentration of 1,500Unit/mL. Unlike fluorescently labelled 
insulin, the preparation of recombinant HI solution would require it to be 
solubilised at 1-10 mg/mL in dilute acetic (1%) or hydrochloric acid, pH 2-3. 
Although the labelling of FITC to insulin has increased its solubility at neutral pH 
since lyophilised FITC-insulin can be formulated in water and diluting fluid at 
pH7, it is questionable that the equilibrium solubility of FITC-insulin could be 
further improved in acidic pH. 
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Although it has been successful in determining the solubility of FITC-insulin 
using the equilibrium solubility test, the overall process was quite time-
consuming and requires a considerably high amount of sample. Moreover, other 
factors influencing the solubility of FITC-insulin such as temperature, stirring 
speed, solvent type, the content of zinc ion have not yet been fully investigated. 
Nevertheless, the capability of FITC-insulin to be readily formulated in diluting 
fluid (pH7) at 1,500Unit/mL (3x higher than any commercially available insulin) 
is highly advantageous to produce a concentrated insulin depot for the in-vitro 
diffusion study to investigate the delivery of FITC-insulin from the closed-looped 
insulin delivery device.  
 
4.4 Chapter summary 
The study has investigated the effect of phenol, m-cresol and diluting fluid 
(containing m-cresol, glycerol and zinc oxide) on the stability profiles of FITC-
insulin (Actrapid®/Novorapid®) conjugates in solution when subjected to 
change in temperature over time. These stability profiles were examined based 
on the degree of deconjugation (the presence of free FITC) and formation of 
other FITC-labelled species which exhibit reduced biological activity. The 
fluorescence intensity of FITC-insulin was also determined as a function of pH 
to determine its best pH working range. Furthermore, the equilibrium solubility 
of FITC-insulin was examined using the EqC (shake-flask) method to determine 
its maximum concentration that can remain in a homogeneous system as 
formulated in diluting fluid at pH7. The overall results have highlighted some key 
finding as follows: 
➢ The presence of unlabelled insulin in the conjugated product will likely 
contribute to the formation of other labelling species which can affect the 
biological activity of the original conjugate being investigated. The finding 
suggested that there should be an absence of unlabelled insulin in its 
fluorescently labelled products, especially in those experiments where 
the biological activity of insulin is paramount. For example, for a study 
investigating the insulin signalling pathways where its biological activity 
would need to be measured or determined for an extended period then 
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ideally batch to batch variations in the use of fluorescently labelled insulin 
in the presence of unlabelled insulin are undesirable. 
➢ Although water can be the solvent of choice for preparing most products 
of fluorescently labelled insulin conjugates, depending on the 
experimental design and objective, their working formulation should be 
freshly prepared and used within 24 hours for all in-vivo and in-vitro 
studies setting at 37°C or three days at ambient temperature. Notably, 
pre-formulated solution of FITC-insulin is also possible, providing that it 
should be used within three months of preparation, and the samples are 
kept at 2-8°C with protection from light. 
➢ The use of diluting fluid as formulated in many commercially available 
insulin injections has successfully enhanced the stability of FITC-insulin 
for up to seven days, even at a high temperature of 37°C. For 
experiments performed at ambient temperature, the solution of FITC-
insulin were found to stable for up to two months after being made in its 
diluting fluid. Besides, the shelf-life for this pre-made stock solution would 
expect to last for up to 6 months if storing at 2-8°C with protection from 
light. Furthermore, lyophilised FITC- insulin would expect to remain 
conjugated for several years and so far, Mono sample synthesised after 
four years has remained unchanged.  
➢ Similar to FITC, its conjugate with insulin is also sensitive to pH changes 
and exhibited the best fluorescence intensity at pH8 while precipitated at 
pH4-6. However, after a week of storage at room temperature, the 
fluorescence intensity loss was least observed at pH7 (~5%) while ~ four 
times this lost was observed at pH 6,8 and 9. Although it is always 
advisable to only use a freshly prepared solution of FITC-insulin, their 
best working pH range should also be kept within pH7. 
➢ The maximum concentration of lyophilised FITC-insulin that can dissolve 
in 1mL of diluting fluid containing m-cresol, glycerol and zinc oxide at 
pH7 was at 52mg/mL (equivalent to 1,500 Unit/mL) after 48h based on 
the equilibrium solubility test. This concentration is significantly higher 
 
 164 
than any clinically used insulin preparations in which the highest is 
formulated at 500 Unit/mL. 
➢ The labelling of FITC to insulin must have altered the structural 
configuration of insulin to a certain extent that can improve its solubility at 
neutral pH since 52mg/mL FITC-insulin can be freely solubilised in 
diluting fluid at pH7, while the preparation of insulin solution would 
require solubilising in acid at pH2-3. 
➢ Further testing is necessary to investigate the effect of zinc oxide content 
alone on the stability of FITC-insulin since the presence of zinc ion would 
facilitate the formation of hexameric insulin, which is less prone to 


























 : Drug delivery mechanism and diffusion kinetics 




Understanding the capability and performance of the INsmart device (a closed-
loop insulin delivery system) is fundamentally important in developing an 
artificial pancreas that is capable of delivering the required daily correct insulin 
dose in response to changing blood glucose levels. It is well understood that the 
best therapy for diabetes is one that mimics the physiological process of normal 
glucose control which operates by a negative biochemical feedback. The 
human pancreas behaves as a self-regulated or closed-loop insulin delivery 
system in the body. It operates automatically and continuously according to 
changes in blood glucose levels that trigger appropriate responses by releasing 
insulin or glucagon to maintain homeostasis as detailed in section 1.1.1. The 
potential benefits of an implantable INsmart device include the capability of 
keeping glucose levels under control to minimise diabetes-associated 
complications which are common in most current treatments of diabetes. 
Consequently, it could improve the quality of life for people with diabetes and 
increase longevity. Minimising diabetes complications also means that it could 
save expensive treatment costs from renal failure and cardiovascular diseases 
relating to diabetes, which represent nearly 10% of the annual NHS 
expenditure. In this chapter concepts of molecular transport in solutions across 
barriers by mean of simple diffusion will be discussed to aid the understanding 
of insulin release mechanisms from the INsmart device. Additionally, the 
diffusion kinetics of FITC-Actrapid® conjugate in the glucose responsive gel will 
be studied to establish the release profiles of insulin diffusing through the 




Diffusion is the basic mechanism of transport for molecules in living organisms. 
It is defined as a physical process of mass transfer or net movement of 
individual molecules from an area of high concentration to another one of low 
concentration by random movements in solution. Diffusion in living organisms, 
especially the human body is essentially the key mode for the absorption of 
digested nutrients, gas exchange, transportation of hormones such as 
oestrogens and metabolites towards their target organs and most importantly 
for nearly every event in embryonic development (Cocucci et al., 2017; Basak, 
Sengupta and Chattopadhyay, 2019; Schavemaker, Boersma and Poolman, 
2018). Generally, there are two main types of diffusion namely simple diffusion 
and facilitated diffusion. As their names suggest, simple or passive diffusion is 
merely the movement of molecules down their concentration gradients whereas 
facilitated diffusion is a carrier-mediated transport system that allows molecules 
to move along a concentration gradient. Examples of simple diffusion include 
the spreading of perfume or smells in the air; movement of oxygen molecules 
through the capillary membrane into cells and carbon dioxide removal from cells 
to enter the bloodstream. In most biological systems, diffusion occurs across a 
lipid bilayer known as a semi-permeable membrane that has pores and 
openings to allow the passage of specific molecules. Facilitated diffusion is 
necessary for the movement of large or polar molecules like carbohydrates or 
nucleic acids across the hydrophobic lipid bilayer via pores or channels made of 
transmembrane proteins (facilitators) (Robertson, 2018; Möller et al., 2019; 
Rea, De Angelis and Baschetti, 2019; Gaur, Mishra and Gupta, 2014). 
The study of molecular transport across artificial or biological barriers and 
movement of drug substances in solutions is considerably important in 
understanding the context of drug delivery. Principally, simple diffusion is the 
basic transmembrane process for many small drugs (Mabrouk et al., 2019; 
Dahlgren and Lennernäs, 2019; Zhang et al., 2019; Brodin, Steffansen and 
Nielsen, 2010). It applies to several important processes in drug delivery 
including dissolution of drugs from granules, powders or tablets; drug release 
from suppository or ointment bases; permeation and distribution of drug 
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substances in living cell. It also forms the basis of other drug manufacturing 
processes such as lyophilisation; ultrafiltration; passage of water vapour, gases, 
drugs and additives through coatings, packaging, films (Jacob, 2015; Albisa et 
al., 2018; Tona et al., 2019). 
Generally, the flux of a solute is defined as the mass or number of molecules 
moving through a given cross-sectional area during a given period of time, thus 
presenting measurement of molecular transport across a barrier or mass 
transport of molecules in a solution. Transport investigations of drug or prodrug 
candidates across a barrier tissue like small intestinal cell culture models or 
tissue models are the most common biopharmaceutical use of flux studies. An 
experimental setup for flux studies typically includes a donor compartment with 
a defined initial concentration and volume of compound, a barrier structure with 
a well-defined thickness and cross-sectional area, and a receiver compartment 
with a defined initial concentration and volume. Furthermore, diffusion flux is 
also useful in establishing selection criteria and screening for candidate drug 
compound or to predict in-vivo bioavailability of a given drug substance (Jacob, 
2015; Stewart et al., 2017; Gadgil et al., 2019; Uhl and Liu, 2019). 
The need to understand the mass transfer behaviour of insulin through the 
glucose-responsive gel is fundamental for the optimisation and application of 
the INsmart device. This is because of the variable diffusional characteristic in 
the gel that control the diffusion. The ultimate aim of the device is to mimic the 
real-time response to changing glucose levels from the human pancreas. 
Providing that the device performance is at its optimum (no leak or blockage, 
correct gel thickness and content, appropriate surface area and sufficient insulin 
in reservoir), the response of the gel to changing glucose levels is the main 
factor affecting insulin delivery from the device (as detailed in section 5.1.2). 
This emphasised the importance of understanding the insulin release kinetics 
from the device to establish the mechanism behind getting the correct insulin 
dose for each glucose challenge. It also helps determine the service intervals at 
which the insulin solution in the reservoir needs refilling or when the gel might 
have lost its potency and would need to be replaced (Jacob, 2015). Ideally, the 
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profile of insulin release from the device should follow the natural pattern of 
basal and bolus insulin release from a normal human pancreas.  
5.1.2 Glucose-responsive gel 
The development of a novel glucose-responsive gel material has formed the 
basis of the closed-loop insulin delivery system. This smart gel exhibits a fast 
gel-sol transition that responds reversibly to glucose triggers. Upon interaction 
with glucose, the viscosity of this gel material can be lowered. The gel is a 
hydrophilic, viscoelastic material which is formed by an interaction between 
dextran (a branched glucose polymer produced by Leuconostoc 
mesenteroides) and the lectin concanavalin A (con A) from Canavalia 
ensiformis (Jack bean, Type VI) with glucose-specific receptors (refer to Error! R
eference source not found.) (Tanna,Taylor et al.2006; Tanna, Sahota et 
al.2006; Jacob 2015).  
 
Figure 5-1:Illustration of the Con A-dextran crosslink gel structure and the displacement of 
saccharides moieties by free glucose (Adapted from Taylor 2020). 
Notably, lectin con A is a protein that exists as a dimer at pH below 5.8 and as a 
tetramer at physiological pH. Each identical component of its dimeric and 
tetrameric structures has a binding subunit for the cooperative accommodation 
of divalent metal ions and appropriate configuration of carbohydrates with 
terminal glucose, fructose or mannose. Figure 5-2 shows the scheme of lectin 
con A configurations from monomer, canonical dimer in which the two 





tetramer with binding sites for metal ions and glucose (Cavada et al., 2019; 
Jacob, 2015). 
 
Figure 5-2: 3D structures of lectin Con A oligomerisation showing the binding sites of metal ions 
(silver) and glucose (yellow) in the tetramer (adapted from Cavada et al., 2019) 
The mechanism for gel-sol transition of the smart gel depends on a competitive 
displacement of a glucose-bearing polysaccharide from the lectin receptors by 
free glucose molecules, thus dismantling the three-dimensional gel network. As 
a result, the gel viscosity falls in the presence of glucose but reforms after 
glucose removal. The glucose responsiveness of this smartly designed gel 
network implies that insulin can be delivered through a gel layer whose viscosity 
reversibly changes in response to glucose content. Therefore, in the presence 
of glucose, insulin stored in the core material of the gel is released more rapidly 
than when glucose is absent (Tanna, Sahota et al.2006). 
In a further evolution of the smart gel design, the gel material forming part of the 
implantable closed-loop insulin delivery device used in the in-vivo pig studies 
was a partially polymerised product of dextran methacrylate (dex-MA) and con 
A methacrylamide (con A-MA). The product creates large molecular structures 
by a limited distribution of covalent bonds but not a solid hydrogel. Notably, both 
the polymerised counterpart and simple mixture of dextran and con A form 
glucose-sensitive gels that exhibit a reversible change in viscosity on contact 




Figure 5-3 presents an overview of the glucose responsiveness of the gel 
material contained in the insulin delivery device.              
 
Figure 5-3: An overview of the gel action contained in insulin delivery device. (Adapted from 
Jacob 2015) 
5.1.3 Design of the INsmart device 
Open-loop insulin delivery systems 
A modified open-loop insulin delivery system using a conventional externally 
sighted pump combines continuous subcutaneous insulin infusions (CSII) from 
an external insulin pump with continuous monitoring of glucose levels via a SC 
sensor. The latter communicates glucose readings to the pump using radio 
transmitter. The insulin pump delivers basal insulin into the abdominal SC tissue 
at an appropriate rate for the patient but mealtime bolus insulin doses need to 
be triggered manually. This is because the automated system cannot yet be 
trusted not to produce severe hypoglycaemia due to insulin overdose, thus 
highlighting the inability of pumps to safely deliver the higher insulin dose 
(Farmer Jr, Edgar and Peppas, 2008b; Karges et al., 2017; Bally et al., 2017). 
CSII has a number of advantages over the conventional insulin therapy with 
multiple daily injections (MDI) such as modest reduction in insulin dose, 
providing better glycaemic control as measures by HbA1c, having higher patient 
compliance and satisfaction (Skyler 2010; Jacob 2015). However, there are 
some disadvantages including higher therapy costs, risk of incidents of non-
delivery and diabetic ketoacidosis due to potential pump failures, sensor 
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connection errors, and the need to be attached to the system. One of the major 
drawbacks of the open-loop is its lag time between SC blood glucose levels 
detected by CSII system and the real-time BG level from the vascular when BG 
changes rapidly i.e. during exercise, resulting in a delayed response of up to 
20mins  (Basu et al., 2014; Zaharieva et al., 2019). This means that a falling BG 
level in the vascular may not be detected immediately from the interstitial space 
where the SC sensor detects glucose and a large insulin dose may be delivered 
inappropriately.  
Closed-loop insulin delivery systems 
A closed-loop insulin delivery system monitors the change in glucose levels 
automatically and dispenses an accurate dose of insulin accordingly, both of 
which occur continuously in real time, which solves most of the lag time issues 
experienced by CSII system. The main concept of a closed system is based on 
its many capabilities including the maintenance of near normal glycaemic levels 
in real-time, prevention of long-term hyperglycaemic effects caused by the lag 
time, lowering the healthcare costs especially those associated with diabetes 
complications and improving the quality of life for patients (Jacob 2015). Ideally, 
a closed-loop delivery system should closely mimic the physiological release of 
insulin from normal pancreatic beta cells. The ideal system should accomplish 
several criteria including being glucose-specific and able to transmit variable 
insulin release rates to plasma in real-time; responding to changing glucose 
levels in an acceptable timescale and in a dose-related rate manner. There is 
also a requirement to operate long term without leak of insulin and components 
or creation of non-biocompatible interactions within the body after implant. 
Another key criterion for this system is that it should deliver readily available 
insulin or analogues without the need of specific conjugates such as 
glycosylated forms; and should not introduce increased need (down regulation) 
(Taylor, Sahota 2013).    
The design of an implantable INsmart device (artificial pancreas) for the 
management of diabetes is based on the instant changes occurring in the 
glucose responsive gel in response to changing glucose levels and thereby 
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modulating the release of insulin through a rigid casing, which forms a gateway 
to the insulin reservoir. As mentioned above, this smart gel containing diffusing 
insulin from the reservoir should exhibit a fast gel-sol transition with a primary 
response specifically to glucose. The device, which is designed to be implanted 
in the peritoneal cavity works on a rapid feedback mechanism of the smart gel 
to control insulin release. This mechanism (refer to Figure 5-4) based on the 
fast exchanges between the peritoneal fluid and blood to mimic a normal 
pancreas action and therefore may overcome inherent problems faced by 
current biologically or electronically based closed-loop systems to maintain 
normal BG levels. 
 
Figure 5-4: Rapid feedback mechanism of the smart gel device. 
 
Figure 5-5 shows the working prototypes of the implantable artificial pancreas 
designed and manufactures by Renfrew International (Leicester, UK). 
 





One of the many advantages of this device is that it provides a closed-loop 
insulin delivery system with accurate dose rate based on a glucose-specific 
chemical response. It also removes the need to inject insulin manually without 
electronic or moving parts like other types of artificial pancreas. Furthermore, it 
is simple to implant without the need for immunosuppressive drugs like 
transplant treatments and easily refillable. It is also aesthetically preferable to 
external portable pumps which is visible on the surface of skin. 
Error! Reference source not found. presents components of the INsmart device i
n sequential arrangements of membranes, gel spacer and grids.  
 
Figure 5-6: A developmental model of the INsmart device showing individual component 
arrangement (Taken from Jacob 2015). 
The device is designed to prevent any internal swelling of the gel and distortion 
of the semipermeable membranes by confining the gel in the tight construction. 
The working model parts are made of stainless steel, polycarbonate and resin 
which could be replaced with polyurethane in future designs or making them 
entirely with polycarbonate to make these parts lighter. In order to achieve 
biocompatibility, the refill plumbing circuits have tubing made of polyethylene-
lined polyurethane that connects the luer connections from the device to the fill 
ports under the skin. This tubing material manufactured by SAI strategic 
applications incorporated also makes it compatible with insulin and therefore 
minimising risk of interactions and systemic errors. Furthermore, all device parts 






5.2 Materials and Methods 
5.2.1 Materials and equipment 
Con A-Methacylamide (Con A-MA) was synthesised in house with DS 40-60% 
lysines methacrylated (Biomaterials 2006), M-cresol, glycerol and zinc oxide 
were purchased from Sigma-Aldrich Chemical Company Ltd (UK). Igracure 
2959 was from Ciba Geigy (UK). Parafilm was from Brand R (UK). Metal 
perforated disk (50% surface area) was custom made by Renfew limited 
(Loughborough, UK). Silicone gaskets were purchased from Fisher 
(Loughborough, UK). 0.2m and 0.025m filters were from Whatman (UK). 
Visking tubing was ordered from SpectroPor (UK). Diluting fluid (0.0005%w/v 
Zinc Oxide;1.6%w/v glycerol; 0.25%w/v M-cresol; pH7.5), synthesised FITC-
insulin (section 2.2.4). Dextran methacylate (Dex-MA) was also synthesised 
inhouse with DS 2.6%. Milli-Q water with pH adjusted to 8 was used throughout. 
Peristaltic pumps used for the experimental flow setting include Watson Marlow 
101U (Pump A) and Watson Marlow (Pump B). Other equipment includes Grant 
water bath (UK), Fisher scientific heater plate (Loughborough, UK), Perkin 
Elmer Precisely LS55 Luminescence Spectrometer interfaced with FL Winlab 
software (UK). 
5.2.2 In-vitro diffusion test rig set-up   
The diffusion test rig custom built for the purposes of this work contains various 
individual components which were assembled as shown in Figure 5-7 
 
Figure 5-7: Schematic drawing of the experimental rig set-up with black arrows displaying the 




The receptor compartment which houses the INsmart device was filled with 
600mL of milli-Q water (pH adjusted to 8) to ensure the device was fully 
submerged and any air bubbles present in the tubing were eliminated by 
purging the lines. The receptor compartment was continuously stirred 
throughout the experiment with the magnetic stirrer bar placed directly beneath 
the device to circulate any bubbles on the device surface. Two separate water 
baths were used, the first being to maintain the temperature in the receptor 
compartment at 37ºC and was placed below the receptor. The second provided 
warm bath to the jacket of the receptor via pump A by maintaining a continuous 
flow of warm water from the heating water bath to the exterior surrounding of 
the receptor compartment to compensate the heat lost during experimental 
process. Pump B enables real time diffusion measurements by providing a 
continuous flow of the receptor solution to a quartz fluorimeter flow cell (cuvette) 
and the FITC-Actrapid® released was recorded every 2 mins from the 
fluorimeter software. The presence of any air bubbles in the cuvette was 
regularly checked to ensure no flawed results. The fluorimeter was pre-set with 
excitation and emission of 494nm and 518nm respectively and the slit width 
maintained at 2.5nm. 
5.2.3 Preparation of the smart gel 
200mg of con A-MA was dissolved in 2g of diluting fluid (0.0005%w/v zinc 
oxide;1.6%w/v glycerol; 0.25%w/v m-cresol; pH8) with the addition of a 20L 
photoinitiator, Irgacure 2959 (0.8%w/v) and then mixed with 200mg of dex-MA. 
The mixture was continuously stirred until becoming homogenous to from a 
viscous solution which was covered in foil and allowed to stand for an hour at 
room temperature. After that, the mixture was poured between two glass plates 
separated by a 60m thick gasket. Once the mixture has spread uniformly 
between plates, it was then irradiated under UV light (356nm,10mJcm-2) for 
5mins to allow the crosslinking process of the gel to occur. The slightly opaque 
partially cross-linked gel of ConA-MA and dex-MA was removed from the plates 
and stored at 4ºC for at least 24h prior to testing. 
5.2.4 Preparation of 1000Unit/mL FITC-insulin formulation for the reservoir. 
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Chapter 2 has detailed the synthesis of FITC-insulin conjugates which were 
used in this diffusion study to investigate the release profiles of insulin from the 
INsmart device. 
35mg of FITC-insulin powder was dissolved in 1mL of diluting fluid (as detailed 
in section 5.2.3) to achieve a final concentration of 1000 Unit/mL. The solution 
was either used immediately to fill the device reservoir prior to experimental 
work or stored at 4ºC until further use. 
 
5.2.5 Assembly of the INsmart device 
The INsmart device used here was an experimental, one sided, small scale one 
made out of polycarbonate without plumping. It was used to develop the in-vitro 
and in-vivo (rodent) systems. There is a number of different components 
forming parts of this experimental device as listed in Table 5-1 
Table 5-1: Lists of components used in device assembly 
Individual components Numbers used 
Parafilm gaskets in multiple layers 5 
0.4mm Millipore gaskets 3 
Metal perforated plates  2 




The device was carefully assembled from the base up towards the top. Figure 
5-8 shows the order for individual components of the device assembly. 
 





The assembly of the device was as follows: 
1. A parafilm gasket was greased and added to the base followed by a 
0.4mm Millipore gasket which was topped by another greased parafilm 
gasket.  
2. The first metal perforated disk 1 of 2 was added, followed by the third 
greased parafilm gasket then topped with a 12mm membrane (0.2 -
0.025m pore size or 100kDa Visking tubing cut into 12mm disks) 
3. Two 0.4mm Millipore gaskets creating the gel space were placed on top 
of the membrane before adding the smart gel into it. Ideally, the gel must 
form a flat layer in line with the 0.4mm Millipore gaskets with fully 
occupied gel space to be appropriately packed. Improper addition of gel 
in excess or too little can cause possible leakage, leading to false results. 
4. Once the gel has been added, another 12mm filter was carefully placed 
on top of the gel followed by a greased parafilm gasket.  
5. The second metal perforated disk was then added, topping with the last 
parafilm gasket.  
6. Finally, the top component of the device, whose rims were greased, was 
placed on with care taken to ensure that the whole device was airtight, 
reducing chances of leakage. Once the device has been aligned, 
greased screws were fitted to lock the entire device together.  
7. 0.5mL FITC-insulin stock was then filled from the central hole on the top 
shell of the device using a 1mL syringe. Extra care was taken while filling 
the device to ensure no air bubble resided within the reservoir. A final 
screw then closed the central hole on the top shell entirely for the 
complete assembly of the device as shown in Figure 5-9. 
8. The INsmart device was immersed in distilled water and placed at 4C 
overnight prior to be used in experiments. This was to allow the gel to 
swell osmotically and also to see if any visible dye was leaking from the 
device via the rims or front. The metal perforated plates should allow 
minimal excess swelling (no bulge), thus preserve the flat gel surface but 
with enough swelling to fill the device space. Noting that the space is 
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limited and thus the physical strength of the plates, screw threads must 
balance the osmotic force. 
 
Figure 5-9: Complete assembly of the INsmart device containing FITC-insulin reservoir showing 
no leaks after assembling and 24h storage in water. 
5.2.6 Experimental test. 
For each diffusion experiment, the receptor was topped up with Milli-Q water 
(pH adjusted to 8) to the 600mL mark if required and a baseline reading was 
obtained by running the experimental system in water for 60mins. The INsmart 
device containing FITC-insulin reservoir was then placed into the jacketed jar of 
the receptor compartment circuit with constant magnetic stirring, directly 
underneath it to ensure that any diffused drug from the front and no bubbles 
built up on the metal grid face. The system was left running for another 60 mins 
to obtain a baseline reading for the basal insulin release profile. After this time, 
glucose triggers at different concentrations (0.1%,0.2% and 0.5% w/v) were 
applied to the system either in single trigger or multiple triggers to assess the 
release profiles of FITC-insulin reservoir. These triggers were conducted by 
introducing powdered glucose of appropriate weight for the 600mL receptor. 
Once the chosen trigger time has elapsed, the receptor was fully emptied and 
replaced with fresh Milli-Q water (pH8) until the next glucose trigger. 
 
5.3 Results and Discussions 
 
5.3.1 The effect of long glucose triggers (0.1%, 0.2% and 0.5% w/v) and 




The long release profiles of FITC-insulin in response to a single trigger of 
physiologically relevant glucose concentrations (0.1%,0.2% and 0.5% w/v) was 
investigated by challenging the smart gel in the device with glucose added to 
the receptor solution at the same single timepoint in separate experiments. 
Figure 5-10 shows a change in FITC-insulin gradient values from the device 
baseline (basal FITC-insulin level) and the glucose challenge in response to 
0.1%w/v glucose trigger. 
 
Figure 5-10: FITC-insulin release profiles at 0.1% w/v glucose trigger showing the water 
baseline in yellow, the device baseline (FITC-insulin basal level) in red and during glucose 
trigger in green. 
In the first 60 mins of the experiment, water (pH8) was run through the 
apparatus to ascertain a stable blank and to establish a baseline level for water 
(yellow line). After this time, the INsmart device containing 500 Unit of FITC-
insulin reservoir and smart gel as described in section 5.2.5 was added to the 
receptor compartment. The FITC-insulin basal release (red line) was measured 
for the next 240 mins. At 300 mins 0.1%w/v glucose was added to the receptor 
solution and the release profile of FITC-insulin (green line) was monitored for ~ 
22h (overnight). Immediately after the addition of glucose, there was a surge of 
FITC-insulin released into the receptor solution lasting for ~ 45 mins as showed 
from the increased fluorescence intensity from 300-345 mins. This observation 
suggested that there has been an immediate response from the device as 
y = 0.0002x + 0.1989















0.1% glucose added 
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glucose came into contact with the smart gel, leading to a fall in the smart gel 
viscosity. This resulted in an increase in the gradient as FITC-insulin diffused 
out of the gel layer into the receptor solution. This increased rate of FITC-insulin 
release was observed from 345 mins to 1200 mins. After reaching the peak 
release at 1178 mins, the diffusion rate of FITC-insulin showed a linear phase 
as the drug concentration remained unchanged from 1200-1300 mins. This 
suggested that FITC-insulin is no longer being released from the reservoir into 
the receptor. Since the glucose level remained stable in the receptor 
compartment, the low viscosity of the gel should also remain constant, allowing 
the constant enhanced rate of FITC-insulin release. The degree of FITC-insulin 
release was determined by the activation ratio (=17) of the gradient obtained 
during glucose trigger (0.0034) over FITC-insulin basal release (0.0002). 
Figure 5-11 presents a change in gradient from FITC-insulin diffusion 
experiments in response to 0.2%w/v glucose trigger. 
 
Figure 5-11: FITC-insulin release profiles at 0.2% w/v glucose trigger showing the water 
baseline in yellow, the FITC-insulin basal level in red and during glucose trigger in green. 
As before, a basal release profile in the receptor solution was established 
between 60-300 mins (red line). 0.2%w/v glucose was then added to the 
receptor solution at 300 mins and as with 0.1% w/v glucose trigger, there was 
an immediate surge of FITC-insulin release for the first 15 mins of the glucose 
challenge. This was followed by a gradually increased release over 15h (green 
y = 0.0004x - 1.9
















line) until reaching a linear phase (plateau) (from 1200 mins to 1400 mins) as 
observed in the 0.1% w/v glucose trigger. Although 0.2%w/v glucose stimulated 
a much higher rate of FITC-insulin release, the initial burst seems much lower 
than the 0.1% w/v glucose trigger. However, its release degree as determined 
by the activation ratio (=53) of the gradient during glucose trigger (0.0211) over 
FITC-insulin basal gradient (0.0004) was three time higher than the activation 
ratio calculated from 0.1%w/v trigger. This result suggests that although there 
was an immediate response from the device to both glucose challenges, the 
degree of FITC-insulin release varies with different glucose concentrations. 
However, since the same gel used in the 0.1%w/v trigger also responded to 
0.2% glucose trigger as seen by the boost FITC-insulin release, it is still of 
interest to establish when the fast gel-sol transition become irreversible 
meaning that glucose level is no longer the rate determining step for FITC-
insulin release from the reservoir.  
Figure 5-12 displays changes in gradient values during the device baseline 
measure and glucose challenge showing the release of FITC-insulin from the 
device in response to 0.5%w/v glucose trigger. 
 
Figure 5-12:FITC-insulin release profiles at 0.5% w/v glucose trigger showing the water baseline 
in yellow, the FITC-insulin basal level in red and during glucose trigger in green. 
Similar to previous experiments, the device baseline measurements were 
obtained during 60-300 mins (red line). Upon the addition of 0.5%w/w glucose 
y = 0.0007x + 0.1



















to the receptor solution, there was a much higher surge of FITC-insulin release 
seen in the first 15 mins of trigger, after which the release continued to increase 
gradually over the next 35 mins. Unlike the lower glucose triggers, the peak 
release of FITC-insulin from the 0.5%w/w glucose trigger was rapidly achieved 
within 50 mins. However, after reaching the peak release, the dose rate also 
remained constant as similarly observed in the 0.1% and 0.2% w/v glucose 
triggers. Not only showing a much more rapid response, the activation ratio 
calculated for 0.5%w/v glucose trigger (74) was also the highest compared to 
lower values of 0.1% (17) and 0.2% w/v glucose triggers (53). Once the 
experiment was terminated, the INsmart device was examined and the gel 
disappeared completely. It is therefore concluded that repeatedly (three times) 
prolonged glucose triggers over 24h period would result in irreversible gel-sol 
transition, thus retaining the gel in it liquified state. As a result, the gel 
components could have escaped from the device through the large pore size 
filter and over time the gel would become more diluted to the point that it has 
turned into a low viscosity solution mixture and completely lost its potency. This 
would certainly prevent glucose being the driving force for the rate of FITC-
insulin release, which at this point is believed to be by mean of simple diffusion 
down its concentration gradient. 
The overall observations suggest that the smart gel exhibits fast gel-sol 
transition upon glucose triggers, followed by a continuous increased rate of 
FITC-insulin release, thus showing zero order release kinetics (drug release 
rate is independent of the drug concentrations). However, once the peak 
release is reached, the dose rate of FITC-insulin would become plateaued 
regardless of the prolonged effect of constant glucose present. This could be 
due to a combination of factors. When the gel is in prolonged contact to glucose 
it will osmotically swell and occupy any micro-voids within the device resulting 
from assembly. The porosity of the membranes is important as dex-MA is 
polydisperse and the polymerisation process may have produced polymeric 
structures which are not large enough to be retained by the membrane pore 
size. This is especially relevant given that we have a lightly polymerised gel 
(irradiation of 5 mins). This short irradiation time is used because we want to 
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maintain the competitive glucose binding part of the gel mechanism and a 
longer irradiation time would produce a more rigid gel (Tanna et al., 2006) which 
may be retained by the membrane pore but at the expense of competitive 
displacement and a reduced insulin release rate. The chosen irradiation times is 
a fine compromise. When the devices were examined after each of the glucose 
triggers the gel layer had been compromised. This suggests that over 
prolonged period in glucose, the gel components could escape from the large 
pore membranes to the exterior. It should be mentioned however in reality such 
prolonged high glucose challenges would be unlikely. 
In a real time scenario, the negative feedback loop would respond quickly to 
changes in glucose level to maintain normal glycaemia and therefore only the 
initial rapid surge of FITC-insulin release as observed with 0.5%w/v glucose 
trigger should occur, following by an increased steady state diffusion as 
compared to basal diffusion rate. The chosen glucose concentrations (0.1%; 
0.2% and 0.5% w/v) correlate to the therapeutic range of plasma glucose 
(5.6mmol/L; 11.1mmol/L and 27.8mmol/L respectively) that would stimulate 
increased insulin release therefore it is expected that the INsmart device would 
respond to these glucose triggers in similar way compared to the physiological 
response.  
 
5.3.2 The effect of different membrane pore size used in the INsmart device 
 
The selection of a suitable membrane is important in designing the device not 
only to enable a flat gel surface for simple diffusion of FITC-insulin in response 
to changing glucose levels but also to prevent the gel materials leaking out of 
the device, which can affect the gel integrity as previously reported during the 
long release tests. 
Figure 5-13 shows the effect of using 0.2m membrane within the device on 
the release profiles of FITC-insulin subjecting to sequential 0.1%,0.2% and 




Figure 5-13:FITC-insulin release profiles through the device using 0.2m membrane in 
response to sequential 0.1%,0.2% and 0.5% w/v glucose multi-trigger showing the water 
baseline in yellow, FITC-insulin basal level in red and during glucose challenges (0.1%;0.2% 
and 0.5%) at three different timepoints in green 
As anticipated, there are three distinct gradient changes seen at each glucose 
trigger with the initial activation ratio calculated for the first 0.1% glucose trigger 
to be 3.8, which increased by 3 with 0.2% glucose trigger and reaching 30 at 
0.5% glucose trigger. The staggered approach with multiple glucose triggers 
showed that the device could respond to multi-triggers of glucose as seen by a 
continuous increased rate of FITC-insulin release during the 5h delivery test. 
However, the degree of FITC-insulin release was much less than observed for 
single trigger tests at any timepoint. Furthermore, the release rate was much 
steadier and there was no burst of initial FITC-insulin release upon the addition 
of glucose as would be the ideal pattern in real case scenarios as it would 
better mimic normal pancreatic activity. This observation could be because as a 
smaller filer sized membrane was used, insulin deposited at the outermost layer 
of the gel would not burst out of the membrane as fast as observed for the 
larger filter sized membrane once the gel liquefied after glucose trigger This 
indicated that multiple glucose triggers at shorter time would allow a much 
apparent linear release of FITC-insulin. In the previous experiment with 
prolonged glucose trigger, the FITC-insulin deposited at the outermost layer of 
the gel would burst out of the device through large membrane pore size 
y = 0.0008x + 0.35 y = 0.003x + 0.1037
y = 0.0091x - 0.8226


























immediately after the glucose triggers kicked in to reduce the gel viscosity, 
resulting in the surge release. However, this was not observed in the sequential 
glucose multi-trigger at different timepoints using the same membrane pore 
size. 
Figure 5-14 presents the effect of using 0.025m filter within the device on the 
release profiles of FITC-insulin subjecting to sequential 0.1%,0.2% and 0.5% 
w/v glucose multi-trigger at different timepoints. 
 
Figure 5-14: FITC-insulin release profiles through the device using 0.025 m membrane in 
response to sequential 0.1%,0.2% and 0.5% w/v glucose multi-trigger showing the water 
baseline in yellow, the FITC-insulin basal measurements in red and during glucose challenges 
(0.1%;0.2% and 0.5%) at three different timepoints in green, with effect thereafter in blue. 
The use of smaller pore size membrane resulted in much better FITC-insulin 
release profiles that follow similar pattern expected in real case scenarios. 
There was an initial increased rate in FITC-insulin release in response to each 
addition of 0.1%,0.2% and 0.5% w/v glucose, reaching its peak release after ~ 
5h from initial trigger, after which a steady state remained for another 7h. The 
total activation ratio indicating the degree of FITC-insulin release was four times 
higher than reported using the bigger pore size (0.2 m) membrane. The result 
suggested that fitting the gel within 0.025m pore size membrane will improve 
the overall performance of the device to achieve physiologically relevant FITC-
insulin release profiles. 
y = 0.0006x y = 0.011x - 1.0521
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Figure 5-15 displays the effect of using Visking MWCO100kDa membrane 
within the device on the release profiles of FITC-insulin subjecting to 
consequential 0.1%,0.2% and 0.5% w/v glucose multi-trigger at various 
timepoints.  
 
Figure 5-15: FITC-insulin release profiles through the device using Visking MWCO 100kDa in 
response to 0.1%,0.2% and 0.5% w/v glucose multi-trigger showing the water baseline in red, 
the device baseline in yellow, during glucose challenge at three different timepoints in green 
and the effect thereafter in blue. 
The increased rate of FITC-insulin release profiles observed with the device test 
using Visking MWCO100kDa membrane followed a similar trend to the 
0.025µm membrane. The difference is that Visking membrane acts as a barrier 
to prevent passage of large molecular weight molecules over 100kDa while 
0.025µm membrane works on pore size of around 300kDa. Notably, there were 
four distinct changes in gradient values following each 0.1%,0.2% and 0.5% w/v 
glucose trigger and the continued effect of 0.5% (blue line), whereas using the 
0.025µm membrane the effect thereafter remained plateau. Although the total 
activation ration calculated (75.6) was not as high as compared to using 
0.025µm membrane (113), the continued increase release of FITC-insulin in 
response to prolonged 0.5% w/v glucose trigger seen with Visking membrane 
suggested that the glucose effect on the gel performance would not wear off 
after multiple triggers. This is because the molecular mass of Con A as 
tetramers at pH8 is 110Da, which would be retained within the membrane inside 
y = 0.0005x y = 0.0097x - 0.9141
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the device. As the gel components are not escaping through the membranes, it 
is unlikely that the gel will dismantle after prolonged multi-glucose triggers and 
could remain rate determining in response to glucose present. 
Overall, both 0.025m and Visking membranes showed better device 
performances in FITC-insulin release, thus are viable parts for the device. 
However, Visking membrane provides a definitive cut of point at which only 
molecules <100kDa i.e. insulin can pass through, hence making it more reliable 
in retaining the gel integrity, yet still allowing adequate insulin diffusion.   
 
5.3.3 The effect of galactose (control) on the insulin release mechanism of the 
glucose-responsive gel. 
Experimental tests with single and multiple glucose triggers showed promising 
results of the smart gel delivery of FITC-insulin. In order to confirm that the gel 
only has specificity for glucose, an experiment was conducted using galactose 
which is identical to glucose in molecular weight and similarly structured. The 
specificity of the smart gel for glucose should be confirmed if galactose did not 
provoke a viscosity change in the smart gel to release FITC-insulin. 
Figure 5-16 shows the effect of galactose on the gel responsiveness to release 
FITC-insulin subjecting to 0.1%,0.2% and 0.5% w/v galactose multi-trigger at 
different timepoints. 
 
Figure 5-16: FITC-insulin release profiles in response to 0.1%,0.2% and 0.5% w/v galactose 
multi-trigger showing the water baseline (yellow), basal FITC-insulin level (red) and during 
galactose challenges (blue) at three different timepoints  
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Although there was still a basal release of insulin from the device throughout 
the experimental course of galactose triggers, minimal change in gradient was 
observed at any timepoint possibly due to the inability of galactose to alter the 
gel-sol transition as seen with glucose triggers. The total activation ratio 
calculated was less than 1 and the overall gradient value (in green) obtained 
from the galactose multi-trigger on reservoir depletion was similar to the basal 
level of FITC-insulin. The results show that the addition of galactose did not 
trigger the same response as seen for glucose. Generally, glucose and 
galactose share a simple structure of a six-carbon ring, making them almost 
identical. However, galactose differs slightly in the orientation of the hydroxyl 
group (OH) at the fourth carbon atom as illustrated in Figure 5-19. As a result, 
the OH group of its second carbon atom is in the axial position rather than the 
equatorial position, which is crucial site for Con A binding.  
 
Figure 5-17: Structures of glucose and galactose. 
The slight change in galactose stereochemistry causes its lack of affinity, 
preventing it from fitting into the lectin receptors to change the three-
dimensional gel network. Because there was no galactose binding to con A, the 
smart gel viscosity remains unchanged and therefore resulting in no release of 
insulin. Although there is still need to test the gel specificity to other sugar types, 
this experiment shows that galactose with similar structure to glucose does not 
provoke a viscosity response in the smart gel. 
5.3.4 The effect of continuous triggers with glucose and other inert sugars on 
the device release mechanism of the glucose-responsive gel. 
Figure 5-18 shows an extended experiment where the INsmart device has 
been set up and triggered multiple times with glucose and other dietary 




Figure 5-18: FITC-insulin release profiles in response to multiple glucose triggers (6) in green and other inert sugars (galactose, βD + glucose, lactose, 
trehalose, sucrose) in blue showing the basal delivery in red and the water baseline in yellow. Noting green arrows indicate glucose trigger points, red 






























water baseline basal delivery 0.25% glucose (1st trigger) basal delivery
0.25% glucose (2nd trigger) basal delivery (overnight) 0.25% glucose (3rd trigger) basal delivery
0.25% glucose (4th trigger) basal delivery 0.25% Galactose (5th trigger) basal delivery
0.25% glucose (6th trigger) basal delivery 0.25% β D+ glucose (7th trigger) basal delivery
0.1% glucose added (8th trigger) further 0.15% glucose added basal delivery 0.25% lactose trigger (9th trigger)




Briefly this device was set up as described in section 6.2.5 with some 
modifications. The membrane used in device comprised dialysis membrane with 
a MWCO of 100kDa which should retain both the dextran-MA (average MW of 
500kDa) and con A-MA (MW of 110kDa). This is because con A-MA is most 
likely in its tetrameric form as the gel was formulated in diluting fluid at pH 8 and 
the receptor was in the pH range 8-8.2 for all the glucose and control 
challenges as well as for the water baseline after each challenge. The 500 Unit 
FITC-insulin reservoir was also formulated in diluting fluid (pH8). After the 
device had been assembled with the FITC-insulin reservoir it was left immersed 
for 6 days at 4ºC in diluting fluid (pH 8). This served two purposes, the first is to 
assess if any of the yellow FITC-insulin had escaped the device via a gross leak 
and the second was to allow the gel to osmotically swell to occupy all the micro 
spaces with the gel thickness so that a surge release did not occur in the first 
few hours of the experiment. After each trigger whether it be glucose or a 
control the receptor was washed through twice with Milli-Q water adjusted to pH 
8-8.2 to remove all practical remains of the trigger material and to ensure that a 
lower gradient water baseline was obtained. The smart gel in the experiment 
was D500-MA (DS2.7%) – con A-MA which had been irradiated for 5 mins in 
diluting fluid (pH 8). This is almost an identical gel to that used in the in-vivo 
diabetic pig experiments previously which resulted in near normoglycemia over 
an extended period (Taylor et al., 2016). The only difference being that it is 
formulated in diluting fluid (pH 8) which is an important further improvement on 
device design. The insulin used in the in-vivo experiments (Humulin R®) is 
formulated in diluting fluid. When the device was surgically implanted in the 
diabetic pigs, the reservoir was filled with diluting fluid for the first two days (Up 
to this point the pigs still had functioning pancreas). This was because the 
diabetic state in the pigs was streptozotocin induced after a few days recovery 
from implantation. The diluting fluid in the reservoir of the device would have 
equilibrated with smart gel during this time as the gel was formulated in distilled 
water for that study. It was therefore thought that in these experiments we 
would formulate the smart gel in diluting fluid from the beginning to avoid this 
step. Also, because FITC-insulin is formulated in diluting fluid it is beneficial that 
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the gel is primed for solvent and pH to avoid any pH differences that may cause 
FITC-insulin to precipitate since it is pH dependent as observed in the stability 
study (Chapter 4).  
The experiment was run continuously for a total of 5940 mins which equates to 
~4.125 days. During this period, the gel was subjected to 6 glucose triggers and 
5 control triggers lasting for ~ 60 mins each except for the 8th trigger which was 
overnight. Five of the glucose triggers were of 0.25% w/v concentration 
corresponding to a 13.9mmol/L which would be a hyperglycaemic state and a 
typical uncorrected BG after a meal in diabetic patients (Heinemann et al., 
2018). In the 8th trigger, the gel was left in 0.1%w/v glucose overnight 
corresponding to 5.6mmol/L, which is what the gel would be exposed to for the 
majority of the time in normoglycemia of diabetic patients to check if the device 
was able to deal with glucose surges like the 13.9mmol/L by outputting more 
insulin. After this long glucose trigger the gel was triggered with an additional 
0.15% (total 0.25%) to show it was still able to allow an increased output of 
FITC-insulin There was an instant response of the device to each glucose 
trigger as seen from the increased output of FITC-insulin (green line) but not in 
the control triggers (blue line). This result emphasised that the smart gel not 
only responds differently to glucose concentration increases, but also responds 
specifically to glucose rather than other saccharides. Figure 5-19 presents the 
structures of lactose, sucrose, trehalose and β-D+glucose showing the different 
rotation of the hydroxyl groups at positions C-3, C-4 and C-6 which are most 




Figure 5-19: Different structures of other saccharides used as control trigger. 
The glucose-responsive behaviour of polysaccharide-con A based material has 
been well-established in various studies of biosensors and drug delivery (Yin et 
al., 2019; Lin et al., 2019; Cavada et al., 2019), therefore it is anticipated that 
glucose would be the only relevant sugar for the application of this smart gel in 
the artificial pancreas. Error! Reference source not found. shows the activation r
atios calculated from the gradient of each trigger in relation to baseline gradient 
where only a basal dose of FITC-insulin is output. 
Table 5-2: Activation ratios corresponding to each glucose trigger for the extended experiment 
over 4 days. 
Triggers Baseline gradient Trigger gradient Activation ratio 
1st (0.25%w/v glucose) 0.0142 0.1165 8.2 
2nd (0.25%w/v glucose) 0.0126 0.1234 9.8 
3rd (0.25%w/v glucose) 0.0044 0.0719 16.3 
4th (0.25%w/v glucose) 0.0016 0.0868 54.3 
5th (0.25%w/v galactose) 0.0068 0.006 0.9 
6th (0.25%w/v glucose) 0.0008 0.0938 117.3 
7th (0.25%w/v β-D+glucose) 0.0064 0.0043 0.7 
8th (0.1%+0.15% w/v glucose) 0.0003 0.0292 97.3 
9th (0.25%w/v lactose) 0.005 0.0012 0.2 
10th (0.25%w/v trehalose)  0.0005 0.0002 0.4 
11th (0.25%w/v sucrose)  0.0002 0.0003 1.5 
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It is noted that the basal delivery period recorded before each trigger (glucose 
and control) varied between 2h (daytime) to 15h (overnight) due to time 
availability, therefore showing different values of baseline gradient. As a result, 
the activation ratio of FITC-insulin output for each glucose trigger also varied 
despite having equal glucose concentrations. It is anticipated that the FITC-
insulin output (thus the activation ratio) would not be identical for each glucose 
trigger of the same concentration due to the different driving forces of FITC-
insulin diffusion as more FITC-insulin is released from the reservoir after each 
response.  However, it is emphasised that the gel still remains rate-determining 
in response to glucose present as demonstrated by the release from 6th long 
glucose trigger (overnight 0.1%w/v glucose and the consequential 0.15 %w/v 
glucose added). 
Figure 5-20 shows another extended experiment similar to the last experiment 
where an artificial pancreas has been set up and triggered multiple times with 
glucose and two controls (lactose and galactose). This device was set up in the 
same way as the previous extended experiment except that the smart gel was 
from a different batch of crosslinked gel. This experiment serves to confirm that 




Figure 5-20: FITC-insulin release profiles in response to multiple glucose triggers (8) in green and other inert sugars (galactose, lactose) in blue 
showing the basal delivery in red and the water baseline in yellow. Noting green arrows indicate glucose trigger points, red arrows show glucose trigger 





























water baseline basal delivery 0.1% glucose (1st trigger) further 0.4% glucose (total of 0.5%)
basal delivery 0.25% glucose (3rd trigger) basal delivery 0.25% glucose (4th trigger)
basal delivery 0.25% glucose (5th trigger) basal delivery 0.25% galactose (6th trigger)
basal delivery 0.25% glucose (7th trigger) basal delivery 0.25% Lactose (8th trigger)
basal delivery 0.25% glucose (9th trigger) basal delivery 0.25% glucose (10th trigger)




The initial setting was similar to the previous extended experiment, only that this 
longer experiment was run continuously for a total of 8000 mins which equates to 
~5.556 days. During this period, the gel was subjected to 8 glucose triggers and 2 
control triggers lasting for ~ 60 mins each except for the 1st trigger with 0.1% w/v 
glucose overnight and the consequential 0.4% w/v glucose addition. The overall 
FITC-insulin output in response to multiple triggers followed similar releasing pattern 
observed in Figure 5-18. The ability of the smart gel to increase FITC-insulin output 
during 60 mins of glucose trigger and then switch off immediately after glucose 
removal in both experiments indicated that they are reproducible. The content of 
FITC-insulin remaining in the reservoir after the termination of the experiment was 
also analysed by HPLC showing 310 Unit of insulin (basal+bolus) has been released 
over 5.6 days from the INsmart device that initially hold 500 Unit. This showed an 
average of 55 Unit per day, which is within the range (35-70 Unit/day) of a typical 
total daily insulin requirement for an adult (70kg) with T1DM (Li and Hussain, 2020). 
Table 5-3 shows the activation ratios calculated from the gradient of each trigger 
when compared to baseline gradient where only a basal dose of FITC-insulin is 
output. 
Table 5-3: Activation ratios of each trigger for the extended experiment over 5 days. 
Triggers Basal gradient Trigger gradient Activation ratio 
1st (0.1% w/v glucose) 
 0.0009 0.0118 13.1 
2nd (+0.4% w/v glucose=0.5% in total)  0.0009 0.0742 82.4 
3rd (0.25%w/v glucose)  0.0028 0.0321 11.5 
4th (0.25%w/v glucose)  0.0024 0.038 15.8 
5th (0.25%w/v glucose)  0.0023 0.0792 34.4 
6th (0.25%w/v galactose) 0.0009 0.0002 0.007 
7th (0.25%w/v glucose)  0.003 0.04 13.7 
8th (0.25%w/v lactose) 0.0029 0.002 0.7 
9th (0.25%w/v glucose)  0.0015 0.0494 32.9 
10th (0.25%w/v glucose)  0.0013 0.0183 14.1 
11th (0.25%w/v glucose)  0.0021 0.069 32.9 
 
Apart from the first three triggers, the activation ratios show a distinct pattern of 
FITC-insulin output for each glucose trigger after the daytime basal delivery (2h) 
compared to overnight basal delivery (16h). For instance, there was more than twice 




compared to the output (14-15) for the same amount of glucose trigger after the 
short basal deliveries. The result indicated that the INsmart device is capable of 
delivering the required daily correct dose rate of insulin in response to changing 
blood glucose levels. Providing that other factors (gel thickness and surface area, 
membrane pore size...) affecting the diffusion of FITC-insulin have been addressed 
accordingly, the overall release pattern of insulin from the device in response to 
change in glucose level is highly achievable using FITC-insulin However, for further 
testing on the device performance, glucose triggers corresponding to three 
mealtimes daily should be applied to further assess the correct dose rate for bolus 
insulin delivery from the device. 
 
5.4 Chapter summary 
 
Formulating the smart gel in diluting fluid at pH 8 was an important further 
improvement on the smart gel (D500-MA (DS2.7%) – con A-MA) previously used in 
the in-vivo diabetic pig experiments, which resulted in near normoglycemia over an 
extended period (Taylor et al., 2016). The performance of the artificial pancreas 
device from this improved smart gel formulation was assessed in-vitro using a 
custom-built diffusion test rig. The following are the key findings from the in-vitro 
experiments: 
• It was highlighted that the gel potency could be lost following prolonged 
glucose trigger (over 24h) when using large pore membrane (0.2m). This is 
highly due to the loss of gel components to both the inside device space and 
the exterior due to large pore membranes after prolonged liquefying. Different 
membrane pore sizes have been used to investigate if the gel components 
could be retained within the membrane inside the device to maintain its 
potency as the rate determining for insulin release in response to glucose 
present. 0.025m and Visking MWCO100kDa pore size membranes showed 
better device performance and therefore are viable membrane parts for the 
device. However, Visking is more practical and reliable owing to its ability to 
provide a definitive cut of point at which only molecules with molecular weight 




• Improvement in the smart gel formulation and the use of correct membrane 
pore size have showed promising and reproducible results in the extended 
experiments where an artificial pancreas has been set up and triggered 
multiple times with glucose and other dietary saccharides which act as 
controls to show the specificity of the gel to glucose challenges. These 
extended experiments have not been set up in any previous in-vitro studies of 
the INsmart device performance. The overall result indicated that the artificial 
pancreas device is capable of delivering the required daily correct dose rate 
for insulin in response to changing BG levels. 
• Providing that other controllable factors (gel thickness and surface area, 
membrane pore size...) in the device design affecting the diffusion of insulin 
have been addressed accordingly, the overall delivery of insulin in response 
to glucose triggers, thus the performance of the artificial pancreas is highly 

















 : Synthesis and Identification of Eosin-5- 




Nowadays, the availability of a robust variety of fluorescent derivatives has enabled 
researchers to tailor conjugations to specific needs for uses in a wide variety of in-
vitro or in-vivo fluorescence-based assays. The addition of a fluorescent label to 
targeted molecules has improved the detection capabilities that they themselves are 
unlikely to possess, emphasising the versatility, sensitivity and quantitative 
characteristics of many fluorescent probes. Moreover, the use of various fluorescent 
dye also enables the detection of multiple targets spontaneously within the same 
assays (Warrier and Kharkar, 2014; Fu and Finney, 2018). 
In this chapter, the labelling of insulin with EITC and RBITC will be performed using 
analogous synthesis method for FITC-insulin conjugate. This practical extension is to 
assess the production of fluorescently labelled insulin using different but related dye 
molecules. Initially, the structural differences of these dyes will be discussed followed 
by some highlights in their applications. Similar analytical methods including RP-
HPLC and MS will be used to identify and characterise promising conjugates. By 
using different molecular weight dyes, the selective production of the desired mono-
labelled conjugate can also be investigated and optimised for wider application 
ranges. Furthermore, the different fluorescent characteristics exhibited by these dyes 
would enable visible differentiation of their conjugate, which could be highly 
applicable for the detection of multiple targets spontaneously.  
6.1.1 EITC 
Similar to FITC, EITC is also a derivative of FSC dye, which belongs to the xanthine 
families that are the most widely utilised fluorophores in biological assay. FSC is a 
classic for its ability to exhibit high quantum yields and its derivatives are useful 
fluorescent probes for labelling peptides and proteins to enable visualisation of these 




core structure that contributes to their fluorescent character. The presence of the 
oxygen bridge between the upper phenyl rings of this fused three-ring structure helps 
create the rigid aromatic system that constricts the molecule to a planar shape, thus 
conferring luminescent qualities (Hermanson, 2013). 
FSC derivatives usually have modifications in their phenyl ring to provide reactivity 
toward particular functional groups in biomolecules, thus allowing rapid labelling of 
proteins and nucleic acids. For instance, FITC is also known as an ITC derivative of 
FSC that has its ring modified at the 5- or 6-carbon positions by the addition of the 
ITC reactive group. Generally, ITC reacts with nucleophiles such as amines, 
sulfhydryl, and the phenolate ion of tyrosine side chains. However, the only stable 
product is with primary amine groups, therefore ITC is almost entirely selective for 
modifying N-terminal amines in proteins (Holmes and Lantz, 2009; Dufour, Stahl and 
Baysse, 2015). 
Meanwhile, EITC is structurally analogous to FITC, the difference being the addition 
of four bromine atoms. It is also referred to as the tetrabromo-5-ITC derivative of 
FSC. Similar to FITC, EITC has two anionic sites, which are the oxyanion at the 
xanthene skeleton and the carboxyl anion at the phenyl ring in the pH 5 to 10 region 
(Chiba, Sato and Suzuki, 1987; Lilly et al., 2018) as shown in Error! Reference s
ource not found.. 
 
Figure 6-1: Structures of Eosin isothiocyanate (EITC) and Fluorescein isothiocyanate (FITC). 
The ITC group at the phenyl ring in both FITC and EITC is a covalent binding site. 
Owing to the addition of four bromine atoms, EITC has a higher molecular mass of 
705Da than 389Da of FITC. The fluorescent properties of FITC include an absorption 




exhibits phosphorescence with an emission maximum at ~680nm. Interestingly, 
EITC exhibits not only the properties of an organo-bromine compound but also an 
FSC and an ITC. Although EITC is better known as an excellent photosensitiser 
rather than selective labelling to amines, its labelling to insulin via the ITC reactive 
group would be similar to FITC. Other applications for EITC include its use as a 
reversible inhibitor of the erythrocyte calcium pump and as an effective 
phosphorescent probe in protein rotational studies (Garland and Moore, 1979; Gatto 
and Milanick, 1993; Cockrell et al., 2015).  
6.1.2 RBITC 
RBITC is a derivative of rhodamine dye which also belongs to the xanthine families 
because it has an aromatic xanthene core structure. The structural difference of 
RBITC (Figure 6-2) compared to FSC is the substitution of nitrogen atoms to replace 
the oxygen atoms which form part of the alcohol and carbonyl functional groups in 
FITC and EITC. Each substituted nitrogen atom also links to two ethyl groups, and in 
the presence of chloride ions at lower pH (in diluted HCl), the nitrogen atom 
replacing the carbonyl functional groups also exhibits a positive charge (Tripathi, 
2013). 
 
Figure 6-2: Structure of Rhodamine B Isothiocyanate (RBITC). 
Although at neutral pH, RBITC exhibits lower quantum yield than FITC in aqueous 
solutions, the main advantage of RBITC is its better stability to photo-bleaching 
(Mugica et al., 2016). It has a molecular weight of 536.08 Da and an absorption 
maximum at 555nm. However, unlike FITC, RBITC exists as an inseparable mixture 




Rhodamine and its derivatives are popular fluorescent probes for labelling all types 
of biomolecules such as chitosan, cyclodextrins and bovine serum albumin (BSA). In 
particular, RBITC-BSA conjugate has been found to be highly specific, sensitive, and 
stable in vitro, thus is useful as a tracer molecule for vascular permeability and 
protein transportation studies (Yang et al., 2017). Other delivery studies also used 
RBITC-insulin conjugates to investigate the in-vitro release and in-vivo insulin 
absorption in rats from aminated gelatin microspheres (Wang, Tabata and Morimoto, 
2006). However, in this study, a full detail of the synthesis process and the 
confirmation of RBITC-insulin conjugate remained unclear. It was only highlighted 
that there is a need to maintain the pH of the reaction using carbonate buffer (pH 
9.4) while the synthesis was conducted at 4°C for 10h, and unreacted dye was 
removed by dialysis. Further synthesis testing is therefore necessary to further 
confirm the production of RBITC-insulin conjugate. Other applications of RBITC 
include its use as an anterograde and retrograde marker of retinal neurons in the 
adult rat (Thanos, Vidal-Sanz and Aguayo, 1987) . It has also been used to label 
type I collagen (C1) and pathogenic bacterum Staphylococcus aureus (Sun et al., 
2015; Depke et al., 2014). 
These fluorescence probes exhibit distinctively different fluorescence characteristics 
that are useful for multiple detections spontaneously. Furthermore, by sharing the 
same amine-reactive group (ITC) it is of interest to investigate if their labelling to 
insulin would produce fluorescently labelled insulin derivatives at the same target 
binding site on the insulin molecule. 
 
6.2 Materials and Methods 
6.2.1 Chemicals and Reagents 
EITC (Pcode: 102159311; CAS: 60520-47-0) and RBITC in mixed isomers 
(PCode:100245687; CAS: 36877-69-7) were purchased from Sigma-Aldrich (UK). 
Actrapid® (HI) was manufactured by Novo Nordisk. NaH2PO4.2H2O and 
Na2HPO4.2H2O; HPLC grade acetone, acetonitrile and trifluoroacetic acid were 
purchased from Fischer Chemicals (Loughborough, UK). EDTA was from Hopkins & 




distilled water was for other preparation processes such as the making of 
buffers;0.1M and 1M NaOH and 0.1M and 1M HCl were used for pH adjustment. 
6.2.2 Preparation of 0.1M Sodium Phosphate buffer pH 5.4 and pH7.0 
1L of phosphate buffer pH5.4 was prepared by dissolving 13.13g of NaH2PO4.2H2O 
and 1.3g of Na2HPO4.2H2O in ~ 500mL of distilled water. After dissolution, the 
solution was made up to 1L in a volumetric flask with distilled water and pH was 
adjusted to 5.4 with 1M NaOH and 1M HCl. 
1L of phosphate buffer pH7 was prepared by dissolving 6.6g of NaH2PO4.2H2O and 
10.27g Na2HPO4.2H2O in ~ 500mL of distilled water. After dissolution, the solution 
was made up to 1L in a volumetric flask with distilled water and pH was adjusted to 
7.0 with 1M NaOH and 1M HCl. 
6.2.3 Synthesis of EITC-insulin conjugate 
Preparation of EITC solution 
5mg/ml of EITC solution was freshly prepared before the conjugation process by 
weighing 5mg of EITC on an analytical balance then dissolving it in 1mL of Acetone, 
and storing in the dark at 4°C until further use. 
Synthesis of EITC-insulin conjugate 
5ml of Actrapid® solution (equivalent to 17.5mg HI) was measured and transferred 
into a clean glass jar with the addition of 0.44mg EDTA. For a 2:1 molar ratio of 
EITC: insulin 0.850mL of 5mg/mL EITC solution was added to the solution mixture 
then the pH was adjusted to 7 with 0.1M NaOH. The conjugate was left to react in 
the dark and magnetically stirred for the allocated reaction time of 2h and 18h. 
Purification of EITC-insulin conjugate produced 
The purification process by GPC followed the same method for FITC as previously 
described in section 2.2.3 
6.2.4 Synthesis of RBITC-insulin conjugate 
Preparation of RBITC solution 
5mg/ml of RBITC solution was freshly prepared and stored in the dark at 4°C until 
further use by weighting 5mg of RBITC on an analytical balance then dissolving it in 




Synthesis of RBITC-insulin conjugate 
For each conjugation, 5ml of Actrapid® solution (equivalent to 17.5mg HI) was 
measured and transferred into a cleaned glass jar with the addition of 0.44mg EDTA. 
For a 2:1 molar ratio of RBITC: insulin 0.643 mL of 5mg/mL RBITC stock solution 
was added to the solution mixture then the pH was adjusted to 7 with 0.1M NaOH. 
The conjugate was left to react in the dark and magnetically stirred for the allocated 
reaction time of 2h and 20h. 
For a 1:1 molar ratio of RBITC: insulin 0.323mL of 5mg/mL RBITC stock solution 
was added to the solution mixture then the pH was adjusted to 7 and 8.5 for two 
separated reaction conditions with 0.1M NaOH. The conjugate was left to react in the 
dark and magnetically stirred for 24h. 
Purification of RBITC-insulin conjugate produced 
After reaction for the allocated time, the conjugation of insulin with RBITC was 
stopped by dropping the pH down to the isoelectric zone of insulin around pH5.3-5.4 
to introduce precipitation. The resultant mixture was then centrifuged for five minutes 
at 2000 rpn, the supernatant was then removed and the pellet washed twice using 
pH5.4 buffer before dissolving in phosphate buffer pH7 (as prepared in section 
7.2.2). The conjugated mixture was then subjected to another cycle of precipitation 
at pH5.3-5.4 and re-centrifugation to remove any unreacted RBITC further.  The re-
washed pellet was also dissolved in phosphate buffer pH7 then dialysed for 48h 
using 1000 Da molecular weight cut off membrane to ensure the final conjugated 
product was free from unreacted RBITC. 
6.2.5 Analytical procedures for the identification of EITC-insulin and RBITC-insulin 
conjugates produced. 
RP-HPLC analyses 
The conjugated products from the synthesis of EITC-insulin and RBITC-insulin after 
purification were analysed using RP-HPLC to identify the species produced and 
confirm the absence of any unreacted EITC and RBITC. The same HPLC system 
and setting as detailed in section 2.2.4 was used except for the following 
chromatographic conditions as shown in Table 6-1 according to each fluorescently 





Table 6-1:Different RP-HPLC conditions used for the detection of fluorescently labelled insulin 
conjugates with EITC and RBITC. 
Samples 
detected 




0-15 min (85% to 55%A), 15-25 min (55% 
to 25%A), and 25-32 min (25% to 35%A) 
where A and B are mobile phases as 
shown below; 
Mobile Phase A:  0.1% Trifluoroacetic 
acid (TFA) in Milli-Q water. 
Mobile Phase B: 90% Acetonitrile/ 10% 
Milli-Q Water/0.1% TFA 
the excitation and 
emission wavelengths 
were set at 490 and 
540nm, respectively to 




0–10min (90% to 60% A), 10–25 min 
(60%to 30% A), and 25–35 min (35% A) 
where A and B are mobile phases as 
shown below; 
Mobile Phase A:  20mmol Ammonium 
acetate in Milli-Q water, pH 6.5 and  
Mobile Phase B: 95% Acetonitrile. 
the excitation and 
emission wavelengths 
were set at 556 and 
576nm, respectively to 
monitor fluorescence data 
 
MS analyses 
MS to determine the mass of the EITC-insulin conjugate produced was performed 
using a Thermofisher LTQ Orbitrap XL (a high-resolution instrument giving accurate 
mass measurement over the mass range: m/z 50–2000 or m/z 200–4000) using the 
nanospray ionisation mode (NSI) at the EPSRC National Mass Spectrometry Facility, 
Swansea University. The solvent used for sample preparation was a mixture of 
water/1:1 water: methanol + 0.1% formic acid. Samples were infused into the source 
of the mass spectrometer using a syringe pump at a flow rate of 10 μL/min. Analyses 
were performed in the positive ion detection mode. Scans were acquired over a 




6.2.6 Fluorescently labelled insulin conjugate storage conditions and lyophilisation 
process 
All fresh labelled conjugates were taken for HPLC analysis immediately after being 
collected from the GPC. The rest of the products would be protected from light and 
kept at -20°C for lyophilisation no later than a week after being synthesised. The 
samples for drying were placed inside a round bottom flask and frozen using liquid 
nitrogen. The frozen flask was then placed on the Heto drywinner for ~ 48h to ensure 
no aqueous solution remained in the flask. An orange-pink powder and a dark pink 
powder remained consisting of the EITC-insulin and RBITC-insulin conjugate 
respectively which were then stored at 4°C until further uses. 
6.3 Results and Discussion 
6.3.1 Synthesis and Identification of EITC-insulin conjugate 
Before identifying which species of EITC-insulin conjugates are being produced 
using RP-HPLC system; it was necessary to confirm complete removal of unreacted 
EITC by GPC as well as the presence of any unlabelled insulin from the final 
products. The detection of peaks at RT of 26.6min; 27.7min,29.1min, 29.9min and 
32.1min illustrated in Figure 6-3 would indicate that the conjugated products also 
contain unreacted EITC thus, requiring further purification. 
 
Figure 6-3: RP-HPLC fluorescence chromatogram of EITC in acetone showing peaks at RT 
26.6min;27.7min;29.1min;29.9min;32.1min 
Figure 6-4. presents the PDA UV chromatogram detected at 215nm for Actrapid® 

































Figure 6-4: PDA UV chromatogram of Actrapid® presenting peaks at RT of 13.2 min for m-cresol and 
16.4 min for native human insulin in Actrapid®. 
The peaks observed at RT of 13.2 min and 16.4 min are corresponding to m-cresol 
and native HI respectively, noting the shift in RT compared to the previous 
chromatogram obtained from FITC-insulin method was due to the different 
composition of mobile phase used. The PDA peak detected at 16.4 min RT for any 
conjugated product would indicate the presence of unlabelled insulin. 
Figure 6-5 shows the combined fluorescence chromatograms for EITC-insulin 
conjugated produced at two reaction times of 2h and 18h.  
 
Figure 6-5: Fluorescence chromatogram of EITC-insulin conjugate synthesised after 2h and 18h 
presenting peak at 20.1minRT for Mono. 
The single fluorescence peak detected at a RT of 20.1min indicates that the EITC- 























































molar ratio (EITC/insulin) using the same synthesis method as FITC-insulin 
suggested that their conjugation process is transferable despite the different 
molecular mass dye. According to their percentage AUP, the fluorescence peak at 
20.1minRT obtained from their HPLC analysis yielded 100% Mono. However, the 
conjugates also contain unlabelled insulin detected from their PDA data at peak 
16.4minRT. Furthermore, 18h reaction time showed a considerably lower amount of 
unlabelled insulin and a higher yield of Mono. Notably, the fluorescence data 
obtained after 18h reaction also showed a minor peak at 22minRt, which could 
indicate di-labelled species yet not at relevant concentrations for HPLC detection. 
Their MS data (Figure 6-6) also confirmed unlabelled insulin present (peak at 5807.7 
m/z). The observed data [6511+H] + indicate only Mono present with no observed 
mass of 7216 for di-labelled species. Notably, the two units shift from the theoretical 
[6513+H] + for Mono could be due to the reduction of a disulphide bond. 
 
Figure 6-6: Mass spectra for EITC-insulin conjugate synthesised after 18h reaction at pH7 using 2:1 
molar ratio (EITC/insulin) showing peak at 5807.7m/z corresponding to unlabelled insulin and the 









By adapting the same reaction conditions that produce only the desire Mono with 
FITC, the synthesis of EITC-insulin conjugate also yielded 100% Mono. However, 
further purification by HPLC may be necessary to remove all unlabelled insulin from 
the conjugated product. It is possible that the larger molecular mass of EITC (705Da) 
from the addition of four bromine atoms might limit EITC navigation around the 
insulin molecule to bind to its target site to some extent. This could be seen from the 
relatively higher production of FITC-insulin conjugate (refer to section 2.3) than 
EITC-insulin conjugate from the same amounts of materials used. Optimal reaction 
conditions may require further adjustment for EITC-insulin synthesis. Binding to the 
IR sites might also be affected by the large size of EITC and the biological activity of 
EITC-insulin conjugate also needs further investigation. 
6.3.2 Synthesis and Identifications RBITC-insulin conjugate 
Figure 6-7 represents the fluorescence chromatogram obtained for the rhodamine 
analogue in methanol showing multiple peaks of RBITC mixed isomer with the most 
abundant peaks at RT of 21.8min; 22.8min; 24.1min and 25.3min. The detection of 
these RBITC peaks in the product of RBITC-insulin conjugate would indicate the 
presence of unreacted RBITC which requires further purification. 
 
Figure 6-7:RP-HPLC fluorescence chromatogram of RBITC in methanol showing multiple peaks of 
mixed isomer at RT 21.8min;22.5min;22.8min;24.1min;24.4min;25.3min; 26,8min and 28.3min. 
Figure 6-8 shows the PDA UV chromatogram of Actrapid detected at 215nm for 
insulin present with peaks observed at RT of 12.3min and 14.5min corresponding to 


































Figure 6-8:PDA UV chromatogram of Actrapid® presenting peaks at RT 12.3 min for m-cresol and 
14.5 min for native HI in Actrapid® 
The difference in RT of Actrapid sample compared to previous chromatogram 
obtained from FITC-insulin method was also due to different mobile phases used. 
The PDA peak detected at 14.5 min RT in this particular method for any EITC-insulin 
conjugate would indicate the presence of unlabelled insulin. 
Unlike FITC and EITC, purification by GPC resulted in weak recovery and separation 
of RBITC-insulin conjugate with excess RBITC as the Sephadex column remained 
pink throughout the GPC process. The strong adsorption of RBITC to the matrix in 
the Sephadex column could be due to the highly hydrophilic properties of RBITC. 
Meanwhile, Sephadex is prepared by cross-linking dextran with epichlorohydrin. 
These highly cross-linked porous particles with covalent bonds provide the matrix 
with a great hydrophilic environment for RBITC to remain in, thus resulting in poor 
separation. The initial attempt to separate unreacted RBITC from its conjugated 
product with insulin using GPC was unsuccessful; therefore, dialysis was another 
purification method of choice to remove unreacted RBITC. 
The synthesis of RBITC-insulin conjugate from 2:1 molar ratio (RBITC/insulin) at pH7 
produced a mixture of two conjugated species with considerably higher amount of 
unlabelled insulin at both short (2h) and long (20h) reaction time compared to 
labelling with FITC and EITC. Besides, unreacted RBITC was the most abundant 
product detected by HPLC with a significantly lower yield of RBITC-insulin conjugate 



























Figure 6-9:RP-HPLC fluorescent chromatogram of RBITC-insulin conjugate synthesised from 2:1 
molar ratio at pH7 after 20h reaction, showing two peaks corresponding to RBITC-insulin conjugate 
indicated by the black double- arrow and multiple peaks corresponding to unreacted RBITC marked 
by the pink double-arrow. 
The observed lower yield of RBITC-Actrapid® conjugate for the same reaction 
conditions could be due to the overall positive charge of RBITC compared to the 
neutral FITC and EITC, making it more difficult for labelling to insulin to occur. 
Besides, the structure of RBITC is considerably different from FITC and EITC 
despite having the same amine-reactive group (ITC), therefore could also result in 
significantly less labelling. A further modification to the reaction condition was 
necessary in order to improve conjugation and minimise having excessively 
unwanted dye that may require more extended dialysis time for complete removal 
from the conjugated product. Furthermore, due to the high polarity of RBITC, its 
complete removal from the conjugated product could also be more challenging. 
Although there have been several compounds of interest labelled with RBITC such 
as chitosan and BSA, very little information was available for the removal of the 
unreacted dye from its conjugated product, or how these conjugates were identified. 
Meanwhile, the difficulty encountered while removing unreacted RBITC from the 
conjugated products owing to the high lipophilicity of RBITC was also reported in the 
synthesis of ATPase labelled with RBITC (Papp, Pikula and Martonosi, 1987).   
In order to maximise the synthesis of RBITC-insulin conjugate, a 1:1 molar ratio 
(RBITC/Actrapid®) for 24h at both pH7 and pH8.5 was employed. The hypothesis 






































the reaction time, there would be more conjugate formed with very little unreacted 
dye left to remove. An increased pH might also facilitate better binding of the ITC 
reactive group with the primary amine of insulin. Furthermore, the literature also 
suggests that reaction conditions at pH9-9.5 were usually required for conjugation to 
aliphatic amine as described in the synthesis of RBITC with BSA, chitosan and 
insulin (Yang et al., 2017; Ma et al., 2008; Wang, Tabata and Morimoto, 2006). 
However, due to the high rate of hydrolysis at the high pH>9 and the low yield of 
conjugation observed with FITC, pH 8.5 was deemed a better choice. Figure 6-10 
presents the combined fluorescence chromatograms for RBITC-insulin conjugate 
synthesised at pH7 and pH8.5, in which the conjugated peaks were highlighted by 
the black double-arrow from RT of 17.7min to 20.1min while the pink double-arrow 
marked peaks from RT 21.8min to 26.4 min corresponding to unreacted RBITC. 
 
Figure 6-10: Combined fluorescence chromatograms of RBITC-insulin conjugate synthesised after 
24h at pH7 (Orange) and pH8.5 (Blue) from 1:1 molar ratio, showing peaks corresponding to RBITC-
insulin conjugate indicated by the black double-arrow and multiple peaks corresponding to unreacted 
RBITC marked by the pink double-arrow. 
The chromatographic data show that the increased pH resulted in the production of 
three conjugated species, although at a significantly lower yield than the synthesis at 
pH7. This suggests that pH >7 may not be ideal for labelling as similarly observed 
from the conjugation with FITC (section 2.3. 5). Reducing the amount of RBITC in 
excess clearly indicated that less unreacted RBITC was present in the conjugated 








































conjugates synthesised so far with RBITC always contain unlabelled insulin and a 
considerably high amount of unreacted dye, none of which is ideal. 
In conclusion, despite trying several purification steps of precipitation and dialysis, 
the final rhodamine conjugation always contains a high amount of unreacted dye. 
This highlights the extreme difficulty encountered for the removal of unreacted 
RBITC. Moreover, the extended dialysis that required for over one week despite 
being kept at 2-8°C might result in deconjugation of RBITC from the insulin molecule, 
thus causing more release of unreacted dye. Overall, the synthesis of RBITC-insulin 
conjugate would yield at least two conjugated species regardless of short or long 
reaction time, and the best reaction conditions (1:1 molar ratio; pH7 and 24h 
reaction) tried so far would yield 50% RBITC-Actrapid® conjugate owing to the 
difficulty in the removal of unreacted dye. Although further purification of the two 
RBITC-insulin conjugates synthesised could be achievable by HPLC, the low yield, 
high risk and cost of damaging the column suggest that further variation method in 
the synthesis of RBITC-insulin conjugate is necessary. 
6.4. Chapter summary 
The present study was designed to investigate the synthesis of fluorescently labelled 
insulin derivatives with EITC and RBITC via the same binding site as FITC. These 
fluorescent candidates share the same amine-reactive group (ITC), which would 
form a strong thiourea linkage with the primary amine of insulin molecules to produce 
covalently labelled fluorescence conjugate. The ability to synthesis other 
fluorescently labelled insulin derivatives could be highly advantageous in a wide 
range of bioanalytical applications, especially for the detection of multiple targets 
spontaneously as well as in advanced drug delivery. 
The main findings are summarised as follow: 
➢ The synthesis of EITC-insulin  from 2:1 molar ratio (EITC/insulin) at pH7 after 
2 and 18hours also yield 100% singly labelled species with a lower amount of 
unlabelled insulin observed after 18h reaction. The RP-HPLC method has 
identified conjugate synthesised was mono-labelled EITC-insulin however the 
product also contains a trace amount of unlabelled insulin, both of which were 
further confirmed by MS. Owing to the structural similarity of FITC and EITC, it 




same. However, further purification by HPLC may be necessary to remove all 
unlabelled insulin from the conjugated product. Alternatively, longer reaction 
time may be necessary to ensure the complete labelling of all insulin molecule 
but may also lead to Di production. To conclusively confirm the use of the 
EITC-insulin conjugate produced inhouse, further studies to investigate its 
stability profile and biological activity may be necessary. 
➢ Although RBITC also has the same amine-reactive group as FITC and EITC, 
its labelling to insulin using similar reaction conditions to FITC and EITC 
showed a significant reduction in the production of RBITC-insulin conjugate. 
Owing to the availability as mixed isomers, there would always be at least two 
species of RBITC-insulin conjugate being produced regardless of short or 
long reaction time. The most distinct structural of RBITC compared to other 
dyes is its overall positive charge that results in the high polarity of RBITC as 
well as its conjugation. However, the difficulty encountered when removing 
unreacted RBITC from its conjugated product in addition to the considerably 











 : Overall conclusions and future work 
7.1 Overall conclusions 
 
Diabetes mellitus, commonly known as diabetes, is a lifelong endocrine disorder that 
is on the rise, affecting 4.7 million people in the UK, of whom 90% have T2DM 
(Whicher, O’Neill and Holt, 2020; Magliano et al., 2019). It is characterised by a 
prolonged high blood glucose level that is due to either the pancreas inability to 
produce insulin (T1DM), or not enough insulin production and the cells of the body 
not responding properly to the insulin produced (insulin resistant T2DM). Insulin is an 
essential hormone that regulates glucose homeostasis. T1DM patients are 
dependent on lifelong administration of exogenous insulin for survival. For patients 
with T2DM, apart from taking antidiabetic drugs, many of them will eventually require 
exogenous insulin to maintain good glycaemic control as the disease progresses. 
Insulin replacement therapy therefore plays an indispensable role in fulfilling the 
treatment goal for all T1DM patients and many more patients with T2DM. It is 
expected that from 2018 to 2030, there will be more than 20% increase in insulin 
users with T2DM (Basu et al., 2019). There have been various approaches into 
different routes of insulin delivery including oral, intranasal, transdermal and inhaler 
to reduce the burden of SC insulin administration. Newer generation of insulin 
analogues serving as insulin bolus and basal to mimic the normal physiological 
activity of endogenous insulin have also been developed. However, the risk of 
hypoglycaemia associated with insulin use remains the most challenging obstacle for 
the evolution of insulin therapy to overcome. One of the most cutting-edge 
technology is the development of insulin replacement therapy via an artificial 
pancreas which is capable of determining the insulin requirement in real-time and 
delivering an accurate insulin dose. In particular, the implantable artificial pancreas 
developed within our research group is based on a principle that insulin can be 
delivered through a novel glucose-sensitive smart gel as a function of changing 
glucose environment.  
In advanced drug development and delivery, fluorescence studies have enabled the 
understanding of many cellular level activities such as biodistribution and metabolism 
with respect to the complexities imposed by the biological systems. Fluorescently 




through various routes including oral, intranasal, transdermal and implanted artificial 
pancreas (Lee, Sang Hoon et al., 2020; Lochhead et al., 2019; Chen, Shyu and 
Chen, 2018; Jacob, 2015). However, there are very few studies addressing the 
quality and characterisation of the fluorescent-labelled insulin being used. The main 
objective of this study was to synthesis a FITC-insulin conjugate that was as 
biologically active as native insulin. Secondly, the stability and solubility profiles of 
FITC-insulin in solution was also examined for long-term storage and future 
application in both in-vitro and in-vivo testing. Thirdly, the performance and kinetics 
of insulin delivery from an implantable artificial pancreas with respect to multiple 
glucose triggers were investigated using FITC-insulin. Lastly, EITC and RBITC were 
assessed as labelling candidates to produce other fluorescent insulin derivatives. 
The following conclusions summaries key findings from this current study:  
➢ Fluorescently labelled insulin was chosen as an improved analytical tool to aid 
detection and quantification of insulin delivery in-vitro from an artificial 
pancreas. This is partly because fluorescence detection offers highly sensitive 
and specific quantification at significantly lower concentration compared to 
UV. In addition, UV detection of insulin could be compromised by the protein 
absorbance from the smart gel components in the device.  
➢ Several reaction times of less than 18h at pH7 using a molar ratio (FITC: 
insulin) of 2:1 are capable of producing the desired mono-labelled FITC-
insulin conjugate. However, the conjugated product always contains some 
unlabelled insulin. As the reaction time was increased over 20h, no unlabelled 
insulin was present but 5% undesirable Di was also produced. The quantities 
switch from Mono to Di productions were observed between 19h to 20h 
reaction and at pH≥8. 
➢ Adjusting the pH of the reaction close to the pKa of the individual amino acid 
FITC binding sites at A1 (pKa of 8.4); B1(pKa of 7.1) and B29 (pKa>9.8) could 
not selectively target labelling to a specific site. However, reaction at pH≥8 
showed some degree of selective labelling at both A1 and B1 positions, 
resulting in the production of two mono-labelled species and 3% Di even at a 
short reaction time of 2h. Reaction at pH≥9 resulted in a mixture of FITC-
insulin conjugates including Mono, Di and Tri. Meanwhile, only the reactions 




mono-labelled species, which was found to be at the B1 position. However, 
unlabelled insulin was also present due to the short reaction time. 
➢ Further purification of the FITC-Actrapid® conjugate (produced at 2:1 molar 
ratio, pH 7 after 18h reaction) by HPLC has successfully removed any 
unlabelled insulin to achieve 100% pure Mono conjugate which was confirmed 
by RP-HPLC and MS. Fragmentation of this species by electrospray MS has 
confirmed FITC label at the B1 position. 
➢ The biological activity of four FITC-insulin species (MonoA1, MonoB1, Di and 
Tri) was assessed in HUVEC and C2C12 skeletal muscle cells via the insulin 
signalling pathway by examining the levels of pAKT and cell surface GLUT4. 
These markers were chosen because AKT is a key signal transduction 
mediator for GLUT4 synthesis and translocation to the cell membrane, thus 
allow the insulin-dependent transport of glucose into the cell. Different levels 
of pAKT obtained from Western Blot analysis indicated that the insulin 
molecule labelled at the B1 position behaved most similarly to native insulin 
while Di and Tri as well as MonoA1 significantly reduced the insulin signalling 
pathway by virtue of AKT activation. Other conjugates showed reduced 
effects from 78% down to 51% of the native insulin activity with MonoA1 and 
Di respectively. The significantly low activity (0.06%) observed with Tri would 
indicate a complete loss of biological activity due to the inability of IR to 
recognise the receptor-binding site of this tri-substituted insulin. 
➢ The preliminary test for GLUT4 translocation in HUVEC could not confirm the 
presence of GLUT4, indicating that the intracellular uptakes of glucose in 
HUVEC occur via other types of GLUT which is insulin-independent such as 
GLUT1. The use of C2C12 skeletal muscle cells to further confirm the 
biological effect of the most active FITC-insulin conjugate (MonoB1) on 
GLUT4 translocation by immunofluorescent showed no significant difference 
in the GLUT4 cell surface level compared to native insulin. This observation 
suggests that the mono-labelled FITC-insulin conjugate at B1 produced 
inhouse was as biologically active as native insulin. 
➢ The stability of FITC-insulin in solution can be enhanced for all three 
temperatures studied (2-8°C,20°C and 37°C) using diluting fluid (0.0005%w/v 
Zinc Oxide;1.6%w/v glycerol; 0.25%w/v m-cresol; pH7.0), which is typically 




formulate FITC-insulin diluting fluid for use in all in-vivo and in-vitro studies 
setting at 37°C as this formulation showed stability for up to seven days. 
FITC-insulin formulated in diluting fluid can last for up to 2 months at ambient 
temperature and up to 6 months if storing at 2-8°C with protection from light.  
➢ FITC-insulin exhibited the best fluorescence intensity at pH8 but precipitated 
at pH4-6. However, after a week of storage at room temperature, the 
fluorescence intensity loss was least observed at pH7 (~5%) while ~ four 
times this loss was observed at pH 6,8 and 9. Although it is always advisable 
to use a freshly prepared FITC-insulin solutions, their best working pH range 
should also be kept within pH7. 
➢ The maximum concentration of lyophilised FITC-insulin that can dissolve in 
1mL of diluting fluid (pH7) was at 52mg/mL (equivalent to 1,500Unit/mL) 
based on the equilibrium solubility test. This concentration is significantly 
higher than any clinically used insulin preparations maximising at 500Unit/mL. 
It is reported that the B1 substitution with FITC could improve the solubility of 
insulin at neutral pH because the unchanged form of human insulin powder 
would require solubilising in acidic condition at pH2-3. 
➢ It was highlighted in the in-vitro diffusion study that the gel components could 
be lost following prolonged glucose trigger (over 20h) when using large pore 
size membrane (0.2m) in the INsmart device. This is highly due to the gel 
components diffusing out of the device through the membrane pores after 
prolonged liquifying, thus affecting the gel potency. Different membrane pore 
sizes have been used to investigate if the gel components could be retained 
within the membranes inside the device to maintain its potency as the rate 
determining for insulin release in response to changing glucose. 0.025m 
pore size and Visking MWCO100kDa membranes showed better device 
performance and therefore are viable parts for the device. However, Visking 
membrane is more practical and reliable owing to its ability to provide a 
definitive cut of point at which only molecules with molecular weight of less 
than 100kDa can pass through. 
➢  Improvement in the smart gel formulation prepared in diluting fluid and the 
use of correct membrane pore size for the INsmart device have showed 




where the device has been set up and triggered multiple times with glucose 
and other dietary saccharides acting as controls to show the specificity of the 
smart gel to glucose challenges. These extended experiments have not been 
set up in any previous in-vitro studies of the INsmart device performance. The 
overall result indicated that the INsmart device is capable of delivering the 
required daily bolus insulin dose which can be boosted in response to multiple 
increases in glucose levels. 
➢  The synthesis of EITC-insulin using 2:1 molar ratio (EITC/insulin) at pH7 after 
a reaction time of 18h has successfully produced Mono but unlabelled insulin 
was also present. The labelling position and biological activity of this 
conjugate have not yet been confirmed. Although EITC conjugation with 
insulin using the same synthesis method as FITC-insulin could be 
reproducible, further removal of unlabelled insulin using HPLC is necessary. 
Alternatively, longer reaction time may be necessary to ensure complete 
labelling but may also lead to the production of Di and Tri as observed in the 
synthesis of FITC-insulin. 
➢ Although RBITC also share the same amine-reactive group as FITC and 
EITC, its labelling to insulin using the same synthesis method showed a 
considerably low production of RBITC-insulin conjugate. Owing to the 
availability as mixed isomers, it is understood that at least two species of 
RBITC-insulin will be produced regardless of the reaction conditions. The 
overall positive charge of RBITC that is distinctively different to other dyes 
might have make it more difficult for ITC reaction with insulin. The resultant 
positive charge of RBITC-insulin has been found to be advantageous for its 
transportation across the plasma membrane; however, the difficulty 
encountered when removing unreacted RBITC from its conjugation in addition 
to the considerably lower yield suggested that further development in the 
synthetic method is necessary. 
7.2 Future work plans 
Keys findings from this research suggest several courses of action for further study 
as follow: 
➢ It was highly anticipated that during the conjugation with FITC, insulin exists in 




on the insulin. Further research would be useful to investigate the effect of 
zinc removal to facilitate insulin monomer formation by using various 
concentrations of EDTA (higher than 200mM) on the production of FITC-
insulin conjugate. 
➢ FITC is partially soluble in water while insulin is insoluble in water however the 
findings of this study indicated that their conjugation is freely soluble in water 
at 50mg/mL. Further work is needed to fully understand the implication of 
FITC labelling to insulin solubility in which the lyophilised FITC-Insulin 
conjugate can be readily dissolve in water without the need to use acidic 
diluent as required for powder insulin. 
➢ Most excipients in diluting fluid also help enhance the stability of insulin in 
pharmaceutical preparations by facilitating the formation of insulin hexamer. 
The results from the stability study also support the idea that FITC-Insulin 
conjugate can also be formulated in diluting fluid for better shelf-life protection, 
especially for experiments carried out at 37°C over an extended period. A 
greater focus on the stabilising effect of individual excipients in diluting fluid or 
in different combination could produce interesting findings that account more 
for the formation of FITC-Insulin monomer, dimer or hexamer. 
➢ EITC can potentially be used as an alternate fluorescent probe for insulin 
labelling. Further investigation into the biological activity of EITC-Insulin could 
shed more light on the application of multiple fluorescent labels of insulin for 
advanced delivery research and biological response of insulin spontaneously.  
➢ The stability enhancement effect of diluting fluid has made it possible to use 
FITC-Insulin for the in-vitro diffusion study at 37°C over an extended period of 
7 days to examine the performance and kinetics of insulin delivery from the 
INsmart device. Further diffusion experiment with multiple glucose triggers at 
three different time points corresponding to three meals intake per day could 
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Appendix 1-Chromatogram data and Mass spectra of chapter 3 
 
Figure A1 1: Fluorescence chromatogram for 100Unit/mL MonoA1 conjugate isolated from the FITC-
insulin synthesis of 1h reaction at pH8.4 and 2:1 molar ratio (FITC/insulin) showing a single Mono 
peak at a RT of 21.3min 
 
Figure A1 2: Fluorescence chromatogram for 100Unit/mL MonoB1 conjugate isolated from the FITC-
insulin synthesis of 18h reaction at pH7 and 2:1 molar ratio (FITC/insulin) showing a single Mono 





























































Figure A1 3: Fluorescence chromatogram for 100Unit/mL Di conjugate isolated from the FITC-insulin 
synthesis of 72h reaction at pH7 and 3:1 molar ratio (FITC/insulin) showing a single Di peak at a RT 
of 22.6min. 
 
Figure A1 4: Fluorescence chromatogram for 100Unit/mL Tri conjugate isolated from the FITC-insulin 






























































Figure A1 5: Mass spectra for MonoA1, MonoB1, Di and Tri conjugates isolated for the biological 
activity test (peaks present in raw data at m/z 1240.34 z5 corresponding to mono-labelled conjugates, 





































































































































































































































RT: 0.13-1.16  AV: 41 





b1+a1#6-119  RT: 
0.03-0.60  AV: 114 F: 




di_label#7-157  RT: 
0.03-0.80  AV: 151 F: 




tri_label#1-62  RT: 
0.00-0.37  AV: 62 F: 










Appendix 2-Chromatogram data for chapter 4 
 
Figure A2 1: Fluorescence chromatogram of FITC-insulin conjugates formulated in water after 5 
months storage at 2-8°C showing the begin loss in original Mono conjugate at a RT of 21.9min (95% 
AUP) and the appearance of Di conjugate at a RT of 22.6min (1.4%AUP) as well as free FITC peaks 
(3.6%AUP) at RT of 12min and 14min, none of which was detected in the original Mono conjugates 
 
Figure A2 2: Fluorescence chromatogram of FITC-insulin conjugates formulated in diluting fluid after 6 
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